MXPA00008295A - Inhibitors of phospholipase enzymes - Google Patents
Inhibitors of phospholipase enzymesInfo
- Publication number
- MXPA00008295A MXPA00008295A MXPA/A/2000/008295A MXPA00008295A MXPA00008295A MX PA00008295 A MXPA00008295 A MX PA00008295A MX PA00008295 A MXPA00008295 A MX PA00008295A MX PA00008295 A MXPA00008295 A MX PA00008295A
- Authority
- MX
- Mexico
- Prior art keywords
- alkyl
- phenyl
- pharmaceutically acceptable
- cooh
- methyl
- Prior art date
Links
- 102000015439 Phospholipases Human genes 0.000 title claims abstract description 15
- 108010064785 Phospholipases Proteins 0.000 title claims abstract description 15
- 230000002401 inhibitory effect Effects 0.000 title claims description 24
- 239000003112 inhibitor Substances 0.000 title description 13
- 150000001875 compounds Chemical class 0.000 claims abstract description 190
- 239000000203 mixture Substances 0.000 claims abstract description 64
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 32
- 230000000694 effects Effects 0.000 claims abstract description 21
- -1 phenyl -O- Chemical class 0.000 claims description 222
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 165
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 158
- 125000000217 alkyl group Chemical group 0.000 claims description 156
- 239000002253 acid Substances 0.000 claims description 133
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 132
- 125000003545 alkoxy group Chemical group 0.000 claims description 131
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 121
- SIKJAQJRHWYJAI-UHFFFAOYSA-N indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 108
- 239000011780 sodium chloride Substances 0.000 claims description 108
- 229910052736 halogen Inorganic materials 0.000 claims description 106
- 150000003839 salts Chemical class 0.000 claims description 106
- 150000002367 halogens Chemical class 0.000 claims description 98
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 96
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 85
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 83
- 239000005711 Benzoic acid Substances 0.000 claims description 78
- 235000010233 benzoic acid Nutrition 0.000 claims description 75
- 125000001424 substituent group Chemical group 0.000 claims description 57
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 48
- 125000005979 2-naphthyloxy group Chemical group 0.000 claims description 38
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 33
- 125000004076 pyridyl group Chemical group 0.000 claims description 30
- 229910052757 nitrogen Inorganic materials 0.000 claims description 29
- 125000006638 cyclopentyl carbonyl group Chemical group 0.000 claims description 28
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 27
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 24
- 229910052717 sulfur Inorganic materials 0.000 claims description 24
- 150000003536 tetrazoles Chemical class 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 23
- 125000001544 thienyl group Chemical group 0.000 claims description 23
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 22
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 20
- 229910052799 carbon Inorganic materials 0.000 claims description 19
- 125000002541 furyl group Chemical group 0.000 claims description 19
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 19
- 125000005842 heteroatoms Chemical group 0.000 claims description 17
- 125000000623 heterocyclic group Chemical group 0.000 claims description 13
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 12
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 11
- XRLDSWLMHUQECH-UHFFFAOYSA-N cyclopentanecarboxamide Chemical compound NC(=O)C1CCCC1 XRLDSWLMHUQECH-UHFFFAOYSA-N 0.000 claims description 11
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 11
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 125000001624 naphthyl group Chemical group 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- 125000006518 morpholino carbonyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])N(C(*)=O)C1([H])[H] 0.000 claims description 9
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 8
- 125000002757 morpholinyl group Chemical group 0.000 claims description 8
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 8
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 8
- 230000001225 therapeutic Effects 0.000 claims description 8
- 125000002619 bicyclic group Chemical group 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 7
- 125000005493 quinolyl group Chemical group 0.000 claims description 7
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims description 5
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 claims description 5
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 5
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 5
- 229940113083 morpholine Drugs 0.000 claims description 5
- WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 5
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 5
- 125000001216 2-naphthoyl group Chemical group C1=C(C=CC2=CC=CC=C12)C(=O)* 0.000 claims description 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 4
- IANQTJSKSUMEQM-UHFFFAOYSA-N Benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 claims description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 4
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000006309 butyl amino group Chemical group 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N furane Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 3
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- 125000004429 atoms Chemical group 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 3
- SMWDFEZZVXVKRB-UHFFFAOYSA-N quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 125000001088 1-naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 claims description 2
- 125000006180 3-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1[H])C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butanoic acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000005647 linker group Chemical group 0.000 claims description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 2
- 125000001736 nosyl group Chemical group S(=O)(=O)(C1=CC=C([N+](=O)[O-])C=C1)* 0.000 claims description 2
- 125000006187 phenyl benzyl group Chemical group 0.000 claims description 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 2
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000005458 thianyl group Chemical group 0.000 claims description 2
- 230000031990 negative regulation of inflammatory response Effects 0.000 claims 5
- 239000000546 pharmaceutic aid Substances 0.000 claims 5
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- YJTCXUDVHWLYPB-UHFFFAOYSA-N 1-[1-[[4-(1,3-benzothiazole-2-carbonyl)phenyl]methyl]-5-benzylsulfanyl-2-(naphthalen-2-ylsulfanylmethyl)indol-3-yl]ethanone Chemical compound C1=C2C(C(=O)C)=C(CSC=3C=C4C=CC=CC4=CC=3)N(CC=3C=CC(=CC=3)C(=O)C=3SC4=CC=CC=C4N=3)C2=CC=C1SCC1=CC=CC=C1 YJTCXUDVHWLYPB-UHFFFAOYSA-N 0.000 claims 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 claims 1
- PXWGBEVVBHLZAD-UHFFFAOYSA-N 2-[3-benzoyl-2-(naphthalen-2-yloxymethyl)-5-phenylmethoxyindol-1-yl]acetic acid Chemical compound C12=CC(OCC=3C=CC=CC=3)=CC=C2N(CC(=O)O)C(COC=2C=C3C=CC=CC3=CC=2)=C1C(=O)C1=CC=CC=C1 PXWGBEVVBHLZAD-UHFFFAOYSA-N 0.000 claims 1
- CXJAFLQWMOMYOW-UHFFFAOYSA-N 3-chlorofuran-2,5-dione Chemical compound ClC1=CC(=O)OC1=O CXJAFLQWMOMYOW-UHFFFAOYSA-N 0.000 claims 1
- HCHSFVKTMDUFAW-UHFFFAOYSA-N 4-[5-(cyclopentanecarbonylamino)-2-(naphthalen-2-yloxymethyl)-3-(pyrrolidine-1-carbonyl)indol-1-yl]butanoic acid Chemical compound C12=CC(NC(=O)C3CCCC3)=CC=C2N(CCCC(=O)O)C(COC=2C=C3C=CC=CC3=CC=2)=C1C(=O)N1CCCC1 HCHSFVKTMDUFAW-UHFFFAOYSA-N 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 claims 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 1
- 125000005186 naphthyloxy group Chemical group C1(=CC=CC2=CC=CC=C12)O* 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N γ-Hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 claims 1
- 102100010404 PLA2G4A Human genes 0.000 abstract description 12
- 101710029802 PLA2G4A Proteins 0.000 abstract description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 340
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 134
- 235000019439 ethyl acetate Nutrition 0.000 description 125
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 86
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 80
- 238000006243 chemical reaction Methods 0.000 description 79
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 79
- 239000000047 product Substances 0.000 description 67
- 239000000243 solution Substances 0.000 description 59
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 58
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 54
- 239000008079 hexane Substances 0.000 description 47
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 42
- 238000000034 method Methods 0.000 description 41
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
- 238000004587 chromatography analysis Methods 0.000 description 38
- 150000002148 esters Chemical class 0.000 description 36
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Chemical compound [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 36
- 239000012044 organic layer Substances 0.000 description 31
- 150000001412 amines Chemical class 0.000 description 29
- 239000011541 reaction mixture Substances 0.000 description 28
- 150000001408 amides Chemical class 0.000 description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 26
- 239000010410 layer Substances 0.000 description 25
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 23
- 239000000463 material Substances 0.000 description 23
- 238000001665 trituration Methods 0.000 description 23
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 22
- 238000000746 purification Methods 0.000 description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 21
- 239000002904 solvent Substances 0.000 description 21
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 20
- 239000012267 brine Substances 0.000 description 20
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 20
- 238000007792 addition Methods 0.000 description 19
- 238000004166 bioassay Methods 0.000 description 18
- 238000003756 stirring Methods 0.000 description 17
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
- 238000001953 recrystallisation Methods 0.000 description 16
- 101700068305 COP1 Proteins 0.000 description 15
- 101700037066 COP3 Proteins 0.000 description 15
- 101700086301 Ear1 Proteins 0.000 description 15
- 238000011097 chromatography purification Methods 0.000 description 15
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 15
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 15
- 235000019341 magnesium sulphate Nutrition 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 14
- 108090000790 Enzymes Proteins 0.000 description 14
- 101700007039 PA21 Proteins 0.000 description 14
- 101700016159 PA22 Proteins 0.000 description 14
- 101700040243 PA23 Proteins 0.000 description 14
- 101700071566 PA2A2 Proteins 0.000 description 14
- 101710031203 PA2CS Proteins 0.000 description 14
- 101700039989 PA2V Proteins 0.000 description 14
- 101700014500 PA2X1 Proteins 0.000 description 14
- 101700036609 PA2X2 Proteins 0.000 description 14
- 101700024882 PLA2 Proteins 0.000 description 14
- 102100001381 PLA2G1B Human genes 0.000 description 14
- 101710029814 PLA2G1B Proteins 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 14
- 210000004027 cells Anatomy 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- 101710033049 xecG Proteins 0.000 description 14
- 239000002585 base Substances 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 12
- 150000003180 prostaglandins Chemical class 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 11
- 150000002617 leukotrienes Chemical class 0.000 description 11
- 150000002632 lipids Chemical class 0.000 description 11
- 229960001663 sulfanilamide Drugs 0.000 description 11
- 229940114079 Arachidonic Acid Drugs 0.000 description 10
- YZXBAPSDXZZRGB-DOFZRALJSA-N Arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 10
- 235000021342 arachidonic acid Nutrition 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-Dimethylaminophenol Substances CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 9
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 9
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 9
- 150000002576 ketones Chemical class 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- 239000000741 silica gel Substances 0.000 description 9
- 229910002027 silica gel Inorganic materials 0.000 description 9
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
- 101700057035 KAT5 Proteins 0.000 description 8
- 229940082622 Prostaglandin cardiac therapy preparations Drugs 0.000 description 8
- 229940077717 Prostaglandin drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) Drugs 0.000 description 8
- FDDDEECHVMSUSB-UHFFFAOYSA-N Sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 8
- 229940094443 oxytocics Prostaglandins Drugs 0.000 description 8
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 7
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 7
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 7
- 239000002260 anti-inflammatory agent Substances 0.000 description 7
- 238000003818 flash chromatography Methods 0.000 description 7
- 230000002757 inflammatory Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- OZAIFHULBGXAKX-VAWYXSNFSA-N Azobisisobutyronitrile Chemical compound N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- QPRFAFKPBOLMDI-UHFFFAOYSA-N bis(2-methylphenyl)methanone Chemical compound CC1=CC=CC=C1C(=O)C1=CC=CC=C1C QPRFAFKPBOLMDI-UHFFFAOYSA-N 0.000 description 6
- 230000000875 corresponding Effects 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000002480 mineral oil Substances 0.000 description 6
- 235000010446 mineral oil Nutrition 0.000 description 6
- 230000002829 reduced Effects 0.000 description 6
- 230000001603 reducing Effects 0.000 description 6
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Substances [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 description 6
- 229910000033 sodium borohydride Inorganic materials 0.000 description 6
- ODGROJYWQXFQOZ-UHFFFAOYSA-N sodium;boron(1-) Chemical compound [B-].[Na+] ODGROJYWQXFQOZ-UHFFFAOYSA-N 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 5
- FPGGTKZVZWFYPV-UHFFFAOYSA-M Tetra-n-butylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 125000005883 dithianyl group Chemical group 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 150000002475 indoles Chemical class 0.000 description 5
- 210000003622 mature neutrocyte Anatomy 0.000 description 5
- 238000006722 reduction reaction Methods 0.000 description 5
- AKVJDXBLRZFJFZ-UHFFFAOYSA-N 1,3-dibromo-1,3-diphenylpropan-2-one Chemical compound C=1C=CC=CC=1C(Br)C(=O)C(Br)C1=CC=CC=C1 AKVJDXBLRZFJFZ-UHFFFAOYSA-N 0.000 description 4
- IOJUPLGTWVMSFF-UHFFFAOYSA-N Benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N Carbon tetrachloride Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 229940113118 Carrageenan Drugs 0.000 description 4
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N Coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- KRHYYFGTRYWZRS-UHFFFAOYSA-N HF Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 4
- VNYSSYRCGWBHLG-AMOLWHMGSA-N Leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 4
- 102000008072 Lymphokines Human genes 0.000 description 4
- 108010074338 Lymphokines Proteins 0.000 description 4
- QARBMVPHQWIHKH-UHFFFAOYSA-N Methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 4
- HVAUUPRFYPCOCA-AREMUKBSSA-O PAF Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP(O)(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-O 0.000 description 4
- 101700059544 PTGR1 Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- SQGYOTSLMSWVJD-UHFFFAOYSA-N Silver nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 4
- RMVRSNDYEFQCLF-UHFFFAOYSA-N Thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 4
- 239000000679 carrageenan Substances 0.000 description 4
- 235000010418 carrageenan Nutrition 0.000 description 4
- 229920001525 carrageenan Polymers 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- HPQVWDOOUQVBTO-UHFFFAOYSA-N lithium aluminium hydride Substances [Li+].[Al-] HPQVWDOOUQVBTO-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- AGGHKNBCHLWKHY-UHFFFAOYSA-N sodium;triacetyloxyboron(1-) Chemical compound [Na+].CC(=O)O[B-](OC(C)=O)OC(C)=O AGGHKNBCHLWKHY-UHFFFAOYSA-N 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000002194 synthesizing Effects 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 3
- WETWJCDKMRHUPV-UHFFFAOYSA-N Acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 3
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 3
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 210000002966 Serum Anatomy 0.000 description 3
- HJUGFYREWKUQJT-UHFFFAOYSA-N Tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 3
- 239000012346 acetyl chloride Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 150000001263 acyl chlorides Chemical class 0.000 description 3
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 3
- 239000011260 aqueous acid Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- RFKZUAOAYVHBOY-UHFFFAOYSA-M copper(1+);acetate Chemical compound [Cu+].CC([O-])=O RFKZUAOAYVHBOY-UHFFFAOYSA-M 0.000 description 3
- WEPUZBYKXNKSDH-UHFFFAOYSA-N cyclopentanecarbonyl chloride Chemical compound ClC(=O)C1CCCC1 WEPUZBYKXNKSDH-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000003834 intracellular Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 3
- 150000004702 methyl esters Chemical class 0.000 description 3
- NSNPSJGHTQIXDO-UHFFFAOYSA-N naphthalene-1-carbonyl chloride Chemical compound C1=CC=C2C(C(=O)Cl)=CC=CC2=C1 NSNPSJGHTQIXDO-UHFFFAOYSA-N 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- 238000010626 work up procedure Methods 0.000 description 3
- HWBIQJOWCBKZJW-UHFFFAOYSA-N $l^{1}-silanyloxysilicon Chemical compound [Si]O[Si] HWBIQJOWCBKZJW-UHFFFAOYSA-N 0.000 description 2
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-Bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 2
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 2
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-Lutidine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- YHOYYHYBFSYOSQ-UHFFFAOYSA-N 3-methylbenzoyl chloride Chemical compound CC1=CC=CC(C(Cl)=O)=C1 YHOYYHYBFSYOSQ-UHFFFAOYSA-N 0.000 description 2
- 208000006673 Asthma Diseases 0.000 description 2
- 101710013859 At1g04680 Proteins 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N Benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N Benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- PASDCCFISLVPSO-UHFFFAOYSA-N Benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N Benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N Decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 210000002683 Foot Anatomy 0.000 description 2
- 229910004373 HOAc Inorganic materials 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N Indometacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 241001024304 Mino Species 0.000 description 2
- PWBJWDKDPAPGED-UHFFFAOYSA-N N'-chlorobutanediamide Chemical compound NC(=O)CCC(=O)NCl PWBJWDKDPAPGED-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N Oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 101700085733 PELA Proteins 0.000 description 2
- 101710040930 PTGS2 Proteins 0.000 description 2
- 102100015381 PTGS2 Human genes 0.000 description 2
- 108010058864 Phospholipases A2 Proteins 0.000 description 2
- 229940067631 Phospholipids Drugs 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- GRVFOGOEDUUMBP-UHFFFAOYSA-N Sodium sulfide Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N Trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- DXGTUUQHTDOFFQ-UHFFFAOYSA-N [N].C1=CC=C2NC=CC2=C1 Chemical compound [N].C1=CC=C2NC=CC2=C1 DXGTUUQHTDOFFQ-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 230000002051 biphasic Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atoms Chemical group C* 0.000 description 2
- 230000024881 catalytic activity Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 229960000956 coumarin Drugs 0.000 description 2
- 235000001671 coumarin Nutrition 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 239000008355 dextrose injection Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- OTMSDBZUPAUEDD-UHFFFAOYSA-N ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 2
- DVFJMQCNICEPAI-UHFFFAOYSA-N ethyl 5-nitro-1H-indole-2-carboxylate Chemical compound [O-][N+](=O)C1=CC=C2NC(C(=O)OCC)=CC2=C1 DVFJMQCNICEPAI-UHFFFAOYSA-N 0.000 description 2
- DCIFXYFKVKDOLL-UHFFFAOYSA-N ethyl 5-phenylmethoxy-1H-indole-2-carboxylate Chemical compound C=1C=C2NC(C(=O)OCC)=CC2=CC=1OCC1=CC=CC=C1 DCIFXYFKVKDOLL-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 238000002642 intravenous therapy Methods 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 150000002513 isocyanates Chemical class 0.000 description 2
- 125000001810 isothiocyanato group Chemical group *N=C=S 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 239000002609 media Substances 0.000 description 2
- 230000001404 mediated Effects 0.000 description 2
- VZDNXXPBYLGWOS-UHFFFAOYSA-N methyl 3-aminobenzoate Chemical compound COC(=O)C1=CC=CC(N)=C1 VZDNXXPBYLGWOS-UHFFFAOYSA-N 0.000 description 2
- QDHHCQZDFGDHMP-UHFFFAOYSA-N monochloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- RFCQDOVPMUSZMN-UHFFFAOYSA-N naphthalene-2-thiol Chemical compound C1=CC=CC2=CC(S)=CC=C21 RFCQDOVPMUSZMN-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000003389 potentiating Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 230000000171 quenching Effects 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 239000003638 reducing agent Substances 0.000 description 2
- 230000001105 regulatory Effects 0.000 description 2
- 229910001961 silver nitrate Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000001187 sodium carbonate Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N t-BuOH Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- FGTJJHCZWOVVNH-UHFFFAOYSA-N tert-butyl-[tert-butyl(dimethyl)silyl]oxy-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)O[Si](C)(C)C(C)(C)C FGTJJHCZWOVVNH-UHFFFAOYSA-N 0.000 description 2
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 2
- 230000001732 thrombotic Effects 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- HKPUZZOQHBYMPZ-UHFFFAOYSA-N 1-$l^{1}-sulfanylpropane Chemical group CCC[S] HKPUZZOQHBYMPZ-UHFFFAOYSA-N 0.000 description 1
- SQAODFLQTZPERA-UHFFFAOYSA-N 1-[1-[[3-(1,3-benzothiazole-2-carbonyl)phenyl]methyl]-5-benzylsulfanyl-2-(naphthalen-2-ylsulfanylmethyl)indol-3-yl]ethanone Chemical compound C1=C2C(C(=O)C)=C(CSC=3C=C4C=CC=CC4=CC=3)N(CC=3C=C(C=CC=3)C(=O)C=3SC4=CC=CC=C4N=3)C2=CC=C1SCC1=CC=CC=C1 SQAODFLQTZPERA-UHFFFAOYSA-N 0.000 description 1
- SFOYQZYQTQDRIY-UHFFFAOYSA-N 1-chloro-3-iodopropane Chemical compound ClCCCI SFOYQZYQTQDRIY-UHFFFAOYSA-N 0.000 description 1
- VIGAGZWJPRGWLQ-UHFFFAOYSA-N 1-phenyl-2-phenylmethoxybenzene Chemical group C=1C=CC=CC=1COC1=CC=CC=C1C1=CC=CC=C1 VIGAGZWJPRGWLQ-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- TXQAZWIBPGKHOX-UHFFFAOYSA-N 1H-indol-3-amine Chemical compound C1=CC=C2C(N)=CNC2=C1 TXQAZWIBPGKHOX-UHFFFAOYSA-N 0.000 description 1
- ILWGYWSBUWKROZ-UHFFFAOYSA-M 1H-indole;bromide Chemical compound [Br-].C1=CC=C2NC=CC2=C1 ILWGYWSBUWKROZ-UHFFFAOYSA-M 0.000 description 1
- HXVNBWAKAOHACI-UHFFFAOYSA-N 2,4-Dimethyl-3-pentanone Chemical compound CC(C)C(=O)C(C)C HXVNBWAKAOHACI-UHFFFAOYSA-N 0.000 description 1
- BKOOMYPCSUNDGP-UHFFFAOYSA-N 2-Methyl-2-butene Chemical compound CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 description 1
- JWAZRIHNYRIHIV-UHFFFAOYSA-N 2-Naphthol Chemical compound C1=CC=CC2=CC(O)=CC=C21 JWAZRIHNYRIHIV-UHFFFAOYSA-N 0.000 description 1
- MONMFXREYOKQTI-UHFFFAOYSA-M 2-bromopropanoate Chemical compound CC(Br)C([O-])=O MONMFXREYOKQTI-UHFFFAOYSA-M 0.000 description 1
- QSKPIOLLBIHNAC-UHFFFAOYSA-N 2-chloro-acetaldehyde Chemical class ClCC=O QSKPIOLLBIHNAC-UHFFFAOYSA-N 0.000 description 1
- XCZKKZXWDBOGPA-UHFFFAOYSA-N 2-phenylbenzene-1,4-diol Chemical compound OC1=CC=C(O)C(C=2C=CC=CC=2)=C1 XCZKKZXWDBOGPA-UHFFFAOYSA-N 0.000 description 1
- ZMRFRBHYXOQLDK-UHFFFAOYSA-N 2-phenylethanethiol Chemical compound SCCC1=CC=CC=C1 ZMRFRBHYXOQLDK-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2H-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2H-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 description 1
- LCZDCKMQSBGXAH-AWEZNQCLSA-N 3-[[3-[(2S)-2-amino-2-carboxyethyl]-5-methyl-2,6-dioxopyrimidin-1-yl]methyl]-5-phenylthiophene-2-carboxylic acid Chemical compound O=C1C(C)=CN(C[C@H](N)C(O)=O)C(=O)N1CC1=C(C(O)=O)SC(C=2C=CC=CC=2)=C1 LCZDCKMQSBGXAH-AWEZNQCLSA-N 0.000 description 1
- DHXNZYCXMFBMHE-UHFFFAOYSA-M 3-bromopropanoate Chemical compound [O-]C(=O)CCBr DHXNZYCXMFBMHE-UHFFFAOYSA-M 0.000 description 1
- KWIVRAVCZJXOQC-UHFFFAOYSA-N 3H-oxathiazole Chemical compound N1SOC=C1 KWIVRAVCZJXOQC-UHFFFAOYSA-N 0.000 description 1
- CQQSQBRPAJSTFB-UHFFFAOYSA-M 4-(bromomethyl)benzoate Chemical compound [O-]C(=O)C1=CC=C(CBr)C=C1 CQQSQBRPAJSTFB-UHFFFAOYSA-M 0.000 description 1
- QOWSWEBLNVACCL-UHFFFAOYSA-N 4-Bromophenyl acetate Chemical compound OC(=O)CC1=CC=C(Br)C=C1 QOWSWEBLNVACCL-UHFFFAOYSA-N 0.000 description 1
- NQUVCRCCRXRJCK-UHFFFAOYSA-N 4-methylbenzoyl chloride Chemical compound CC1=CC=C(C(Cl)=O)C=C1 NQUVCRCCRXRJCK-UHFFFAOYSA-N 0.000 description 1
- LJFVSIDBFJPKLD-UHFFFAOYSA-N 4-phenylmethoxy-1H-indole Chemical compound C=1C=CC=2NC=CC=2C=1OCC1=CC=CC=C1 LJFVSIDBFJPKLD-UHFFFAOYSA-N 0.000 description 1
- GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 1
- QYNUQALWYRSVHF-ABLWVSNPSA-N 5,10-Methylenetetrahydrofolate Chemical compound C1N2C=3C(=O)NC(N)=NC=3NCC2CN1C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QYNUQALWYRSVHF-ABLWVSNPSA-N 0.000 description 1
- YZXBAPSDXZZRGB-IEJSZXIUSA-N 5,6,8,9,11,12,14,15-octadeuterioicosa-5,8,11,14-tetraenoic acid Chemical compound CCCCCC([2H])=C([2H])CC([2H])=C([2H])CC([2H])=C([2H])CC([2H])=C([2H])CCCC(O)=O YZXBAPSDXZZRGB-IEJSZXIUSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 210000001772 Blood Platelets Anatomy 0.000 description 1
- HIYAVKIYRIFSCZ-CVXKHCKVSA-N CALCIMYCIN Chemical compound CC([C@H]1OC2([C@@H](C[C@H]1C)C)O[C@H]([C@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-CVXKHCKVSA-N 0.000 description 1
- 101700050822 CKX1 Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229960001231 Choline Drugs 0.000 description 1
- 206010009887 Colitis Diseases 0.000 description 1
- XOVJAYNMQDTIJD-UHFFFAOYSA-N Cyclopentobarbital Chemical compound C1CC=CC1C1(CC=C)C(=O)NC(=O)NC1=O XOVJAYNMQDTIJD-UHFFFAOYSA-N 0.000 description 1
- 210000000172 Cytosol Anatomy 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 210000003743 Erythrocytes Anatomy 0.000 description 1
- 108050001049 Extracellular protein Proteins 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 101700038805 FTSH1 Proteins 0.000 description 1
- IRXSLJNXXZKURP-UHFFFAOYSA-N Fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 1
- 229940084362 Forane Drugs 0.000 description 1
- 108091006011 G proteins Proteins 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N GABA Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 102000030007 GTP-Binding Proteins Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 101700056286 HPGDS Proteins 0.000 description 1
- 102100020039 HPGDS Human genes 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N Indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 229960000905 Indomethacin Drugs 0.000 description 1
- 210000004969 Inflammatory Cells Anatomy 0.000 description 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- ULYZAYCEDJDHCC-UHFFFAOYSA-N Isopropyl chloride Chemical compound CC(C)Cl ULYZAYCEDJDHCC-UHFFFAOYSA-N 0.000 description 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N Isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N Isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N Isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 229960005375 Lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-NRHWGSPPSA-N Lutein Natural products O[C@H]1C=C(C)[C@H](/C=C/C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/C=2C(C)(C)C[C@H](O)CC=2C)\C)/C)\C)/C)C(C)(C)C1 KBPHJBAIARWVSC-NRHWGSPPSA-N 0.000 description 1
- 210000002540 Macrophages Anatomy 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N Methyl iodide Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 206010028549 Myeloid leukaemia Diseases 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N N,N-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- KRKPYFLIYNGWTE-UHFFFAOYSA-N N,O-Dimethylhydroxylamine Chemical compound CNOC KRKPYFLIYNGWTE-UHFFFAOYSA-N 0.000 description 1
- 210000000440 Neutrophils Anatomy 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 101710040931 PTGS1 Proteins 0.000 description 1
- 102100006335 PTGS1 Human genes 0.000 description 1
- 210000000496 Pancreas Anatomy 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000035443 Peptidases Human genes 0.000 description 1
- 108091005771 Peptidases Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N Phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- FEMRXDWBWXQOGV-UHFFFAOYSA-N Potassium amide Chemical compound [NH2-].[K+] FEMRXDWBWXQOGV-UHFFFAOYSA-N 0.000 description 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N Prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N Pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N Pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N Pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 241000219492 Quercus Species 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N Quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 210000003324 RBC Anatomy 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- 229940048181 SODIUM SULFIDE NONAHYDRATE Drugs 0.000 description 1
- VGTPCRGMBIAPIM-UHFFFAOYSA-M Sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 1
- 210000000952 Spleen Anatomy 0.000 description 1
- 210000001179 Synovial Fluid Anatomy 0.000 description 1
- AVFUHBJCUUTGCD-UHFFFAOYSA-M [Br-].[Mg+]C Chemical compound [Br-].[Mg+]C AVFUHBJCUUTGCD-UHFFFAOYSA-M 0.000 description 1
- XKCMTUMLHXMCMA-UHFFFAOYSA-N [NH-]S(O)(=O)=O Chemical compound [NH-]S(O)(=O)=O XKCMTUMLHXMCMA-UHFFFAOYSA-N 0.000 description 1
- UGAPHEBNTGUMBB-UHFFFAOYSA-N acetic acid;ethyl acetate Chemical compound CC(O)=O.CCOC(C)=O UGAPHEBNTGUMBB-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000004946 alkenylalkyl group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 150000001348 alkyl chlorides Chemical class 0.000 description 1
- 125000005038 alkynylalkyl group Chemical group 0.000 description 1
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 1
- 229920002892 amber Polymers 0.000 description 1
- 229960003692 aminobutyric acid Drugs 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000005418 aryl aryl group Chemical group 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000003659 bee venom Substances 0.000 description 1
- 229940095076 benzaldehyde Drugs 0.000 description 1
- KYNSBQPICQTCGU-UHFFFAOYSA-N benzopyran Chemical compound C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 229950011260 betanaphthol Drugs 0.000 description 1
- 230000037348 biosynthesis Effects 0.000 description 1
- 230000001851 biosynthetic Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- CVDGHGWEHQIJTE-UHFFFAOYSA-N bromo(bromomethoxy)methane Chemical compound BrCOCBr CVDGHGWEHQIJTE-UHFFFAOYSA-N 0.000 description 1
- WYXUZTXCGKPAEH-UHFFFAOYSA-N bromoethane;magnesium Chemical compound [Mg].CCBr WYXUZTXCGKPAEH-UHFFFAOYSA-N 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- AOGYCOYQMAVAFD-UHFFFAOYSA-M carbonochloridate Chemical class [O-]C(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-M 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- LKYXEULZVGJVTG-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH] LKYXEULZVGJVTG-UHFFFAOYSA-N 0.000 description 1
- CRBHXDCYXIISFC-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CC[O-] CRBHXDCYXIISFC-UHFFFAOYSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000001808 coupling Effects 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- JBDSSBMEKXHSJF-UHFFFAOYSA-M cyclopentanecarboxylate Chemical compound [O-]C(=O)C1CCCC1 JBDSSBMEKXHSJF-UHFFFAOYSA-M 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- OCXGTPDKNBIOTF-UHFFFAOYSA-N dibromo(triphenyl)-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1P(Br)(C=1C=CC=CC=1)(Br)C1=CC=CC=C1 OCXGTPDKNBIOTF-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000001079 digestive Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 108010067755 dinitrophenyl-bovine serum albumin Proteins 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000001605 fetal Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 101700029224 ftsH Proteins 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 230000003394 haemopoietic Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000003106 haloaryl group Chemical group 0.000 description 1
- 150000002390 heteroarenes Chemical class 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 229950007035 homocamfin Drugs 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 230000001771 impaired Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- YDNLNVZZTACNJX-UHFFFAOYSA-N isocyanatomethylbenzene Chemical compound O=C=NCC1=CC=CC=C1 YDNLNVZZTACNJX-UHFFFAOYSA-N 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M isothiocyanate Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 150000004715 keto acids Chemical class 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- OCZDCIYGECBNKL-UHFFFAOYSA-N lithium;alumanuide Chemical compound [Li+].[AlH4-] OCZDCIYGECBNKL-UHFFFAOYSA-N 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 230000002934 lysing Effects 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000006956 minimum essential medium Substances 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- LSNOAQQZECGQNS-UHFFFAOYSA-N morpholine-2-carboxamide Chemical compound NC(=O)C1CNCCO1 LSNOAQQZECGQNS-UHFFFAOYSA-N 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- HNHVTXYLRVGMHD-UHFFFAOYSA-N n-butyl isocyanate Chemical compound CCCCN=C=O HNHVTXYLRVGMHD-UHFFFAOYSA-N 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- 125000004957 naphthylene group Chemical group 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 239000004533 oil dispersion Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000001991 pathophysiological Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- IPWFJLQDVFKJDU-UHFFFAOYSA-N pentanamide Chemical compound CCCCC(N)=O IPWFJLQDVFKJDU-UHFFFAOYSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 101710005265 pgdP Proteins 0.000 description 1
- RLZZZVKAURTHCP-UHFFFAOYSA-N phenanthrene-3,4-diol Chemical compound C1=CC=C2C3=C(O)C(O)=CC=C3C=CC2=C1 RLZZZVKAURTHCP-UHFFFAOYSA-N 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001184 potassium carbonate Substances 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propanol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000006884 silylation reaction Methods 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- ZGHLCBJZQLNUAZ-UHFFFAOYSA-N sodium sulfide nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[S-2] ZGHLCBJZQLNUAZ-UHFFFAOYSA-N 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic Effects 0.000 description 1
- QEOUGFSILBVRCP-UHFFFAOYSA-N tert-butyl-dimethyl-[(5-phenylmethoxy-1H-indol-2-yl)methoxy]silane Chemical compound C=1C=C2NC(CO[Si](C)(C)C(C)(C)C)=CC2=CC=1OCC1=CC=CC=C1 QEOUGFSILBVRCP-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003511 tertiary amides Chemical class 0.000 description 1
- DPOPAJRDYZGTIR-UHFFFAOYSA-N tetrazine Chemical compound C1=CN=NN=N1 DPOPAJRDYZGTIR-UHFFFAOYSA-N 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- BBUQUBATODVRRV-UHFFFAOYSA-N triacetyloxyboron(1-) Chemical compound CC(=O)O[B-](OC(C)=O)OC(C)=O BBUQUBATODVRRV-UHFFFAOYSA-N 0.000 description 1
- KAKQVSNHTBLJCH-UHFFFAOYSA-N trifluoromethanesulfonimidic acid Chemical compound NS(=O)(=O)C(F)(F)F KAKQVSNHTBLJCH-UHFFFAOYSA-N 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 description 1
- 229960005332 zileuton Drugs 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
Abstract
Novel compounds are disclosed which inhibit the activity of phospholipase enzymes, particularly cytosolic phospholipase A2. Pharmaceutical compositions comprising such compounds and methods of treatment using such compositions are also disclosed.
Description
INHIBITORS OF FOSFOLIPASE ENZYMES
Field of Invention
The present invention relates to chemical inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A2 enzymes.
Background of the Invention
Leukotrienes and prostaglandins are important mediators of inflammation, each of whose classes contributes to the development of an inflammatory response in a different way. Leukotrienes collect inflammatory cells such as neutrophils at an inflamed site, promote the extravasation of these cells and stimulate the release of super oxide and proteases that damage the tissue. Leukotrienes also play a pathophysiological role in the hypersensitivity experienced by asthmatics [see for example, B. Samuelson et al., Science, 237: 1171-76 (987)]. Prostaglandins increase inflammation when
REF .: 122352 increase blood flow and therefore the infiltration of leukosites to inflamed sites. Prostaglandins also potentiate the pain response induced by stimuli.
Prostaglandins and leukotrienes are unstable and are not stored in cells but instead are synthesized [W.L. Smith, Biochem. J., 259: 315-324 (1989)] from arachidonic acid in response to stimuli. Prostaglandins are produced from arachidonic acid by the action of the COX-1 and COX-2 oaks. Arachidonic acid is also the substrate for a different pathway of enzymes that leads to the production of lucotides.
The arachidonic acid that is fed in these two different inflammatory trajectories is released from the sn-2 position of the membrane phospholipids by the phospholipase A2 enzymes (hereinafter PLA2). The reaction catalyzed by PLA2 is thought to represent the rate-limiting step in the process of lipid-mediated biosynthesis and the production of inflammatory prostaglandin and leukotrienes. When the phospholipid substrate of PLA2 is of the choline phosphotidyl class, with an ether ligation at the sn-1 position, the produced ipsophospholipid is the immediate precursor of the platelet activating factor (hereinafter referred to as PAF), another potent mediator of inflammation [SI asserman, Hospital Practice, 15: 9-58 (1988)].
The majority of anti-inflammatory therapies have focused on preventing the production of prostaglandins or leukotrienes from these different trajectories, but not in all of them. For example, ibuprofen, aspirin and indomethacin are all NSAIDs which inhibit the production of prostaglandin by COX-l / COX-2, but have no effect on the inflammatory production of leukotrienes from arachidonic acid in other pathways. Conversely, zileuton inhibits only the conversion path from arachidonic acid to leukotriene, without affecting the production of prostaglandin. None of these widely used anti-inflammatory agents affects the production of PAF.
Consequently direct inhibition of PLA2 activity has been suggested as a useful mechanism for a therapeutic agent, that is, to interfere with the inflammatory response, [see for example J. Chang et al, Biochem. Pharmacol., 36: 2429-2436 (1987)]. A family of enzymes of PLA2, characterized by the presence of a sequenced secretion signal and finally secreted from the cell, has been sequenced and structurally defined. These secreted PLA2 have a molecular weight of approximately 14kD and contain seven disulfide bonds that are necessary for activity these PLA2 are found in large quantities in the pancreas of 20 mammals, bee venom, and in various snake venoms. [see for example references 13-15 in Chang at al. Quoted above, and E.A. Dennis, Drug Devel. Res., 10: 205-220 (1987)]. However, the pancreatic enzyme is believed to be useful for a function
^ at ^^^ t ^,. . ,,, », ... .., ,,, ._ > ___, _, _, "w, t ,, A ^ Jto" ^ .. ",. "" "", ..., A "1, - ^ ^., Digestive and that as such should not and as such should not be important in the production of inflammatory mediators whose production should be strongly regulated.
The primary structure of the first non-pancreatic human PLA2 has been determined. This non-pancreatic PLA2 is found in platelets, the synovial fluid, and the spleen and is also a segregated enzyme. This enzyme is a member of the family mentioned above [see for example J.J. Seilhamer et al., J. Biol. Chem., 264: 5335-5338 (1989); R. M. Kramer et al. J. Biol. Chem; 264: 5768-5775 (1989); and A. Kando et al, Biochem. Biophis. Res. Comm., 163: 42-48 (1989)]. However, it is doubtful that this enzyme is important in the synthesis of prostaglandin, leukotrienes and PAF, since non-pancreatic PLA2 is an extra cellular protein that would be difficult to regulate, and the following enzymes in the biosynthetic path for these compounds are intracellular proteins. Furthermore, there is evidence that PLA2 is regulated by the protein kinase C and the G proteins [R. Burch and J. Axelrod, Proc. Nati Acad. Sci. U.S.A., 84: 6374-6378 (1989)] which are cytosolic proteins that must act on intracellular proteins. It would be impossible for non-pancreatic PLA2 to function in the cytosol since the high reduction potential would reduce disulfide bonds and inactivate the enzyme.
A murine PLA has been identified in the murine macrophage cell line designated RA 264.7. A specific activity of 2mol s / min / mg, resistant to reducing conditions, was reported to be associated with the approximately 60kD molecule. However, this protein is not purified until homogeneous. [see, C.C.Leslie et al, Biochem. Biophis. Acta., 963: 476-492 (1988)]. The references cited above are incorporated herein by reference for information regarding the function of phospholipase enzymes, particularly PLA.
A cytosolic phospholipase A2 (hereinafter "c PLA2") has also been identified and cloned. See U.S. Patent Nos. 5,322,776 and 5,354,677, which are incorporated herein by reference as if they were fully established. The enzyme of these patents is an intracellular enzyme PLA2, purified from its natural source or otherwise produced in purified form, which functions intially to produce arachidonic acid in response to inflammatory stimuli.
Now that various phospholipase enzymes have been identified, it would be desirable to identify chemical inhibitors of the action of enzymes, whose inhibitors can be used to treat inflammatory conditions, particularly where the inhibition of the production of prostaglandins, leukotrienes and PAFs are all desired results. . There remains a need in the art for the identification of such anti-inflammatory agents for therapeutic use in a variety of disease states.
Description of the invention
The compounds of this invention have the following formulas
where
Ri and Ri are independently selected from H, halogen, CF3, -OH, -C1-C10 alkyl-, preferably C1-Cd alkyl, -S-C1-C10 alkyl, preferably -SC-C6 alkyl, C1-C10 alkoxy , preferably C 1 -C 6 alkoxy, phenyl -CN, -N 0 2 NH 2, -HN (CX-C 6), -N (C 6 -C 6) 2, phenyl -O-, phenyl -S-, benzyl, benzyl -O- , benzyl -S-, or a portion of the formulas:
R6 is selected from H, CX-C6 alkyl, C6-C6 alkoxy, phenyl, phenyl-O-, benzyl, benzyl-O-, phenyl and benzyl rings, of these groups being optionally substituted by from 1 to 3 selected substituents of .halogen, C? -C6 alkyl, alkoxy, C? -C6, -N02, NH2, -CN, -CF3, or -OH;
R7 is selected from -OH, alkyl -CF3, C? -C6, C? -C6 alkoxy, -NH- (C? -C6 alkyl), -N- (Cx-C6 alkyl) 2, pyridinyl, tiethyl, furyl, pyrrolyl, phenyl, phenyl -0-, benzyl, benzyl -0-, the rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, -CN, C? -C6 alkyl, C? -C6 alkoxy, - N02, -NH2, -CF3, or OH;
R 2 is selected from H, halogen, -CF 3, -OH, C 1 -C 10 alkyl, preferably C 1 -C 6 alkyl, C 1 -C 10 alkoxy, preferably Ci-Cβ alkoxy, -CHO, -CN, -N02, alkyl- NH2, -NH-C? -C6, N (CX-C6 alkyl) 2, -NS02-Cx-C6 alkyl, or -S02-C? -C6 alkyl;
R3 is selected from H, -CF3, C? -C6 lower alkyl, C? -C6 lower alkoxy, C3-C10 cycloalkyl, C3-C10 cycloalkylCi-Ce alkyl, -CHO, halogen, or a portion of the formula -L -M2:
L2 indicates a linking or linking group of the formulas - (CH2) n-, -S-, -O-. -C (O) -, - (CH2) nC (O) -, - (CH2) nC (O) - (CH2) n-, - (CH2) n-0- (CH2) n-, or - (CH2) ) nS- (CH2) "-, -C (O) C (0) X; where X = 0, N
More is selected from the group of lower alkyl C? -C6, lower alkoxy C? -C6, cycloalkyl C3? -C10, phenyl or benzyl, the cycloalkyl, phenyl or benzyl rings being optionally substituted by from 1 to 3 substituents selected from halogen , Ci-Cio alkyl, preferably C 1 -C 3 alkyl, C 1 -C 6 alkoxy, preferably C 1 -C 6 alkoxy, -N 0 2, -NH 2, -CN, or -CF 3; or
a) a five-membered heterocyclic ring containing one or two rings of heteroatoms selected from N, S or 0 including, but not limited to, furan, pyrrolo, thiophene, imidazole, pyrazole, pyrrolidine, or tetrazole, the heterocyclic ring of five members being optionally substituted by from 1 to 3 substituents selected from halogen, i-Cio alkyl, preferably, C?-C6 alkyl, C alcoC alco alkoxy, preferably Ci-Cd alkoxy, -N02, -NH2, -CN , 15 or -CF3; or
b) a six-membered heterocyclic ring containing one, two or three rings of heteroatoms selected from N, S or O including, but not limited to, pyridine, pyrimidine, piperidine, piperazine, or morpholine, the six-membered heterocyclic rings optionally being substituted by from 1 to 3 substituents selected from halogen, Ci-Cio alkyl, preferably
* ^^ s ^ iB-§ «-a - a - j6i- ¿aa ^ -gki '..- fa i - *« *, &;, .i * * ** *. . . *** *? £ * - - - J "'" - "- * - * --- * - * • * * - **. ... -. F - Ufe ugly, **!.
alkyl d-C6, C1-C10 alkoxy, preferably C6-C6 alkoxy, -CHO, N02, -NH2, -CN, -CF3 or OH; or
c) a bicyclic ring portion containing from 8 to 10 atoms in the ring and optionally containing from 1 to 3 ring heteroatoms selected from N, S or 0 including, but not limited to, benzofuran, indole, indoline, naphthalene , purine, or quinoline, the bicyclic ring portion being optionally substituted by from 1 to 3 substituents selected from halogen, Ci-Cio alkyl, preferably Ci-Ce alkyl, Cx-C? alkoxy, preferably Ci-Cß alkoxy, -CHO , N02, -NH, -CN, -CF3 or OH; or
n is an integer from 0 to 3;
R4 is selected from the group of lower alkyl C6-6, lower alkoxy C6-6, cycloalkyl- (CH2) n- C3-C6, cycloalkyl- (CH2) nS- (CH2) n-C3-C5, cycloalkyl- ( CH2) n-0- (CH2) n-C3-C5, or of the groups of:
^ A t jii- a) - (CH2) n-phenyl-O-phenyl, - (CH2) n-pheny1-CH2-phenyl, - (CH2) n-0-pheny1-CH2-pheny1, - ( CH2) n-pheni 1 - (0-CH2-phenyl) 2, - (CH:) n ~ phenyl 1 - (0-CH: - phenyl 1) 2, -CH: - phenyl-C (O) -benzothiazole or a portion of the formulas:
wherein n is an integer, from 0 to 3, preferably from 1 to 3, more preferably 1 to 2, Y is C3-C5 cycloalkyl, phenyl,
Benzyl, naphthyl, pyridinyl, quinolyl, furyl, thianyl or pyrrolyl; the rings of these groups being optionally substituted by from 1 to 3 substituents selected from H, halogen, -CF3, -OH, C? -C6 alkyl, C? -C6 alkoxy, -NH.sub.2, -N02, or a heterocyclic ring of five members containing a heteroatom selected from n, s, or 0, preferably S or 0; or
b) a portion of the formulas - (CH2) n-A, (CH2) n-S-A, or - (CH2) n-0-A, where A is the portion:
where
D is H, C? -C6 lower alkyl, Cx-C6 lower alkoxy, or -CF3;
B and C are independently selected from phenyl, pyrinyl, furyl, thienyl or pyrrolyl groups, each optionally substituted by from 1 to 3, preferably 1 to 2, substituents selected from H, halogen -CF3, -OH, alkyl -C? -C6, C6-C6 alkoxy, or -N02; or
c) a portion of the formulas
wherein Z is 0 or S and the phenyl and pyrimidyl rings of each portion are optionally and independently from 1 to 3 substituents selected from halogen, -CF3, -OH, C?-C6 alkyl, C?-C6 alkoxy, -NH2 , or -N02;
^ ^^^^^^ jg * g «j ^ gffl &to * R5 is selected from -COOH, -C (0) -COOH, (CH2) nC (0) -COOH, - (CH2) n -COOH, -CH = CH-COOH, (CH2) n-tetrazole.
or a selected portion of the formulas -L -M;
wherein L1 is a binding or binding portion selected from a chemical bond, - (CH2) n-, -S-, - 0-, -C (0) -, - (CH2) nC (0), - (CH2 ) nC (0) - (CH2) n, - (CH2) n-0-10 (CH2) n, - (CH.) "- S- (CH2), -C (Z) -N (R6) -, -C (0) -C (Z) - N (R6) - (CH2) n, -C (Z) -NH-S02-, or -C (Z) -NH-S02- (CH2) n,
x is selected from the group of -COOH, - (CH2) n- C00H, - (CH2) n-C (0) -COOH, tetrazole,
V. ^^^^^
where R8, R9 or Ri0 can be linked anywhere in the cyclic or bicyclic system,
R8, in each presentation, is independently selected from H, -COOH, - (CH2) n-C00H, - (CH2) n-C (0) -COOH, tetrazole,
* »T? ^ ". . £ &
R9 is selected from H, halogen, -CF3, -OH, COOH, - (CH2) n -COOH, - (CH2) nC (0) -COOH, alkyl -C? -C6, alkyl -0-C? -Ce , alkyl -NH (Ci-Cß alkyl), or -N (C?-C6 alkyl) 2;
Rio is selected from the group of H, halogen,
CF3, -OH, - (CH2) n -COOH, - (CH2) nC (O) -COOH, alkyl -C? -C6, alkyl -0-C? -C6, alkyl -NH (C? -C6 alkyl) , N (C? -C6 alkyl) z,
. N, "(lower alkyl C-C)
lower alkyl C-C '
Rn is selected from H, lower alkyl Ci-Cβ, cycloalkyl C? -C6, "CF3, -OH, -COOH, - (CH2) n -COOH, - (CH2) n-C (O) -COOH,
,. x A ^ + ^^^^^^^^^ j ^ «£ ^ ífejÍ * with the proviso that the full portion in position 1 of indole or indolina created by any combination of R5, R ?, Ro, Rio» / Ru may contain at least one acid portion selected from or containing a carboxylic acid, a tetrazole, or a portion of the formulas:
n is an integer from 0 to 3;
or a pharmaceutically acceptable salt of the same.
It will be understood that in the above group that the substituents R3 and R are linked to the indol or indoline rings in the 2 or 3 position the Ri, Ri and R2 groups are bonded to one of the carbon atoms at positions 4-5. -, 6-, or 7- of the indol or indoline rings.
A group of compounds within this invention are those in which Ri- and R3 are hydrogen, and the substituents in the other indole or indoline positions are as described above.
Another group invention comprises compounds in which Ri and R3 are hydrogen and the groups Ri, R4 and R5 are as defined above. Within this group there are two additional preferred groups. In the first Ri is in the 5 position in indole or indoline and in the second Ri is in the position 6 in indole or indoline.
In a further preferred group here, Ri is in the 5-position in indole or indoline and is benzyloxy, R and R4 are hydrogen and R3 and R5 are as defined above.
In another preferred group of this invention Ri is in the 5 or 6 position in the indole or indoline and is cyclopentylcarboxamide or cyclopentylcarboxylate, R2 and R4 are hydrogen, and R3 and R5 are as defined above.
- * • *. «...,» - - ^. . ... ^ ttg ^, ^ A preferred group of this invention consists of Ri and R2 at position 5 and / or 6 of the indole or indoline and each is selected from the group consisting of alkoxy Ci-Ce, cyano, sulfonyl and halo, R2 and R4 are hydrogen, and R5 and R5 are as defined above.
It will also be understood that these are additional preferred subgroups within each of the groups placed herein wherein the molecular core is an indole moiety, rather than an indoline. It will also be understood that this is a second group within each wherein the molecular core is an indoline moiety.
Preferred compounds of this invention include those of the following formulas:
; ... - * ti i? «& > & «< * - »« - where Ri is selected from H. halogen, -CF3, -OH, C? -C6 alkyl, C: -C6 alkoxy, -N0;, -HN (dC €), N (C? -C6 ) 2 »phenyl, phenyl-O-, benzyl, benzyl-O-, or a portion of the formulas:
R6 is selected from H, Ci-Cß alkyl, Ci-Cß alkoxy, phenyl, -O-phenyl, benzyl, benzyl-O-, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from Ci-Cg alkyl, C6-C6 alkoxy, -NH2, -N02, -CF3, or -OH;
R7 is selected from - (CH2) n -COOH, - (CH2) nN- (C6-C6 alkyl) 2, - (CH2) n-NH- (C6-C6 alkyl), -CF3, C-alkyl? -C6, C3-C5 cycloalkyl, C? -C6 alkoxy, NH- (C? -C6 alkyl), -N- (C? -C6 alkyl) 2, pyridyl, thienyl, furyl pyrrolyl, phenyl, phenyl-O-, benzyl, benzyl-O-, adamantyl or morpholinyl, the rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, Ci-Cd alkyl, C6-C6 alkoxy, -NH2, -N02, -CF3, or -OH;
R is selected from H, halogen, -CF 3, -OH, C 1 -C 10 alkyl, preferably C 1 -C 6 alkyl, C 1 -C 10 alkoxy, preferably C 1 -C 6 alkoxy, -CHO, -CN, NO 2, -NH 2, - NH-Alkyl-Ci-Ce, N (C? -C6 alkyl) :, N-S02-alkyl- (CH2) n-0-phenyl-CH2-phenyl, or -S02-C? -C6 alkyl;
R3 is selected from the group of lower alkyl C? -C6, lower alkoxy C? -C6, - (CH2) n-cycloalkyl C3-C6, - (CH2) nS-- (CH2) n- C3-C6 cycloalkyl, or groups of: a) - (CH2) n-phenyl-0-phenyl, - (CH2) n-pheni 1-CH2-phenyl, - (CH2) nf-enyl- (0-CH2-f-enyl) 2, -CH- phenyl-C (O) -benzothiazole or a portion of the formulas:
^ (CH2) n ^ ^ (CH2?. (CH2W (CH2
wherein n is an integer from 0 to 3, preferably 1 to 3, more preferably 1 to 2, Y is C3-C6 alkyl, phenyl, benzyl, naphthyl, pyridinyl, quinolyl, furyl, thienyl, or pyrrolyl; the rings of these groups being optionally substituted by from 1 to 3 substituents selected from H, halogen, -CF3, -OH, C? -C6 alkyl, Cx-C6 alkoxy, -NH2, -N02, or 5-membered heterocyclic ring, containing a heteroatom selected from N, S, or O, preferably, S or O; or
b) a portion of the formulas - (CH2) n-A, (CH2) n-S-A, or - (CH2) n-0-A, where A is the portion:
where
D is H, C? -C6 lower alkyl, C? -C6 lower alkoxy, or -CF3;
B and C are independently selected from the phenyl, pyridinyl, furyl, thienyl or pyrrolyl groups, each optionally substituted by from 1 to 3, preferably 1 to 2, substituents selected from H, halogen -CF3, -OH, alkyl -C i -Ce, C 1-6 alkoxy, or -N02; or
c) a portion of the formulas
wherein the phenyl and pyrimidyl rings of each portion are optionally and independently from 1 to 3 substituents selected from halogen, -CF 3, -OH, C 1 -C 6 alkoxy C 6 -C 6 alkyl, -NH 2, or -N 0 2;
R 4 is selected from H, halogen, -Cf 3, -OH, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, benzyl, benzyloxy, phenyl, phenyloxy, -C (O) -phenyl, -C (O) -benzyl,
CH2- (C3-C6 cycloalkyl), -C (0) -OH, -CH = 0,
-C (O) -alkyl C? -C6, -C (O) -O-C? -C6 alkyl, -C (O) -CF3, - (CH) n-S-CH2- (C3-C6 cycloalkyl),
the phenyl and benzyl rings of the relevant groups R3 being optionally substituted by from 1 to 3 groups selected from halogen, Ci-Ce alkyl, Ci-Cβ alkoxy, -N02, -CF3, -C (0) -0H, or -OH;
n is an integer from 0 to 3; R5 is selected from -COOH, -C (0) -COOH, CH2) n-C (O) -COOH, - (CH2) n -COOH, -CH = CH-COOH,
fifteen
R8 is independently selected from H, halogen, -COOH, - (CH2) n -COOH, - (CH2) n-C (O) -COOH, tetrazole,
R9 is selected from H, halogen, -CF3, -OH, - (CH2) n -COOH, - (CH2) nC (O) -COOH, alkyl -C? -C6, alkyl -0-C? -C6, alkyl -NH (C? -C6 alkyl), or -N ('C6-C6 alkyl) 2;
The Rio is selected from the group of H, halogen, CF3, -OH, - (CH2) n -COOH, - (CH2) nC (O) -COOH, alkylC-C6, alkyl -0 -C? -C6, alkyl -NH (C? -C6 alkyl), N (C? -C6 alkyl) z,
lower C] -Cg);
Rn is selected from H, lower alkyl Ci-Ce, -CF3, -COOH, - (CH2) n -COOH, - (CH2) n-C (O) -COOH, or
^^^^^^^^ 2g ^ * iflj £ ¡^^ with the proviso that the complete portion in position 1 of indole or indoline created by any combination of R5, R8,? , Rio / y or Rn may contain at least one acid portion selected from or containing a carboxylic acid, a tetrazole, or a portion of the formulas:
or a pharmaceutically acceptable salt thereof.
Preferred compounds of this invention include those of the following formulas:
. * t 2 &8 M & amp; amp; amp; amp;, Ri is selected from H, halogen, -CF3, -OH, C? -C6 alkyl, C? -C6 alkoxy, -N02, -HN2, phenyl, phenyl-O- , benzyl, benzyl-O-, or a portion of the formulas:
R6 is selected from H, C? -C6 alkyl, C? -C6 alkoxy, phenyl, -O-phenyl, benzyl, benzyl-O-, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 selected substituents of halogen, CX-C6 alkyl, C6-C6 alkoxy, -N02, -CF3, or -OH;
R7 is selected from - (CH2) n -COOH, - (CH2) nN- (C6-C6 alkyl) :, - (CH2) p-NH- (at C 1 -C 6), -CF, C alkyl ? -C6, C3-C5 cycloalkyl, C? -C6 alkoxy, NH- (C? -C6 alkyl), -N- (C? -C6 alkyl) 2, pyridinyl, thienyl, furyl, pyrrolyl, phenyl, phenyl-O -, benzyl, benzyl-O-, adamantyl or morpholinyl, pyridyl, phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C? -C6 alkyl, C? -C6 alkoxy, -N02 , -CF3, or -OH;
R 2 is selected from H, halogen, -CF 3, -OH, Ci-Cι alkyl, preferably C 1 -C 6 alkyl, Ci-Cι alkoxy, preferably C 1 -C 6 alkoxy, -CHO, -CN, NO 2, -NH 2, - NH-alkyl-Ci-Ce, N (C-C6-alkyl) 2, N-S02-C-C6-alkyl, -S02-C-C6-alkyl;
R 3 is selected from H, halogen, -CF 3, -OH, d-C 6 alkyl, C 1 -Cg alkoxy, benzyl, benzyloxy, phenyl, phenyloxy, -C (O) -phenyl, -C (O) -benzyl, CH 2 - (C3-C5 cycloalkyl), -C (0) -OH, -CH = 0, -C (O) -Calkyl-C6, -C (O) -O-C? -C6 alkyl, - C (0) -CF3, - (CH2) nS-CH2- (C? -Calkyl C3-C5),
the phenyl and benzyl rings of the relevant groups R3 being optionally substituted by from 1 to 3 groups selected from halogen, C? -C6 alkyl, C? -C6 alkoxy, -N02, -CF3, -C0 (0) -0H, or -OH;
n is an integer from 0 to 3;
R4 is selected from the groups of lower alkyl Ci-Ce, lower alkoxy d-C6, - (CH2) n-cycloalkyl C3-C5, - (CH2) nS- (CH2) n-cycloalkyl C3-C5, - ( CH2) n-0- (CH2) n-cycloalkyl d-C6, or the groups of:
a) - (CH2) nf -enyl-O-phenyl, - (CH2) n-phenyl-1-CH2-phenyl, - (CH2) n-0-pheny1-CH2-pheny1, - (CH2) n-phenyl- (0-CH: -phenyl) 2, - (CH 2) n -pheni 1- (0-CH 2 -pheni 1) 2, -CH 2 -phen 1-C (0) -benzothiazole or a portion of the formula s:
wherein n is an integer from 0 to 3, preferably 1 to 3, more preferably 1 to 2, Y is C3-C6 alkyl, phenyl, benzyl, naphthyl, pyridinyl, qumolyl, furyl, thienyl, or pyrrolyl; the rings of these groups are optionally substituted by from 1 to 3 substituents selected from H, halogen, -CF3, -OH, C? -C3 alkyl, C? -C6 alkoxy, -N02, or 5 membered heterocyclic ring, containing a heteroatom selected from N, S, or O, preferably, S or O; or
b) a portion of the formulas - (CH2) n-A, (CH;) n-S-A, or - (CH2) n-0-A, where A is the portion:
where
D is H, lower alkyl Ci-Ce, lower alkoxy d-C6, or -CF3,
B and C are independently selected from the phenyl, pyridinyl, furyl, thienyl or pyrrolyl groups, each optionally substituted by from 1 to 3, preferably 1 to 2, substituents selected from H, halogen -CF3, -OH, alkyl -C? ~ C6, alkoxy C? -C6, or -N02; or
a portion of the formulas
«» »&». < & ** > - », •% ie a & He ^ J ^ ^ ^ ^ ^, -
wherein Z is 0 or S and the phenyl and pyrimidyl rings of each portion are optionally and independently from 1 to 3 substituents selected from halogen, -CF3, -OH, C? -C6 alkyl, C? -C6 alkoxy, or -N02;
& ', R5 is selected from -COOH, -C (0) -COOH, (CH2) n-C (O) -COOH, - (CH2) n -COOH, -CH = CH-COOH,
. ^ -Ate ^ te ^
R8 is independently selected from H, COOH, - (CH2) n -COOH, - (CH2) n-C (0) -COOH, tetrazole,
Rg is selected from H, halogen, -CF3, -OH,
- (CH2) n -COOH, - (CH2) nC (0) -COOH, -D-C6 alkyl, -OC-C6 alkyl, -NH (C6-C6 alkyl), or -N (C-alkyl) ? -C6) 2;
Rio is selected from the group of H, halogen, -CF3, -OH, - (CH2) n-C00H, - (CH2) nC (O) -COOH, alkyl -C? -C6, alkyl -0-C? -C6 , alkyl-NH (C 6 alkyl), N (d 6 alkyl) z,
lower C -C),
R n is selected from H, C 1 -C 6 lower alkyl, -CF 3, -COOH, - (CH 2) n -COOH, - (CH 2) n-C (O) -COOH, or
with the proviso that the full portion in position 1 of indole or indoline created by any combination of R5, R8, R9, Rio? and / or Rn may contain at least one acid portion selected from or containing a carboxylic acid, a tetrazole, or a portion of the formula s:
or a pharmaceutically acceptable salt thereof
A group of compounds within this invention are those in which (R3) is in the 3-position is substituted only by hydrogen, and the substituents in the other indole or indoline positions are as described above.
Another group of this invention comprises compounds in which R2 are hydrogen and the groups Ri, R3, and R5 are as defined above. Within this group there are two additional preferred groups. In the first Ri is in position 5 in indole or indoline and in the second Ri is in position 6 in indole or indoline.
In a further preferred group here, Ri is in the 5-position in indole or indoline and is benzyloxy, R2 and are hydrogen and R3 and R5 are as defined above.
It will also be understood that these are additional preferred subgroups within each of the groups placed herein wherein the molecular core is an indole moiety, rather than an indoline. It will also be understood that this is a second group within each wherein the molecular core is an indoline moiety.
Another subset of compounds of this invention have the following formulas:
wherein Ri is selected from H. halogen, -CF, -OH, C? -C6 alkyl, alkoxy dC?, -N02, -HN2, phenyl, phenyl-O-, benzyl, benzyl-O-, or a portion of The formulas :
f? 6 R7
R6 is selected from H, C1-6alkyl, C6-C6alkoxy, phenyl, phenyl-O-, benzyl, benzyl-O-, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from alkyl C? -C6, C? -C6 alkoxy, -N02, -CF3, or -OH;
R7 is selected from - (CH2) n -COOH, - (CH2) nN- (C6-C6 alkyl) :, - (CH2) n-NH- (C6-C6 alkyl), "CF3, C-alkyl? ~ C6, C3-C5 cycloalkyl, C1- alkoxy, NH- (C6 alkyl), -N- (C1-C6 alkyl), pyridyl, thienyl, furyl pyrrolyl, phenyl, phenyl-O-, benzyl, benzyl- O-, adamantyl or morpholinyl, the pyridinyl, phenyl and benzyl rings of these 5 groups being optionally substituted by from 1 to 3 substituents selected from halogen, Ci-d alkyl, C? -C6 alkoxy, -N02, -CF3, or - OH;
R2 is selected from H, halogen, -CF3, -OH, Ci-Cio alkyl, preferably Ci-d alkyl, Ci-Cio alkoxy, preferably C6-C6 alkoxy, -CHO, -CN, N02, -NH2, - NH-C 1 -C 6 alkyl, N (C 6 -C 6 alkyl), N-S 0 2 -alkyl- (CH 2) n-0-phenyl-CH 2 -phen 1, o-15 S0 2-C 1 -C 6 alkyl;
R3 is selected from the group of lower alkyl Ci-Cβ, lower alkoxy C? -Cd, - (CH2) n- C3-C6 cycloalkyl, - (CH2) n-S-- (CH2) n- C3-C6 cycloalkyl, or
groups of:
a) - (CH2) n-phenyl-0-phenyl, - (CH2) n-pheni 1 -CH2-phenyl, - (CH: r.-Of enyl, - (CH2) n- (0-CH2 phenyl) 2, CH 2 -pheni 1-C (O) -benzothiazole or a portion of the
formulas:
wherein n is an integer from 0 to 3, preferably 1 to 3, more preferably 1 to 2, Y is cyclo alkyl d-, phenyl benzyl, naphthyl, pyridinyl, quinolyl, furyl, thienyl, or pyrrolyl; the rings of these groups are optionally substituted by from 1 to 3 substituents selected from H, halogen, -CF3, -OH, C? -C6 alkyl, Ci-Ce alkoxy, -N02, or a 5-membered heterocyclic ring, containing a heteroatom selected from N, S, or O, preferably, S or O; or
b) a portion of the formulas - (CH2) n-A, (CH2) n-S-A, or - (CH2) n-0-A, where A is the portion:
wherein D is H, C 1 -C 6 lower alkyl, Ci-C 6 lower alkoxy, or -CF 3;
B and C are independently selected from the phenyl, pyridinyl, furyl, thienyl or pyrrolyl groups, each optionally substituted by from 1 to 3, preferably 1 to 2, substituents selected from H, halogen -CF3, -OH, alkyl -Ci- CO, Ci-C6 alkoxy or -N02; or
c) a portion of the formulas:
wherein Z is 0 or S and the phenyl and pyrimidyl rings of each portion are optionally and independently from 1 to 3 substituents selected from halogen, -CF3, -OH, Ci-C6 alkyl, C6-C6 alkoxy, or -N02, -NH2;
R 4 is selected from H, halogen, -CF 3, -OH, C 1 -C 6 alkyl, dd alkoxy, benzyl, benzyloxy, phenyl, phenyloxy, -C (0) -phenyl, -C (0) -benzyl, CH 2 - (C3-C6 cycloalkyl), -C (0) -OH, -CH = 0, -C (O) -alkyl C? -C6, -C (O) -O-C alkyl? - C 6, -C (O) -CF 3, - (CH 2) n-S-CH 2 - (C 3 -C 6 cycloalkyl),
the phenyl and benzyl rings of the relevant groups R3 being optionally substituted by from 1 to 3 groups selected from halogen, d-C6 alkyl, C6-C6 alkoxy, -N02, -CF3, -CO (O) -OH, or - OH;
n is an integer from 0 to 3;
R5 is selected from -COOH, -C (0) -COOH, (CH2) n-C (O) -COOH, - (CH2) n -COOH, -CH = CH-COOH,
- ^ ut * ^ s ^ JS ^ .- * ^^ -, or R8, is selected from H, -COOH, - (CH2) n -COOH, (CH2) n-C (O) -COOH, tetrazole,
-
Rg is selected from H, halogen, -CF3, -OH, (CH2) n -COOH, - (CH2) nC (O) -COOH, -d-C-alkyl, -0-C-C6 alkyl, -NH ( C 1 -C 6 alkyl), or -N (ci-c 6 alkyl) 2;
Rio is selected from the group of H, halogen,
CF3, -OH, - (CH2) n-COOH, - (CH2) nC (O) -COOH, -C1-C6 alkyl, -0-C-C6 alkyl, -NH (C6-C6 alkyl), N (C? -C6 alkyl) 2,
i or lower C.-C-);
Rn is selected from H, lower alkyl C? ~ D, -CF3, -COOH, - (CH2) n -COOH, - (CH2) n-C (0) -COOH, or
with the proviso that the entire portion at position 1 created by any combination of R5, Re, R9, Rio »and or Rn may contain at least one acid portion selected from or containing a carboxylic acid, a tetrazole, or a portion of the formulas:
. . 1
or a pharmaceutically acceptable salt thereof.
Among the additionally preferred compounds of this invention are those having the formulas:
wherein Ri is selected from -HN2, phenyl, phenyl-O-, benzyl, benzyl-O-, -N-benzyl, -N-benzyl-O-phenyl, -S-benzyl or a portion of the formulas:
R6 is selected from H, C? -C6 alkyl, C? -C6 alkoxy, phenyl, phenyl-O-, benzyl, benzyl-O-, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 selected substituents of C? -C6 alkyl, C? -C6 alkoxy, -N02, -CF3, or -OH;
R7 is selected from - (CH2) n -COOH, - (CH2) nN- (d-C6 alkyl) 2, - (CH2) n-NH- (C 1 -C 6 alkyl), -CF 3, C 1 alkyl- C6, C3-C5 cycloalkyl, C6-C6 alkoxy, -NH- (C6-C6 alkyl), -N- (C6-C6 alkyl) 2, pyridyl, thienyl, furyl pyrrolyl, phenyl, phenyl-O-, benzyl, benzyl-O-, adamantyl or morpholinyl, the rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C? -C6 alkyl, d-C6 alkoxy,? N02, -CF3, or -OH;
n is an integer from 0 to 3;
R 3 is selected from halogen, C 1-4 alkyl, C? -C6 alkoxy, -CF3, -CH = 0, -C (O) -C? -C6 alkyl, -C (0) -0- C? -C6 alkyl, - C (0) -OH, -C (0) -CF3, -C (O) -phenyl, -C (O) -benzyl, -C (O) -pyrrolyl, -C (O) -thienyl, -C (O) -furanyl, or -C (0) -moefolinyl;
R4 is selected from the group of, - (CH2) n- (cycloalkyl d-), - (CH2) nS- (CH2) n- (cycloalkyl C3-C6), - (CH2) n-0- (CH2) n - (C3-C6 cycloalkyl), (CH2) nS- C6-C6 alkyl, the groups of:
. " . . «* -» -. . * "*,. - * ». "-. _a-A - «-. j. ~ *. ,, - > -t, - ^ -a -a «ate ^ & -» a) -C (O) -O- (CH2) n-cycloalkyl, - (CH2) n-phenyl, - (CH2) nO-phenyl, - ( CH2) nS-phenyle, - (CH2) nS- (CH2) n-phenyl, - (CH2) n-phenyl-O-phenyle, - (CH2) n-phenyl-CH2-f enyl, - (CH2) n-0- phenyi-CH2-phenylo, (CH2) n-phenyl- (0-CH2-phenyl) 2, -C (O) -O- phenyle,
C (0) -O-benzyl, -C (0) -0-p? Rdidyl, -C (0) -0-naphthyl, - (CH2) nS-naphthyl, - (CH2) nS-pi r idini lo , - (CH2) n-pyridinyl, or - (CH2) n-na ft i lo, - (CH2) n-0-naphthyl, the phenyl, pyridinyl, and naphthyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from H, halogen, -CF3, -OH, C alquilo-d alkyl, Ci-Cd alkoxy, -N02, or a ring containing five heterocyclic heteroatom members, selected from N, S, or 0, preferably S, or 0; or
b) a portion of the formulas - (CH2) n_A, (CH2) n-S-A, or - (CH2) n-0-A, where A is the portion:
wherein D is H, C 1 -C 6 lower alkyl, C 6 -C 6 alkoxy,
• CF 3 '
R5 is selected from -COOH, -C (0) -COOH, (CH2) n-C (O) -COOH, - (CH2) n -COOH, -CH = CH-COOH,
, 0
R8 is selected from H, -COOH, - (CH2) n -COOH, (CH2) n-C (O) -COOH, tetrazole,
Rg is selected from H, halogen, -CF3, -OH, (CH2) n -COOH, - (CH2) nC (O) -COOH, alkyl -C? -C6, alkyl -0-C? -C6, -NH (C? -C6 alkyl), or -N (C? -C6 alkyl) 2;
Rio is selected from the group of H, halogen, CF3, -OH, - (CH2) n -COOH, - (CH2) n "(O) -COOH, alkyl -dd, alkyl-0-C? -C6, -NH (C? -C6 alkyl), N (C? -C6 alkyl) 2,
(lower alkyl C -C
. * «*. . ^. ,, », ^". ^^^^ g ^^ t Rn is selected from H, lower alkyl C? ~ C6, • CF3, -COOH, - (CH2) n -COOH, - (CH2) n ~ C (0) -COOH, or
with the proviso that the complete portion in position 1 of indole or indoline created by any combination of R5, R8, Rg, Rio, and / or Rn may contain at least one acid portion selected from or containing a carboxylic acid, a tetrazole , or a portion of the formulas:
or a pharmaceutically acceptable salt thereof
Detailed Description of the Preferred Modalities.
As used herein, the terms "aryl" and "substituted aryl" will be understood to include monocyclic ring portions, particularly including five and six membered monocyclics, aromatics and heteroaromatics and aromatic and heteroaromatic bicyclic ring portions, particularly including those which they have from 9 to 10 atoms in the ring. Among these aryl groups it will be understood that they are phenyl ring, including those found in phenoxy, benzyl, benzyloxy, biphenyl and other such portions. The aryl and heteroaryl groups of this invention also include the following:
a) a ring of five heterocyclic members containing one or two heteroatoms in the ring selected from N, S or 0 including, but not limited to, furan, pyrrole, thiophene, imidazole, pyrazole, isothiazole, isoxazole, pyrrolidine, pyrrolma, imide zol idina, pyrazol idine, pyrazole, pyrazoline, imidazole, tetrazole, or oxathiazole; or b) a six-membered heterocyclic ring containing one, two or three heteroatoms in the selected ring of N, S or 0 including, but not limited to, pyran, pyridine, pyrazine, pyrimidine, pyridazine, piperazine, tetrazine, thiazine, thiadizine, oxazine, or morpholine; or
c) a bicyclic ring portion optionally containing from 1 to 3 heteroatoms in the ring selected from N, S or O including, but not limited to, benzofuran, chromene, indole, isoindole, indoline, isoindylin, naphthalene, purine, indolizine , indazole, quinoline, isoquinoline, quinolizine, quinazoline, phthalazine, 15 or naphthyridine.
The "substituted aryl" groups of this invention include such portions which are optionally substituted by from 1 to 3 substituents selected from halogen, Ci-Cio alkyl, preferably Ci-C alquilo alkyl, Ci-C alco alkoxy, preferably Ci-d alkoxy , -CHO, -COOH or esters thereof, N02, -NH2, -CN, CF3 or -OH or combinations thereof, such as -CH2CF3, 25 NH (CH3), etc.
> - ^ »« «- w &« «. ^ Tt? Naia? A» ai¿í? Maa ^ -. *, ** * ** "f s,, *",,. *, ^., ...... I ?? Ar t, M ^ -, ....,. ...? - * i? ai ^^ A preferred subset of these groups, optionally substituted as described, includes portions formed from benzene, pyridine, naphthylene or quinoline rings. A further preferred group includes those of furan rings pyrrole, thiophene, pyrimidine and morpholine. A preferred group of aromatic and cyclic groups includes benzofuran, indole, naphthalene and quinoline rings.
The alkenyl and alkynyl alkyl groups referred to herein indicate such groups having from 1 to 10 preferably from 1 to 6 carbon atoms and may be linear, branched or cyclic. Unless indicated otherwise, it is preferred that these groups be linear or branched. The halogens herein are understood to include F, Cl, Br, and I.
As used herein, "phospholipase enzyme activity" means the positive activity in an assay for phospholipid metabolism (preferably one of the assays described in Example 86 below.) A compound has "phospholipase enzyme inhibitory activity". when in > the activity of a phospholipase (preferably c PLA2) in some available assay (preferably an assay described below in example 86 or example 87) for enzyme activity In the preferred embodiments a compound has (1) value IC50 of less than about 25μM, preferably less than about 6μM, and the lysoPC assay, (2) an Ido value of less than about 50μM in the vesicle assay, (3) an Ido value of less than about lμM in the PMN test, (4) an IC5o value of less than about 15μM in the coumarin test, and / or (5) a measurable activity (preferably at least about 5% reduction in the adema, more preferably at least alred 10% reduction, more preferably at least about 15%, and more preferably 20-30%) in the carrageenan-induced edema test in the rat paw.
The compounds of the present invention are useful for inhibiting the activity of phospholipase enzyme (preferably cPLA2) and therefore, are useful in the "treatment" (ie treatment prevention or decrease) of the
Inflammatory or inflammatory-related responses or conditions (eg rheumatoid arthritis, psoriasis, asthma, inflammatory bowel disease, and other conditions mediated by prostaglandins, leukotrienes or PAF) and other conditions, such as osteoporosis, colitis, myelogenous leukemia, diabetes, atrophy and art heroes clerics is.
The present invention encompasses pharmaceutical compositions and therapeutic methods of treatment or use which compounds of the present invention are employed.
The compounds of the present invention can be used in a pharmaceutical composition when combined with pharmaceutically acceptable carrier. Such a composition may also contain (in addition to a compound or compounds of the present invention and a carrier) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient. The characteristics of the carrier will depend on the route of administration. The pharmaceutical composition may also contain other anti-inflammatory agents. Such additional factors and / or agents may be included in the pharmaceutical composition to produce a synergistic effect with the compounds of the present invention, or to minimize the side effects caused by the compound of the present invention.
The pharmaceutical composition of the invention can be in the form of a liposome, in which compounds of the present invention are combined, in addition to other pharmaceutically acceptable carriers, with amphiphilic agents such as lipids that exist in aggregated form such as miselos, insoluble monolayers, crystals liquids or lamellar layers in aqueous solution. Suitable lipids for the formulation of liposomes include without limitation, monoglycerides and glycerides, sulfatides, li solecy t ina, phospholipids, saponin, villi acids and the like. The preparation of such liposome formulations is within the skill level in the art, as described, for example, in US Patent Nos. 4,235,871; 4,501,728; 4,837,028; and 4,737,323, all. which are incorporated here as a reference.
As used herein, the term "therapeutically effective amount" means the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a significant benefit to the patient, ie, treatment, cure, prevention or diminution of a response or inflammatory condition or an increase in the speed of treatment cure, prevention or reduction of such conditions. When applied to an individual active ingredient, administered alone, the term refers to that ingredient only. When applied to a combination, the term refers to the combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously. '
- - * '•, - • • - * "* i-rt-n- í i I-I" t "atn- - *« »« * .-, < »-,. -, *, -. > > .. .--- - .., ..._ »". . When the method of treatment or use of the present invention is practiced, a therapeutically effective amount of a compound of the present invention is administered to a mammal having a condition to be treated.The compounds of the present invention are they can be administered according to the method of the invention either alone or in combination with other therapies such as treatments employing other anti-inflammatory agents, cytokines, lymphokines or other hematopoietic factors, when co-administered with one or more of other anti-inflammatory agents, cytokines, lymphokines or other hematofibody factors, the compounds of the present invention can be administered either simultaneously with the other anti-inflammatory agents, cytokines, lymphokines, other hematofoetic factors, t-rombolit icos or thrombotic factors, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administration of the compounds of the present invention in combination with other anti-inflammatory agents, cytokines, lymphokines, others
. , T rt, r f,., I ^ rflr - - hema factors, t ombolics, or ant thrombotic factors.
The administration of the compounds of the present invention used in the pharmaceutical composition or to practice the method of the present invention, can be carried out in a variety of conventional forms, such as oral ingestion, inhalation, or cutaneous, subcutaneous or intravenous injection. .
When a therapeutically effective amount of the compounds of the present invention is administered orally, the compounds of the present invention will be in the form of a tablet, capsule, powder, solution or elixir. When administered in tablet form, the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule and powder contain from about 5 to 95% of the compound of the present invention and preferably from about 25 to 90% of the compound of the present invention. When administered in liquid form, a liquid carrier such as water, petroleum, animal or vegetable oils such as peanut oil, mineral oil, soybean oil or sesame oil or synthetic oil may be added. The liquid form of the pharmaceutical composition may further contain a physiological saline solution, dextrose or other solution of saccharides, or glycols such as ethylene glycol, propylene glycol, or polyethylene glycol. When administered in liquid form, the pharmaceutical composition contains from about 0.5 to 90% by weight of the compound of the present invention and preferably from about 1 to 50% of the compound of the present invention.
When a therapeutically effective amount of compounds of the present invention is administered by intravenous, cutaneous or subcutaneous injection, the compounds of the present invention will be in the form of a parenterally acceptable aqueous solution., free of pyrogens. The preparation of such parenterally acceptable protein solutions, having a proper reference to pH, ionicity, stability and the like, are within the skill in the art. A preferred pharmaceutical composition for an intravenous, cutaneous or subcutaneous injection should contain in addition to the compounds of the present invention, an isotonic vehicle such as sodium chloride injection, ringer injection, dextrose injection, dextrose injection and sodium chloride, lactated ringer injection, or other vehicle such as those known in the art. The pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those skilled in the art.
The amount of compounds of the present invention in the pharmaceutical composition of the present invention will depend on the nature and severity of the condition being treated, and on the nature of the previous treatments that patients have undergone. Finally, the attending physician will decide the amount the amount of compound of the present invention with which to treat each patient individually. Imcially the attending physician will administer low doses of the compound of the present invention and observe the patient's response. The higher doses of compounds of the present invention can be administered until an optimal therapeutic effect is obtained by the patient and at the point where the dose is no longer increased. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain from about 0.1 μg to about 100 mg (preferably around 0. lmg to about 50 mg, more preferably about lmg to about 2 mg) of the compound of the present invention per kilogram of body weight.
The duration of intravenous therapy using the pharmaceutical composition of the present invention will vary, depending on the severity of the disease to be treated and the condition and potential uncharacteristic response of each patient individually. It is contemplated that the duration of each application of the compounds of the present invention will be in the range of 24 hours of continuous intravenous administration. Finally, the attending physician will decide on the appropriate duration of intravenous therapy
- "• * - '" ^ -' - • - "* * - using the pharmaceutical composition of the present invention.
The compounds of the present invention can be made according to the methods and examples described below. The synthesis of the preferred compounds of the present invention are described below.
Method A
Ethyl 5-nitro-2-carboxylate indole was chlorinated in the 3-position by the addition of N-chlorosuccinamide in a solvent such as DMF or DMSO at an elevated temperature of 40 ° C-80 ° C. The ester was then reduced in a 3-step procedure. First the ester is hydrolyzed under basic conditions with a base such as sodium hydroxide or potassium hydroxide in a solvent system such as water: methanol: THF. The acid was then activated by the addition of carbonyl diimizole in THF and reduced with a reducing agent such as sodium borohydride or sodium triacetoxy borohydride in an alcohol solvent system such as methanol or ethanol. The resulting alcohol was protected as the TBDMS ether with TBDMSCI in a solvent such as DMF, methylene chloride or THF with a base such as triethylamine or imidazole. The indole nitrogen was then alkyl with 4-bromomethylbenzene or methyl in a solvent such as THF, acetonitrile or DMF with a base such as sodium hydride, n-BuLi or potassium amide of bis (t-rimet-lysilyl) ). The 5-nitro group was then reduced by exposure to H2 in the presence of a catalyst such as a Pt / C or Pd / C in a solvent such as ethyl acetate, methanol or THF or a mixture of two or all three. The amine was then acylated with cyclopentylcarbonyl chloride in a biphasic saturated sodium bicarbonate and methylene chloride system. The Rl was then introduced into a two-step procedure wherein the TBDMS ether was converted to a bromide by exposure with dibromotriphenyl phosphorane in methylene chloride and then the crude bromide was displaced by a variety of thiols or phenols in such a solvent as THF, methylene chloride or DMF in the presence of a base such as potassium carbonate or cesium carbonate. The product esters were then prepared by hydrolysis of the ester under basic conditions with sodium hydroxide in a solvent system such as water: MeOH: THF.
Method B
Acylation at the 3-position of indole I with acylating agent such as naphthoyl chloride, could be achieved using the ethyl magnesium bromide in a solvent such as THF to give II. The alkylation of indole nitrogen could be achieved by exposure with an appropriate base such as sodium hydride followed by treatment with the appropriate one. The deprotection of the hydroxy protecting group with fluoride of
tetrabutylammonium and oxidation with an appropriate oxidizing agent, I provide the IV. A reaction of Horner Wittig with t-hemethoxy fos phonoacetate in an appropriate solvent such as tetrahydrofuran gave the ester
unsaturated V which could be deprotected in position one of the indole with an appropriate reagent system such as hydrofluoric acid in acetonitrile. Saponification of the remaining acid group gave compound VI. 25
Method C
Indole I can be converted to II in two steps: (1) reduction with LAH in a solvent such as THF and (2) silylation with t-butyldimethylsilyl chloride (TBDMSCI) in a solvent such as dichloromethane or DMF in the presence of a base such as imidazole. Treatment of II with a Grignard reagent such as ethyl magnesium bromide in a solvent such as THF at -60 ° C, acylation of the resulting magnesium salt with an appropriate acyl chloride such as acetyl chloride in ether and finally, alkylation in nitrogen with an alkyl halide such as methyl (4-bromomethyl) benzoate in the presence of a strong base such as NaH in DMF results in the ketone III. The cylyl group on III, is removed using tetrabutylammonium fluoride in a solvent such as THF, the resulting alcohol is then converted to bromide using carbon tetrabromide and bi s (difeni 1 fos) ethane in a solvent such as dichloromethane for produce bromine IV. The displacement of IV bromide with a thiol compound in the presence of a base such as cesium carbonate, or with an alcohol in
íaSe-S -f .--. ffi, l, * ** * ",. i, tl ^ t. " . ^ nr-r ,, •? »- *" - ,,,. - * .- *,. ._ ..,. «". . ^. ^. ^ .....
the presence of a strong base such as NaH in DMF results in V (sulfur or ether respectively).
Method D
The protected alcohol was deprotected in an appropriate solvent such as THF and the resulting alcohol was functionalized to a halide using carbon tetrabromide or methanesulfonyl chloride and then reacted with an oxygen nucleophile, coupled with a previous deprotonation with a strong base such as sodium hydride or a sulfur ucleophil in the presence of c.sub.-io carbonate in DMF or THF. The nitro group could then be reduced to an amine by means of the Pt / carbon hydrogenation protocol or the sodium borohydride procedure of the copper acetate. The resulting amine could be hydrolysed using a standard procedure of sodium hydroxide in THF / MeOH or coupled to a variety of acylating reagents such as acid chloride, chloroformates and isocyanates wherein the reactions are generally carried out in the presence of a base in a solvent such as THF or dichloromethane. The amine could also be
~? '^ "* ^ -' ~ - '~ * -' - '-« - ^ .., #, 1,1 -,, I «t -'i ....),.", -. .. ,, ».. ... * .. ^. ^. ^ ... ^ ** ,,. * A., .. ^^^ -... m,,". * .. .. .. ^ ..,.,. ,, ",.,", _ {. «A -. ^ ..
acylating by means of an EDCI coupling process with a variety of acids. The starting amine could also be alkylated by a reductive amination procedure using a variety of sodium aldehydes and triacetoxyborohydride as a reducing agent. These functional amines could be hydrolyzed to result in the desired acids which could also be converted to the acyl sulfonamide by EDCI coupling with a sulfonamine. Alternatively, the functionalized amines could be further alkylated by reaction with a strong base and an alkyl halide and then hydrolysed under normal conditions to produce the required product.
Method E
The starting indole, with or without the C2 substitution, was functionalized to C3 by the use of DMF / POC13 conditions or the magnesium salt of the indole was acylated with a variety of acid chlorides to form the ketones. These products were then N-alkylated by the action of a strong base and a variety of alkyl or haloaryl esters. When R 'is a nitro group, at this time the nitro was reduced with Pt / C and H2 or copper acetate and sodium borohydride to the amine which was then acylated with a variety of isocyanates, chloroformiates, alkylated acid chlorides in a reductive way with amines or coupled with acids. The resulting esters were hydrolyzed to the desired acids which could also be converted to the acyl sulfonamide.
Method A
! > apl thioether alkyl thioether alkyl ether alkyl ether Method B
OMc
Method C DLiAlH. THF 2) TBD SCI. Imidazole
FTSH, CSC03 \ R "'OH, NaH or K, C03
.--. "'- *" * - * - Method D
h '* "in carbon
Method E
EDCI? .NSO, R - E emplo 1 Acid 4- ( { 3-Chloro-5- [(cyclopentylcarbonyl) amino] -2- [(phenethylsulfanyl) methyl] -1H-indole-1-yl.} - methyl) benzoic
Step 1 - 5-Ni t -roindol-2-ethyl carboxylate (21.1 g) was dissolved in DMF (500 mL). To this dark brown solution, a solution of N-chlorosuccinamide (12 g in 125 mL of DMF) was added over a period of 5 minutes, the reaction mixture was heated to 50 ° C for 1.5 hours. It was determined that the reaction was completed by TLC. The reaction was cooled to room temperature, diluted with water (2 L), and extracted with ethyl acetate (3 X 1 L). The organic layers were combined, dried over MgSO4, filtered and concentrated. The result was the desired ethyl ester (96 g of moisture with DMF) which was carried out in the next step without further purification.
Step 2 - Ethyl ester was dissolved in methanol (400 mL) and THF (800 mL). To this clear brown solution, 2N NaOH (450 mL) was added. The black mixture was stirred at room temperature overnight. The reaction was not fully completed (TLC) therefore, an additional 7.2 g of NaOH pellets was added. After 7 hours, the reaction was complete. Approximately 1 L of solvent was removed by rotary evaporation. The residue was dissolved with ethyl acetate and water and acidified with 2N HCl to pH 2. The mixture was then extracted with ethyl acetate (3 X 1 L). The combined organic layers were dried over MgSO4, filtered and concentrated to give the acid (24.3 g, 100%) as a brown solid.
Step 3 - Carboxylic acid (24 g) was dissolved in THF (700 mL). CDI (16.2 g) was added to this clear amber solution. The mixture was stirred at room temperature for 1.5 hours, during which time it became a light brown suspension. The reaction was cooled in an ice bath. Sodium borohydride (10.8 g) was slowly added. Ethanol (140 mL) was then added. A gas evolution was observed. After 2 hours, the TLC analysis indicated that the reaction was complete. To adjust the pH to 2, 2N HCl was added. The reaction was then extracted with ethyl acetate (3 X 600 mL). The combined organic layers were dried (MgSO4), filtered and concentrated to yield the desired alcohol (28.5 g) as a brown solid.
Step 4 - The alcohol prepared above (25.4 g), imidazole (18.6 g), and tert-butyldimethylsilyl chloride (13.3 g) was dissolved in DMF (350 mL). The reaction was stirred overnight and found to be incomplete. Therefore, imidazole (18.7 g) and t-butyldimethylsilyl chloride (18.6 g) were added. After 1 hour, the reaction was complete. Water (1.5 L) was added and the mixture was extracted with ethyl acetate (3 X 500 mL). The combined organic layers were evaporated to dryness to give the protected alcohol in crude 5- tert-butyldimethyl. The crude material was dissolved in ethyl acetate, absorbed on silica gel, and evaporated to dryness. After filling in a column of silica gel and eluting with 15% ethyl acetate in hexane, the desired protected alcohol (18.5 g, 69% of step 1) was isolated as bright yellow crystals.
- "** '•"' * - '-: H "- - - ~ - - - --- - -t .- .t« i jAv ".-.- tt ... - - __. , "» ..._ .. "." ... i .. "•» •. »- Step 5 - The alcohol protected in tert-butyldimethylsilyl (1.0 g) was dissolved in DMF (10 g). mL). The yellow solution was cooled in an ice bath. Sodium hydride (147 mg) was added. After 15 minutes, 4- (bromomet i 1) benzoate (807 mg) was added to the dark red solution. After 15 minutes, TLC analysis indicated that the reaction was complete. The reaction was emptied into cold IN HCl. Water (100 mL) was added and the solution was extracted with ethyl acetate. The combined organic layers were evaporated to dry to give the crude N-alkylated indole as an orange solid. The crude solid was absorbed in silica gel, added to a column of silica gel and eluted with 15% ethyl acetate in hexanes to give the desired N-alkylated indole (1.05 g, 73%) as a yellow solid. i lio.
Step 6 - The N-alkylated indole (3.8 g) was dissolved in THF (50 mL) and 5% Pt / C (1.6 g) was added. The hydrogen was purged and the reaction was stirred at room temperature overnight. The reaction was filtered (celite) and concentrated. Column chromatography (35% ethyl acetate in hexane) gave the desired amine (1.7 g) as an off white solid.
Step 7 - To a solution of the above amine (1.6 g, 3.5 mmol) in CH2C12 (10 mL) and saturated sodium bicarbonate (10 mL) was added cyclopentyl carbonyl chloride (0.467 mL, 1.1 equivalent). The reaction was stirred 45 minutes, taken up in ethyl acetate (100 mL), washed with brine (3 X 20 mL), dried (MgSO 4), filtered and concentrated. Chromatography (20% ethyl acetate / hexanes) provided the desired product (1.55 g, 82%) as a pale yellow oil.
Step 8 - To a solution of the above amide (0.6 g, 1.1 mmol) in dichloromethane (3 mL) at 0 ° C, was added dibromotr i feni 1 fos forane (0.5 g, 1.1 equivalents). The reaction was stirred at room temperature for 2 hours, taken up in ethyl acetate (50 mL), washed with brine (3 X 10 mL), dried (MgSO4) and concentrated and taken immediately to the next step.
Step 9 - To a solution of the crude bromide prepared above (0.54 mmol) in DMF
«« »***« - »" "(2 mL, degassed) was added phenylethyl mercaptan (0.08 g, 1.1 equivalents) followed by cesium carbonate (0.21 g, 1.2 equivalents). The reaction was stirred 1 hour, taken up in ethyl acetate (20 mL), washed with brine (3 X 5 mL), dried (MgSO 4), filtered and concentrated. Chromatography (25% ethyl acetate / hexanes) provided the desired compound (0.17 g, 56%) as a colorless oil.
Step 10 - To a solution of the above ester in THF (1 mL) and MeOH (0.5 mL) was added NaOH (0.28 mL, 5 M, 5 equivalents). The reaction was stirred 4 hours, acidified with sodium biphosphate, emptied into ethyl acetate, washed with brine and dried (MgSO4). The title compound (0.157, 98%) was triturated from ethyl acetate with hexanes.
Each of the compounds of the following Examples 2 to 11 were prepared by a first step as illustrated in Example 1, step 9, using the appropriate thiol, followed by a second step as described in Example 1, step 10.
EXAMPLE 2 4- [(3-Chloro-5- [(cyclopentylcarbonyl) amino] -2 { [(2-furylmethyl) sulfanyl-ethyl] -lH-indol-1-yl) -methyl] -benzoic acid.
EXAMPLE 3 4- [(3-Chloro-5- [(cyclopentylcarbonyl) amino] -2 { [(4-hydroxy-6-phenyl-2-pyrimidinyl) sulfanyl] methyl} -lH-indole-1 -yl) methyl] benzoic.
Example 4 Acid 4-. { [3-chloro-5- [(cyclopentylcarbonyl) amino] 2- ( { [4- (2-thienyl) -2-pyrimidinyl] sulfanyl} methyl) -lH-indol-1-yl] methyl} benzoic
Example 5 4- (. {3-Chloro-5- [(cyclopentylcarbonyl) amino] -2- [(2,4-dibromophenoxy) methyl] -H-indol-1-yl} methyl) benzoic acid.
Example 6: 4- ( { 3-Chloro-5- [(cyclopentylcarbonyl) amino] •
2- [(cyclopentyl sulfanyl) methyl] -lH-indol-1- »il} methyl) benzoic.
EXAMPLE 7 4- (. {3-Chloro-5- [(cyclopentylcarbonyl) amino] 2- [(propyl sulfanyl) methyl] -lH-indol-1-yl] methyl) benzoic acid.
Example 8: 4- ( { 2- { [4- (tert-Butyl) phenoxy] methyl.} - 3-chloro-5- [(cyclopentylcarbonyl) amino] -lH-indol-1-10-yl. .}. methyl) benzoic acid.
EXAMPLE 9 4- (. {3-Chloro-5- [(cyclopentylcarbonyl) amino] -2- [(2-guinolinyl-sul-anil) -methyl] -lH-indol-1-yl} -methyl) -benzoic acid.
EXAMPLE 10 4- [(3-Chloro-5- [(cyclopentylcarbonyl) amino] -2- {. [(Cyclopropylmethyl) sulfanyl] methyl} - lH-indol-1-yl) methyl] benzo co.
EXAMPLE 11 4- (. {2- [(Benzhydryl sulphyl) methyl] -3-chloro-5- [(cyclopentylcarbonyl) amino] -lH-indol-1-yl] methyl] benzoic acid.
^^^^ Hg ^ The compounds of the following Examples 12 to 14 were prepared by:
Step 1 - The material prepared in Example 1, step 6, was acylated in position 5 using the protocol of Example 1, step 7, with the appropriate acylating reagent.
Step 2 - The title compound was prepared from the intermediate of Step 1 following the procedure described in Example 1, steps 8 to 10, using the appropriate thiol.
Example 12 4- ( { 5- [(3-carboxypropanoyl) amino] -3-chloro-2- [(phenethylsulfanyl) methyl] -lH-indol-1-yl] methyl) benzoic acid.
EXAMPLE 13 4- [(5- [(3-Carboxypropanoyl) amino] -3-chloro-2. {[[(3-methylbenzyl) sulfanyl-Jethyl} -1H-indol-1-yl) methyl] -benzoic acid .
Example 14
& amp; & amp; & amp; < 4 > 4- (. {2- ( { [4-tert-butyl) benzyl] sulfanyl}. Methyl) -5- [(3- carboxypropanoyl) amino] -3-chloro-lH-indol-1-yl} methyl) benzoic.
EXAMPLE 15 4- (. {3-Chloro-5- (3-furoylamino) -2- [(2-naphthylsulfanyl) methyl] -lH-indol-1-yl} yl) benzoic acid. The title compound was prepared as described in Example 43 using the appropriate acylating reagent.
The following Examples 17 to 21 were prepared as described in Example 43 using the appropriate acylating reagent.
Example 17 Acid 4- ( { 3-Chloro-5-. {[[3- (diethylamino) propanoyl] amino} -2- [(2-naphsulfanyl) methyl] -lH-indole- il.}. me il) benzoic
Example 18
4- (. {3-Chloro-2- [(2-naphthylsulfanyl) methyl] -5 - [(3-thienylcarbonyl) amino] -lH-indol-1-yl} ethyl) benzoic acid.
EXAMPLE 19 4- ( { 5. {[[(Benzylamino) carbonyl] amino]} -3-chloro-2- [(2-naphthylsulfanyl) methyl] -lH-indol-1-yl}. methyl) benzoic.
EXAMPLE 20 4 - (. {5- [{[[(Butylamino) carbonyl] amino]} - 3-chloro-2- [(2-naphthyl sulfanyl) methyl] -lH-indol-1-yl} acid. methyl) benzoic
Example 21 3- [(. {1- (4-carboxybenzyl) -3-chloro-2- [(2-naphthyl sulfanyl) methyl] -lH-indol-5-yl} amino) carbonyl] benzoic acid.
Example 22 Acid 4-. { [5- (benzyloxy) -2- [(E) -2-carboxylethenyl] -3- (2-naphthoyl) -1H-indol-1-yl] methyl} benzoic
Step 1 A solution of 2 (tert-butyldimethylsilyloxymethyl) -5-benzyloxyindole (2.0 g, 5.4 mmol) in anhydrous ether (10 ml) was cooled to -78 ° C and a solution of ethylmagnesium bromide (3.0M) was added. in ether, 4.0 ml, 12.0 mmol) dropwise. The mixture was stirred at -60 ° C to -65 ° C for 2 hours during which time the homogeneous solution became a thick yellow mixture. A solution of naphthoyl chloride (2.28 g, 12.0 mmol) in ether (8 ml) was then added. After stirring for 2 hours at -60 ° C to -40 ° C, the reaction mixture was carefully quenched with saturated aqueous sodium bicarbonate and diluted with EtOAc. The combined organic layers were washed with brine, dried and concentrated. Flash chromatography (Hex / Acet ona, 6/1) gave 2.2 g (78%) of 17 as a yellow foam.
Step 2
To a solution cooled on ice (0 ° C) of the previous intermediate (1.0 g, 1.9 mmol) in DMF
(10 ml) was added sodium hydride (0.12 g, 2.1 mmol). The ice bath was removed after 10
g ^^ .- ^ .- ^ .- ^^^ - ^ - ^ - ,,; ^, ^, - ^^,! ^^^, !!!!!!!!! ^, !! !!!!!!!!! ^^, ^ * ^^^ minutes and the reaction was stirred at room temperature for 30 minutes at which time the bromomethyl ether SEM (0.5 ml, 2.8 mmol) was added dropwise. The mixture was stirred at room temperature for 4 h, water was added and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and concentrated. Flash chromatography (Hex / Acetone, 6/1) gave 1.22 g (81%) of the desired intermediate as an off white foam.
Step 3
To a solution of the previous one (6.6 g, 8.4 mmol) in THF (80 ml) was added tetrabutylammonium fluoride (1.0 M in THF, 21 ml). The reaction was stirred at room temperature for 2 hours, water was added and the mixture was extracted with EtOAc. The combined organic layers were washed with water, brine, dried and concentrated. Flash chromatography (Hex / EtOAc, 4: 1) gave 3.8 g (67%) of the alcohol as a thick, colorless oil. The alcohol was dissolved in THF (50 ml) and Mn02 (5.5 g, 63.2 mmol) was added. The reaction was stirred for 22 hours and filtered through a pad of celite. The concentration of the filtrate gave 3.7 g (96%) of the desired intermediate as a light yellow foam.
Step 4
To a solution cooled with ice (0 ° C) of trimethyl-ilphosphonoacetate (0.12 ml, 0.7 mmol) in DMF (5 ml) was added sodium hydride (0.027 g, 0.8 mmol). After 30 minutes, a solution of the above intermediate (0.5 g, 0.7 mmol) in 5 ml of DMF was added. The ice bath was removed and the reaction allowed to remain overnight. Water was added and the mixture was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over MgSO4 and concentrated. Flash chromatography (Hex / EtOAc, 3/2) gave 0.2 g of the desired intermediate (37%) as a white foam.
Step 5 Acid 4-. { [5- (benzyloxy) -2- [(E) -2-carboxyethenyl] -3- (2-naphthoyl) -IH-indol-l-yl] methyl} benzoic.
..
To a solution of the above intermediate (0.5 g, 0.7 mmol) in acetonitrile (10 ml) was added 48% aqueous hydrofluoric acid (5 ml). After 2 hours, water was added and the product was extracted with ethyl acetate. The organic layer was washed with water, brine and dried over magnesium sulfate. The concentration gave a crude solid which was dissolved in THF (2 ml) and MeOH (lml) and a solution of IN sodium hydroxide (2 ml). After stirring overnight at room temperature, the reaction was acidified to pH = 3 with a 10% solution of HCl and extracted with ethyl acetate. Flash chromatography (CH2C12 / MeOH, 10/1) gave the title compound (0.2 g, 50%) as a white solid.
EXAMPLE 23 4- (. {3-Acetyl-5- (benzyloxy) -2- [(2-naphthylsulfanyl) methyl] -lH-indol-1-yl} me) benzoic acid.
Step 1 Ethyl 5-benzyloxy-2-indolcarboxylate (30 g, 102 mmol) was dissolved in 250 mL of THF and cooled to 0 ° C, and Lithium Aluminum Hydride (LAH) (255 mL of a solution) was added. 1. OM in THF) by means of an addition funnel for 40 minutes, the reaction was stirred an additional 2 hours at 0 ° C and then worked up by the addition of 4N NaOH (190 mL). The resulting salts were filtered and washed with ethyl acetate (3 X 400 mL), the filtrates were combined and dried over MgSO4 and concentrated to yield 24.8 g.
Step 2 The crude indole alcohol prepared in step 1 (8.3 g, 32.6 mmol) was dissolved in DMF (10.5 mL). To this solution was added imidazole (5.5 g, 81.5 mmole) and t-butyldimethylsilyl chloride (5.4 g, 35.8 mmole). The mixture was stirred at room temperature overnight. The reaction was poured into water and extracted with ethyl acetate (3X). The organic layers were dried over magnesium sulfate and concentrated. The crude material was purified on silica gel using Hexane: ethyl acetate 19: 1 to give the pure product (11.9 g, 31 mmol, 94% yield, TLC_0.8 Rf in Toluene: Ethyl acetate 2: 1).
Step 3 The solution of the indole protected in silyl prepared in step 2 (2 g, 6.56 mmol) in ether (20 mL) was added dropwise to magnesium ethyl bromide (2.4 mL of a 3M solution in ether, 7.2 mmol. ) in ether (10 ml), the last one maintained at -78 ° C. the reaction was stirred at -60 ° C for 2 hours. Then acetylchloride (0.51 mL, 7.2 mmol) in ether (4 mL) was added slowly. The reaction was maintained between -50 ° C and -60 ° C
for another 2 hours. The reaction was then quenched with saturated sodium bicarbonate. It was extracted with ethyl acetate (3X). The organic layers were dried over magnesium sulfate and concentrated. The crude material was purified in a
column of silica gel using Hexane: Ethyl acetate 19: 1 to give the pure product (1.2 g, 50%).
Step 4 To indole (1.2 g, 2.9 mmol, prepared in step 3 above) in 10.5 ml of 20 DMF, sodium hydride (0.13 g, in a 60% oil dispersion, 3.23 mmol) was added at room temperature . The reaction was stirred for 30 minutes. methyl (-bromomet il) benzoate (0.81 g, 3.53 mmol) was added at this time and the
The reaction was stirred overnight. When completing the
^ * ^^^^? G < The reaction was monitored (monitored by TLC), quenched with water, extracted with ethyl acetate (3X). The organic layers were dried over magnesium sulfate, concentrated and used for the next step.
Step 5 A mixture of the silyl-protected indole prepared in step 4 above (0.65 g, 1.2 mmol) and ammonium tetra-butyl lutein (2.9 mL of a 1M solution in tetrahydrofuran, 2.9 mmol) in tetrahydrofuran (6 mL) was stirred at room temperature for one hour. At this time, the reaction was diluted with ethyl acetate and water, extracted with ethyl acetate (3X), dried over magnesium sulfate and concentrated. The crude material was purified on silica gel using Hexane: Ethyl acetate 1: 1 to yield pure alcohol (0.47 g, 91%).
Step 6 The indole alcohol 0.3 0.61 mmol), carbon tetrabromide (0.27 g, 0.81 mmol) and 1,3-bis (diphenylphosphino) propane (0.21 g, 0.51 mmol) was taken in dichloromethane (8.4 mL) and stirred for 16 hours at which time the reaction was diluted with dichloromethane and half ammonium chloride. The aqueous layer was extracted with ethyl acetate (3X) dried over magnesium sulfate and concentrated. The crude material was purified on silica gel using Hexane: Ethyl acetate 2: 1 to yield pure alcohol (0.27 g, 78%).
Step 7 The indole bromide prepared in step 6 (0.1 g, 0.2 mmol) was dissolved in dimethylformamide (0.4 mL, it is strongly recommended to degas the solvent) cesium carbonate (0.2 g, 0.6 mmol) was added and then 2 was added. -naftalent ethyl iool (0.034 g, 0.22 mmol) and the mixture was stirred for 1 day, then the reaction was emptied into 1/2 saturated ammonium chloride and extracted with ethyl acetate (3X), dried, concentrated and chromatographed (Hexane: Ethyl acetate 3: 1) to yield 0.05 g (57%) of the pure product.
Step 8 The ester (0.2 g, 0.34 mmol) prepared in step 7 above, was dissolved in 4.0 mL of THF / methanol 1/1 and then IN sodium hydroxide (2.5 mL) was added and the resulting mixture was stirred for 16 minutes. hours at room temperature, the work gave the crude product which was purified by means of chromatography (Hexane: Ethyl acetate 1: 1, with 1% acetic acid) to yield (0.17 g, 85%) of the sol.
Example 24 Acid 4-. { [5- (benzyloxy) -2- [(2-naphthylsulfanyl) ethyl] -3- (2,2,2-trifluoroacetyl) -lH-indol-1-yl] methyl} benzoic
Step 1 This intermediate was prepared from indole, prepared in the step of Example 23 and trifluoroacetic anhydride, according to the procedure described in step 1 of Example 23.
Step 2: This intermediate was prepared according to the procedure described in step 4 of Example 23, but using the indole derivative prepared in step 1 above and methyl (4-bromomethyl) benzoate.
Step 3 To a solution of the indole alcohol prepared in step 2 (0.1 g, 0.2 mmol) and triethylamine (0.04 mL, 0.3 mmol) in dichloromethane (0.4 mL), methanesulfonyl chloride (0.02 mL, 0.24 mmol) was added drop drop to 0 ° C. the reaction was stirred for 1.5 hours and then the dichloromethane was removed. To the residue in 0.4 mL of DMF at 0 ° C was added 2-naphthalene thiol (0.034 g, _ 0.22 mmol). Then CsC03 (0.96 g, 0.3 mmol) was added and the reaction mixture was stirred at room temperature overnight, and then the reaction was emptied into brine and extracted with ethyl acetate (3X), dried, concentrated and
chromatography (Hexane: Acetate t or ethyl 3: 1) to yield 0.064 g (50%) of the pure product.
Step 4: The title compound was prepared from the ester, prepared from step 3 above, according to the procedure described in step 8 of Example 23.
Example 25 4- (. {5- [4-aminobuoyl) amino] -3-chloro-2 acid
[(2-naphsulfanyl) methyl] -lH-indol-1-yl} methyl) benzoic.
Step 1 The t-butyl-sil i-protected alcohol (25 g) from step 6 of Example 1 was dissolved in 25 THF (200 mL) and then fluroride was added.
tetrabutylammonium (125 mL of a l.OM solution) and the mixture was stirred for 10 minutes at room temperature and then the reaction was diluted with water and the THF was concentrated, ethyl acetate was added and the layers were separated, the aqueous layer it was extracted three times with ethyl acetate, the combined organic layers were dried and concentrated to yield the desired alcohol (21.5 g).
Step 2 The alcohol (13.1 g) from step 1 was suspended in dichloromethane (450 mL), cooled to 0 ° C and triethylamine (10 mL) and methanesulfonyl chloride (4.0 mL) were added and the resulting mixture was allowed to warm to room temperature overnight, at which time it was diluted with saturated sodium bicarbonate, added and the reaction was diluted with dichloromethane, the layers were separated, the aqueous layer was extracted three times with dichloromethane, the combined organic layers were dried , concentrated to yield the desired chloride (13.5 g).
Step 3 To the chloride (13.5 g) generated in step 2 was added DMF (150 mL), cesium carbonate (33.5 g) and then the solution was degassed by bubbling argon through the solution for 20 minutes and then 2 was added. -naphthalene thiol and the reaction was stirred for 20 minutes at room temperature, then water as well as ethyl acetate was added, the layers were separated and the combined organic layers were concentrated to a thick mixture which was stirred overnight and then the mixture Thicken was filtered and the solid was triturated with 40% ethyl acetate in hexane to deliver the desired disulfide (12.2 g) in 69% yield.
Step 4 The product from step three (11.25 g) was dissolved in THF (500 mL), methanol (500 mL) and then copper acetate II (19.2 g) suspended in water (300 mL) was added as well as more THF (100 mL). mL) and then sodium borohydride (11.2 g) was added in portions. After 2.5 hours of stirring at room temperature, the foamy black solution was diluted with saturated sodium bicarbonate and the layers were separated, the aqueous layer was extracted three times with ethyl acetate, the combined organic layers were dried and concentrated and chromatographed to yield the desired amine (9.0 g) in 85% yield.
• • - • '* * *' - * faj * ta'1- ^ Step 5: The amine from the previous step was coupled to the 4-aminobutyric acid protected by fmoc followed by the procedure outlined in step 1, Example 43, followed by trituration with dichloromethane giving the amide in 43% yield.
Step 6: The amide (1.0 equivalent) from step 5 was dissolved in methanol (5 mg / ml) and piperidine (0.024 ml / mg) and then the reaction was stirred at room temperature for two hours, concentrated and chromatographed to the desired performance of the product in a quantitative yield.
Step 7: The step amino ester was hydrolyzed using the conditions summarized by step 2 of Example 43 to deliver the title compound in 54%.
Example 26: 4- ( { 3-Chloro-5- [(cyclopentylcarbonyl) amino]]
2- [(2-naphthyl sulfanyl) me il] -lH-indol-1-yl} I il) benzoic.
Step 1 The amine (1.0 equivalent) from step 4 of Example 25 was dissolved in CH2C12 (0.3 M) and then an equivalent amount of saturated sodium bicarbonate was added and then the appropriate acid chloride (1.2 equivalents) was added. The biphasic reaction mixture was stirred vigorously until TLC analysis indicated that the reaction had been completed (usually in a few hours) and then the reaction was diluted with dichloromethane and water, the layers were separated, the aqueous layer was extracted three times with dichloromethane, the combined organic layers were dried, concentrated and chro- mated, or used crude, to yield the desired amide in 50% yield.
Step 2: The ester from the previous step was dissolved in THF / MeOH (3: 1) and then IN NaOH (3.0 equivalents) was added and the reaction was stirred until the analysis showed that the reaction had been completed. The reaction was then concentrated, diluted with water, acidified to a pH of 2 with concentrated HCL, extracted with 3X ethyl acetate, the combined organics were dried over concentrated magnesium sulfate and purified by chromatography to yield the desired acid in a 69% yield.
EXAMPLE 27 4- ( { 3-Chloro- [(2-naphthylsulfanyl) methyl] -5 - [(2-quinoxalinylcarbonyl) amino] -lH-indol-1-yl.] Methyl) benzoic acid
Step 1: The amine from step 4 of Example 25 was treated with the appropriate acid chloride according to the general procedure for Example 71, step 1, to deliver the amide in a 76% yield.
Step 2: The ester from step 1 was hydrolyzed under the conditions summarized by step 2 of Example 26 to yield the desired acid in a 53% yield.
EXAMPLE 28 4- ( { 3-Chloro-5- [(2,2-dimethylpropanoyl) amino] -2 - [(2-naphthylsulfanyl) methyl] -lH-indol-1-yl.] Methyl) benzoic acid .
Step 1: The amine from step 4 of Example 25 was treated with the appropriate acid chloride according to the general procedure for the
Example 71, step 1, to deliver the amide in a 100% yield.
Step 2: The ester from step 1 was hydrolysed under the conditions summarized for step 2 of Example 26 to yield the desired acid in a 79% yield.
EXAMPLE 29 4- ( { 5. {[[(Benzyloxy) carbonyl] amino] -3-chloro-2- [(2-na-ylsulfanyl) methyl] -lH-indol-1-yl} acid} me il) benzoic.
Step 1 The amine from step 4 of Example 25 was treated with the appropriate acid chloride according to the general procedure for the
Example 71, step 1, to deliver the amide in 96% yield.
Step 2 The ester of step 1 was hydrolyzed under the conditions summarized for step 2 of Example 26 to yield the desired acid.
EXAMPLE 30 4- (. {3-Chloro-5. {[[(Cyclopeniloxy) carbonyl] amino) -2- [(2-naphthylsulfanyl) -yl] -lH-indol-1-yl} I il) benzoic.
Step 1: The amine from step 4 of Example 25 was treated with acetic anhydride in accordance with the general procedure for Example 71, step 1, to deliver the amide in 92% yield.
Step 2: The ester from step 1 was hydrolyzed under the conditions outlined for step 2 of Example 26 to yield the desired acid.
EXAMPLE 31 4- (. {5- (Acetylamino) -3-chloro-2- [(2-naphsulfanyl) methyl] -lH-indol-1-yl} me) benzoic acid.
Step 1: The amine from step 4 of Example 25 was treated with acetic anhydride according to the general procedure for Example 71, step 1, to deliver the amide in a 77% yield.
Step 2 The ester of step 1 was hydrolyzed under the conditions summarized by step 2 of Example 26 to yield the desired acid in a 29% yield.
EXAMPLE 32 Acid 4- (. {5- [{[[(buylamino) carbonyl] mino} -3-chloro-2- [(2-naphthylsulfanyl) methyl] -lH-indol-1-yl} il) benzoic.
Step 1: THF (0.12 M) was added to amine 15 (1.0 equivalent) generated in step 4, the reaction mixture was cooled to 0 ° C and then butyl isocyanate (1.1 equivalents) was added and the mixture was warmed up Room temperature overnight and the reaction was diluted with 1/2 ammonium chloride, the layers were separated, the aqueous layer was extracted three times with ethyl acetate, the combined organic layers were dried and concentrated and purified by chromatography to yield the desired urea in a yield of 57%.
»" - »> .... Jj-hiMi ~ -. «Aaafe. . .. «. A-j, »« «» - -. -. •• - ---- .. »- .. - ~ -J > . . * .... - - * ?? - ..., v 4 ,, *. t,. «Kiaa-utí ^ Step 2 The ester of step 1 was hydrolyzed under the conditions summarized by step 2 of Example 26 to yield the desired acid in 41%.
EXAMPLE 33 4- (. {5- [{[[(buylamino) carbonyl] amino]} -3-chloro-2- [(2-naphthylsulfanyl) methyl] -lH-indole-1-yl} acid} me il) benzoic. Step 1: In accordance with the procedure for Example 32, step 1, the amine was treated with benzyl isocyanate to deliver the title compound in 16% yield. Step 2: The ester of step 1 was hydrolysed under the conditions summarized by step 2 of Example 26 to yield the desired acid in 100%.
EXAMPLE 34 4- ( { 3-Chloro-5- [(morpholinocarbonyl) amino] -2 - [(2-naphthylsulfanyl) methyl] -lH-indol-1-yl] -me il) benzoic acid.
Step 1 The amine (1.0 equivalent) generated above in step 4 was weighed into a flask with only 4-dimethylaminopyridine (1.5 equivalents) and then taken in dichloromethane (0.08 M) and then 4-chloride was added. morphol incarbonyl (1.5 equivalent) and the reaction was stirred overnight at room temperature and then heated to 40 ° C for 4 hours and then worked up by the addition of ethyl acetate and saturated ammonium chloride at 1/2The layers were separated, the aqueous layer was extracted three times with ethyl acetate, the combined organic layers were dried and concentrated and purified by chromatography to yield the desired urea in 100% yield.
Step 2 The ester of step 1 was hydrolyzed under the conditions summarized for step 2 of Example 26 to yield the desired acid by 79%.
EXAMPLE 35 4- (. {5- (Benzylamino) -3-chloro-2- [(2-naphsulfanyl) -yl] -lH-indol-1-yl}. And yl) benzoic acid.
...- < ! - > .-- ..--. Step 1: The amine (1.0 equivalent) from step 1 was dissolved in dichloroethane and then benzaldehyde (1.0 equivalent) was added followed by acetic acid (1.0 mL / 1 mmol) and the reaction was stirred by 20 minutes and then sodium triacetoxyborohydride (1.3 equivalent) was added and the reaction was stirred overnight at room temperature, quenched by the addition of aqueous diethanolamine and dichloromethane, the layers were separated, the aqueous layer was extracted three times with dichloromethane , the combined organic layers were dried and concentrated by means of chromatography to yield the desired urea in 74% yield.
Step 2 The ester of step 1 was hydrolyzed under the conditions summarized by step 2 of Example 26 to yield the desired acid by 49%.
EXAMPLE 36 4- (. {3-Chloro-2- [(2-naphthylsulfanyl) methyl] -5 - [(3-phenoxybenzyl) amino] -lH-indol-1-yl} me) benzoic acid .
Step 1: In accordance with the procedure for step 1 of Example 35, the amine from step 4 of Example 25 was treated with the appropriate aldehyde to yield the desired secondary amine in a 38% yield.
Step 2 The ester of step 1 was hydrolyzed under the conditions summarized by step 2 of Example 26 to yield the desired acid by 87%.
EXAMPLE 37 4- (. {3-Chloro-5- [(cyclopentylcarbonyl) (methyl) amino] -2 - [(2-naphthylsulfanyl) methyl] -lH-indol-1-yl} methyl) benzoic acid.
Step 1: To the ester generated in step 1 of the synthesis of Example 27, DMF (0.05 M) was added, the reaction was cooled to 0 ° C and then sodium hydride (10 equivalents) was added and the mixture was stirred for 30 minutes, then methyl iodide (10 equivalents) was added and the resulting mixture was stirred overnight at room temperature and then diluted with ethyl acetate and 1/2 saturated ammonium chloride, the layers were
r. *,. tíxi .. ** < ** . . - * * .- *. *. < *. JJ .. .-. .. ".. --n,« > The separated aqueous layer was extracted three times with ethyl acetate, the combined organic layers were dried and concentrated and purified by means of chromatography to yield the desired methylated amide in a 56% yield.
Step 2: The ester of step 1 was hydrolyzed under the conditions summarized by step 2 of Example 26 to yield the desired acid by 57%.
EXAMPLE 38 4- (. {5- [Acetyl (benzyl) amino] -3-chloro-2- [(2-naphsulfanyl) methyl] -lH-indol-1-yl] methyl) benzoic acid.
Step 1 The amide synthesized in step 1 of the
Example 31 Benzyl was made in accordance with the procedure step 1 for Example 37 to yield the tertiary amide in 90% yield.
Step 2: The ester of step 1 was hydrolyzed under the conditions summarized for step 2 of Example 26 to yield the desired acid in 41%.
Example 39: 4- ( { 3-Chloro-2- [(2-naphsulfanyl) methyl] -5- [(ehydro-3-furanylcarbonyl) amino] -lH-indol-1-yl} methyl] benzoic.
Step 1: To the indole amine (1.0 equivalent) was added the acid (1.2 equivalents), the dimethylaminopyridine (10 mol%), the hydrochloride of 1- (3-dimethylaminopropy 1) -3-et i -carbodiimide (1.5 equivalents) and then DMF (0.3 M) and the reaction was stirred under nitrogen for 24 hours at room temperature, at which time it was poured into a solution of 1/2 saturated ammonium chloride and ethyl acetate and then the layers were separated and the aqueous layer was extracted 3 times, the combined organic layers were washed with 2X water, dried, concentrated and chromatographed to yield 55% of the title compound.
Step 2 The ester from step 1 was hydrolyzed under the conditions summarized for step 2 of Example 26 to yield the desired acid by 55%.
Example 40 4- (. {3-Chloro-2- [(2-naphthylsulfanyl) methyl] -5 - [(3-thienylcarbonyl) amino] -lH-indol-1-yl} methyl) benzoic acid.
Step 1: In accordance with the procedure for step 1 of Example 39, the amine from step 4 of Example 25 is treated with the acid required to yield the amide in 100% yield. Step 2: The ester of step 1 was hydrolyzed under the conditions summarized for step 2 of Example 26 to yield the desired acid in 21%.
Example 41: 4- (. {3-Chloro-2- [(2-naphthylsulfanyl) methyl] -5 - [(1-adamylcarbonyl) amino] -lH-indol-1-yl} methyl) benzoic acid.
Step 1: In accordance with the procedure for step 1 of Example 39, the amine from step 4 of Example 25 was treated with the acid required to yield the amide in 100% yield.
_ J_ i_ £ j ^ J_ > ~ _ _ ^ III - - - - - * * - ** • - * '--- A ..- ..'.
Step 2: The ester from step 1 was hydrolysed under the conditions summarized for 1 step 2 of Example 26 to yield the desired acid by 35%.
Example 42 3- [(. {1- (4-carboxybenzyl) -3-chloro-2 - [(2-naphthylsulfanyl) methyl] -lH-indol-1-yl} methyl) benzoic acid.
Step 1: In accordance with the procedure for step 1 of Example 39, the amine from step 4 of Example 25 was treated with the acid required to yield the amide in 100% yield.
Step 2: The ester of step 1 was hydrolyzed under the conditions summarized for step 2 of Example 26 to yield the desired acid by 20%.
EXAMPLE 43 4- ( { 3-Chloro-2- [(2-naphthylsulfanyl) me-il] -5- [(3-phenylpropanoyl) amino] -lH-indol-1-yl} .me il) benzoic acid .
Step 1: In accordance with the procedure for step 1 of Example 39, the amine from step 4 of Example 25 was treated with the acid required to yield the amide in 100% yield.
Step 2: The ester of step 1 was hydrolyzed. under the conditions summarized by step 2 of Example 26 to yield the desired acid by 32%.
EXAMPLE 44 4- (. {5-Amino-3-chloro-2- [(2-naphsulfanyl) methyl] -lH-indol-1-yl} methyl) benzoic acid.
Step 1: The amine generated in step 4 was hydrolyzed according to the procedure for step 2 of Example 26 to yield 79% yield.
Example 45 N-. { 3-Chloro-l- (4-. {[[(Methylsulfonyl) amino] carbonyl} benzyl) -2- [(2-naphsulfanyl) methyl] -1H-indol-5-yl} Cyclopentanecarboxamide.
Step 1: To Example 26 (1.0 eqlent), EDCI (1.5 eqlent), DMAP (1.0 eqlent),
In a flask under nitrogen, DMF (0.08M) was added to the methanol sulfonamide (1.0 eqlent) and the reaction was stirred overnight at room temperature. and then work was done by the addition of a solution of 1/2 saturated ammonium chloride and ethyl acetate and then the layers were separated and the aqueous layer was extracted 3 times, the combined organic layers were washed with 2X water, concentrated and chromatographed to yield 27% of the title compound.
Example 46 N-. { 3-Chloro-2- [(2-naphthylsulfyl) methyl] -1 - [4 - (. {[[(4-nitrophenyl) sulfonyl] amino} carbonyl) benzyl] -1H-indole-5-yl} Cyclopentanecarboxamide.
Step 1: The appropriate sulfonamide was added to Example 26 under the conditions outlined for step 1, Example 45, to yield the desired acylsulfonamide in 43% yield.
Example 47 N-. { 3-chloro-l- [4- ( { [(2-methyl enyl) sul onyl] amino.} Carbonyl) benzyl] -2- [(2-
^^ "naphthylsulfanyl) methyl-lH-indol-5-yl} cyclopen anocarboxamide.
Step 1: To the Example 26 the appropriate sulfonamide was added under the conditions summarized for step 1, Example 45, to yield the desired acyl sulphonamide in 40% yield.
EXAMPLE 48 N- [3-Chloro-2- [(2-naphsulfanyl) methyl] -1- (4-. {[[(Phenylsulfonyl) amino] carbonyl] benzyl) -1H-indol-5-yl] Cyclopentanecarboxamide.
Step 1: The appropriate sulfonamide was added to Example 26 under the conditions outlined for step 1, Example 45, to yield the desired acylsulfonamide in 40% yield.
Example 9 N-. { 3-chloro-2- [(2-naphsulfanyl) methyl] -1- [4- (. {[[(Tri-loromethyl) sulfonyl] amino} carbonyl) benzyl] -1H-indol-5-yl} Cyclopentanecarboxamide.
Step 1 To the Example 26 the appropriate sulfonamide was added under the conditions summarized for step 1, Example 45, to yield the desired 1% sulfonamide in 67%. of performance.
Example 50 4- [5- [(Cyclopentylcarbonyl) amino] -2- [(2-naphidoxy) methyl] -3- (1-pyrrolidinylcarbonyl) -1H-indol-1-yl] butanoic acid.
Step 1 Ethyl 5-nitroindol-2-carboxylate (1 equivalent) was dissolved in THF / MeOH / H20 (3: 1: 1 0.21M) followed by the addition of LH0H.H20 (1.38 equivalent), stirred at 25 ° C. ° C, during the night. The reaction mixture was then acidified to pH = 1 with a solution of IN HCl and extracted with ethyl acetate. Worked with water, brine, dried and the concentration provides the raw product in a yield of 99%.
Step 2 The crude acid (1 equivalent) from step 1 was dissolved in THF (0.14 M) and to this was added diimidazole carbonyl (1 equivalent) at 25 ° C for 1.5 hours. The reaction mixture was then cooled to 0 ° C. Sodium borohydride (2.86 equivalents) was added in several portions followed by the addition of EtOH (0.71 M), stirring at 25 ° C overnight. The reaction mixture at this point was acidified with 2N HCl to pH = 2, and extracted with ethyl acetate. Worked with water, brine, dried and the concentration gave the raw product in a 95% yield.
Step 3 Into a furnace drying flask was added the crude indole alcohol (1 equivalent) from step 2 followed by anhydrous DMF (0.135 M). To this was added imidazole (1.3 equivalents) and TBSC1 (1.2 equivalent), stirred at 25 ° C for 1 hour. Worked with ethyl acetate / water followed by chromatographic purification to provide the desired product in 79% yield.
Step 4: The equivalent silyl-protected indole), from step 3, was dissolved in anhydrous DMF (0.13M) in an oven-dried flask. To this was added NaH (60% dispersion in mineral oil, 1.2 equivalents) and stirred
- "- - • • • • * * ----» > - • •. - 25 ° C for 1 hour after which 4-bromobutyl ethyl (1.2 equivalent) and Kl (1.2) were added. The reaction mixture was then heated to 60 ° C for 2 hours.The work with ethyl acetate / water followed by chromatographic chromatographic purification gave the desired product in 93% yield.
Step 5 The alkylated indole (1 equivalent) from step 4 was dissolved in THF (0.05 M) and TBAF (1.0 M / THF, 1.1 equivalent) was added dropwise at 25 ° C, stirring 1 hour. Work with ethyl acetate / water followed by chromatographic purification provided the desired product quantitatively.
Step 6 The indole alcohol (1 equivalent) from step 5 was dissolved in anhydrous DMF (0.16 M) followed by the addition of P0C13 (10 equivalents) dropwise at 0 ° C. it was heated at 80 ° C, overnight. Work with ethyl acetate / water and washing the organic layer with IN NaOH, water, brine followed by purification by concentration and chromatography provided the desired product in 64% yield.
Step 7 A mixture of the chloro aldehyde derivative (1 equivalent) from step 6, 325 mesh of K2C03 (2.4 equivalents), 2-naphthol. (1.2 equivalent) and Kl (1.2 equivalent) was suspended in anhydrous acetonitrile (0.2 M) and heated at 70 ° C for 1.5 hours. Work with ethyl acetate / water followed by chromatographic purification gave the desired product in a 65% yield.
Step 8: The indole derivative naphthyloxy (1 equivalent) was dissolved from step 7 in anhydrous THF (0.023 M) and to this was added 5% Pt / C (40% by weight) under nitrogen and hydrogenated with a balloon H2 for 2.5 hours. The reaction mixture was then filtered through Celite and concentrated to give the crude product in 96% yield.
Step 9: The indole amino derivative (1 equivalent) from step 8 was dissolved in anhydrous CH2C12 (0.07 M) followed by the dropwise addition of Et3N (1.4 equivalent) and cyclopentylcarbonyl chloride (1.2 equivalent) at 0 ° C . It was stirred at 25 ° C for 0.5 hour after which the reaction mixture was quenched with saturated NaHCO 3 solution and stirred overnight. The organic layer was separated and washed with brine, it dried up. The product was obtained in a 66% yield after recrystallization from 30% ethyl acetate / hexane.
Step 10 The indole from step 9 (1 equivalent) was weighed in a flask with only NaH2P04 (12 equivalents), t-butyl alcohol (0.13 M), water (0.13 M), 2-methyl-2-butene (46 equivalents) and to this mixture was added Na02Cl (12 equivalents) at 25 ° C the reaction mixture was then heated to 65 ° C overnight, worked up with ethyl acetate / water followed by trituration with CH2C12 / hexane (4: 6) at 0 ° C for 1 hour providing the desired product in a 63% yield.
Step 11 The acid (1 equivalent) from step 10 was weighed into a flask and to this was added EDCI (3 equivalents), DMAP (1.2 equivalent), pyrrolidine (1.2 equivalent) followed by anhydrous THF (0.018 M) and the mixture of reaction then went to
-. ** ****. »-. .-. , -."--.. -.--to **. . ,. *, *. ,,: ..-.-, - * -a-au-i -... »» -. .- ***. 'A ... t - ^ ?? h ^? ^ - reflux temperature for 18 hours. Work with ethyl acetate / water followed by washing the organic layer with IN HCl, saturated bicarbonate and brine. Recrystallization from ethyl acetate / hexane (3: 7) gave the desired product in 89% yield.
Step 12 Amide (1 equivalent) was dissolved from step 11 in THF / MeOH / water (3: 1: 0.025 M l) and to this was added LÍOH.H20 (1.2 equivalents), stirred at 25 ° C overnight . Work with ethyl acetate / water followed by recrystallization from CH2C12 / hexane (1: 1) gave the desired product in 98% yield.
Example 51: Acid 4-. { 5- [(cyclopentylcarbonyl) amino] -3- (morpholinocarbonyl) -2- [(2-naphidoxy) methyl] -1H-indol-1-yl} butanico
Step 1: Step 11 of Example 50 was followed and morpholine was used in 87% yield of the desired product after recrystallization.
Step 2: Step 12 above was followed
(Example 50) and the corresponding morpholino amide was used to provide the desired product in a 96% yield after recrystallization.
Example 52 N- [2- [(2-naphthyloxy) ethyl] -1- (-oxo-4-. {[[(Trifluoromethyl) sulfonyl] amino] butyl) -3- (1-pyrrolidylcarbonyl) -lH- indol-5-yl] cyclopentanecarboxamide.
The acid of Example 50 (1 equivalent) was weighed into a flask and to this was added EDCI (3 equivalents), DMAP (1.2 equivalents), trifluoromethanesulfonamide (1.2 equivalents) followed by anhydrous THF (0.04 M) and the mixture of reaction was stirred at 25 ° C, overnight. Worked with ethyl acetate / water followed by washing the organic layer with IN HCl, saturated bicarbonate and brine. Trituration of the crude product with CH2C12 / hexane (1: 2) at 0 ° C for 1 hour gave the desired product in 96% yield.
EXAMPLE 53 N- [3-Chloro- (morpholinocarbonyl) -2- [(2-naphidoxy) methyl] -1- (4 -oxo-4-. {[[(Trifluoromethyl) sulfonyl] amino} butyl) - lH-indol-5-yl] cyclopentanecarboxamide.
Following step 1 above (Example 52) and using the corresponding acid of Example 51 (step 4, scheme 4) provided the desired product in 96% yield.
Example 53A Acid 4 -. { 5- [(Cyclopentylcarbonyl) amino] -3-formyl-2- [(2-naphthyloxy) methyl] -1H-indol-1-yl} bu añoico
Step 1 The indole (1 equivalent) was dissolved from step 9, Example 50 in THF / MeOH / H20 (3: 1: 1, 0.025 M) and to this was added LÍOH.H20 (1.2 equivalent), stirred at 25 °. C, for 4 hours. Work with ethyl acetate / IN HCl followed by trituration with CH2C12 / hexane gave the desired product in 74% yield.
Example 53B N- [3- (formyl-2- [(2-naphthyloxy) methyl] -1- (4 -oxo-4-. {[[(Tri-loromethyl) sulfonyl] amino.} Buyl) -1H -indol-5-yl] cyclopentanecarboxamide.
Step 1: The acid (1 equivalent) from step 1 of Example 53A was weighed into a flask and to this was added EDCI (1.35 equivalent), DMAP (1.1 equivalent), t rif luoromet anosulfonamide (1.05 equivalent) followed by anhydrous THF ( 0.026 M) and the reaction mixture was stirred at 25 ° C, 3 hours. Worked with ethyl acetate / water followed by washing the organic layer with 0.05N HCl, saturated bicarbonate and brine. The chromatographic purification then gave the desired product in a yield of 94%.
Example 54 5- [(Cyclopentylcarbonyl) amino] -2- [(2-naphiloxy) methyl] -1- (4-oxo-4-. {[[(Tri-loromethyl) sulfonyl] amino] butyl) acid -1H-indole-3-carboxylic acid.
Step 1: The product of Step 1, Example 53B
(1 equivalent) was weighed in a flask with only NaH2P04 (12 equivalents, t-butyl alcohol (0.12 M), water (0.12 M), 2-met i 1-2 -but eno (50 equivalents) and this mixture was Na02Cl (11.8 equivalents) was added at 25 ° C. The reaction mixture was then heated to 60 ° C., 3 hours and left overnight at 25 ° C. work with ethyl acetate / water followed by chromatographic purification. and triturations with CH2C12 / hexane (1: 1) gave the desired product in 57% yield.
EXAMPLE 55 3- (. {4- [5- [(Cyclopentylcarbonyl) mino] -2- [(2-naphidoyloxy) methyl] -3- (1-pyrrolidinylcarbonyl) -1H-indole-1-yl] bu yearl1.}. amino) benzoic.
Step 1 The compound of Example 50 (1 equivalent) was weighed into a flask and to this was added EDCI (3 equivalents), DMPA (1.2 equivalents), methyl 3-aminobenzoate (1.2 equivalents) followed by anhydrous THF (0.04 M) and the reaction mixture was then stirred at 25 ° C for 2 days. Worked with ethyl acetate / water followed by washing the organic layer with IN HCl, saturated bicarbonate and brine. Recritalization from acetate
ethyl / hexane provided the desired product in an 88% yield.
Step 2 The ester (1 equivalent) from step 1 was dissolved in THF / MeOH / water (3: 1: 1, 0.024 M) and to this was added LIOH.H20 (1.2 equivalents), stirred at 25 ° C, during overnight at this point, 1.2 equivalents of LÍOH.H20 were added and stirred for 2 hours. Work with ethyl acetate / IN HCl followed by trituration with CH2C12 / hexane (1: 1) at 0 ° C for 1 hour gave the desired product in 92% yield.
Example 56 3- [(4- {5- [(Cyclopentylcarbonyl) amino] -3- (morpholinocarbonyl) -2 - [(2-naphyloxy) methyl] -1H-indol-1-yl} butanoyl acid amino] benzoic.
Step 1: Following step 1 of Example 55 and the product of Example 51 was used (see scheme 4 for synthesis) the desired product was provided in a yield of 85% after chroma tographic purification.
Step 2: Following step 2 of Example 55 and using the corresponding morpholino from step 1, the desired product was provided in 91% yield.
Example 57 N- [2- [(2-naphthyloxy) methyl] -l-. { 4-oxo-4- [3- ( { [(Trifluoromethyl) sulfonyl] amino} carbonyl) anilino] butyl} -3- (-pyrrolidinylcarbonyl) -lH-indol-5-yl] cyclopentanecarboxamide.
Step 1: The compound of Example 55 (1 equivalent) was passed in a flask and to this was added EDCI (3 equivalents), DMAP (1.2 equivalent), tr if luoromet anosul fonamide (1.2 equivalent) followed by anhydrous THF (0.04 M). ) and the reaction mixture was then stirred at 25 ° C, overnight. Worked with ethyl acetate / water followed by washing the organic layer with IN HCl, saturated bicarbonate and brine. Trituration with HC2Cl / hexane (8: 2) gave the desired product in an 84% yield.
Example 58 N- [3- (Morphonylcarbonyl) -2- [(2 -naphthyloxy) methyl] -1-. { 4-OXO-4- [3- ( { [(Trifluoromethyl) sulfonyl] amino} carbonyl) anilino] butyl} -1H-indol-5-yl) cyclopen anocarboxamide.
Following step 1 of Example 57 and using Example 56 the desired product was provided in an 84% yield.
Example 59 Acid 2- (4-. {[[5- (benzyloxy) -3- (1-naphthoyl) -lH-indol-1-yl] -yl] -phenyl) -acetic acid
Step 1 A solution of MeMgBr in butyl ether 15 (1 M, 1.2 equivalents) was cooled on ice. 4-Benzyloxy indole (1 equivalent) in CH2C12 (0.5 M) was added and the reaction mixture allowed to warm to 25 ° C. After addition of 1-naphthoyl chloride (1 equivalent) in CH2C12 (1 M), the reaction was heated to reflux temperature for 3 hours. Quenching with aqueous NH4C1 and extraction with CHC13 gave the crude ketone, which was purified by recrystallization from hexane / CHCl 3 / MeOH (53% yield). 25
-..... ^ - «« - ^ - ^. =. «. . i. ".,. .a,. ";.? ^ > . .- -. ... - *. b "*. ^. *. Oi ^ - -. . .. j-,. t ¿tf-am-a * ---.
Step 2 An ice cooled solution of the ketone (1 equivalent) from step 1 in DMF (0.2 M) was treated with NaH (690% in mineral oil, 2.5 equivalents). 4-Bromo-phenyl acetic acid (1.1 equivalents) in DMF (0.4 M) was added after 15 minutes and the resulting mixture was stirred overnight at 25 ° C. the reaction was quenched with IN HCl and extracted with EtOAc. The organic extracts were dried and concentrated. The desired product was obtained in a yield of 68% after purification by chromatography and recrystallization from hexane / EtOAc.
EXAMPLE 60 2- (4-. {[[5- (Benzyloxy) -3- (2-naphthoyl) -lH-indol-1-yl] -me.-yl] -phenyl) -acetic acid
Step 1 Following step 1 of Example 59 and using the appropriate acyl chloride, yielded 42% of the desired ketone after recrystallization from hexane / CHC13.
Step 2: A procedure analogous to step 2 of Example 59 yielding 35% of the title compound after chromatographic purification and recrystallization from acetone / pentane.
Example 61 5 2- [4- (. {5- (Benzyloxy) -3- [3,5-bis (rifluoromethyl) benzoyl] -lH-indol-1-yl} methyl) phenyl] acetic acid
Step 1: Following step 1 of Example 59 using the appropriate acyl chloride, yielded 30% of the desired ketone after recrystallization from hexane / CH2C12 / EtOAc.
Step 2: A procedure analogous to step 2, 15 of Example 59 yielded 73% of the title compound after chromathographic purification and recrystallization from CHC13 / MeOH.
Example 62 Acid 4- (. {3-Benzoyl-5- (benzyloxy) -2- [(2-naphthylsulfanyl) methyl] -lH-indol-1-yl} methyl) benzoic acid.
Step 1: The starting ethyl 5-benzyloxyindole-2-carboxylate (Scheme 21, step 1) was treated with
"**" "•» - - * "- - - - ........ - .- • ............ ... .... .to - .,. ... "., ... ,, **, * ,. . i .. M-fc ».--, -......
LAH (1.3 equivalent) in THF (0.27 M) at 0 ° C under nitrogen for 1 hour. He worked with NaOH and water followed by the concentration provided the raw product (100%).
Step 2 The crude alcohol from step 1 was dissolved in DMF (0.38 M) and treated with t-butyldimethyl-ylsilyl chloride (1.16 equivalent) and imidazole (1.26 equivalent) at 25 ° C for 1 day. Work and
The chromatographic purification afforded the crude product (93%).
Step 3 The silyl ether from step 2 was dissolved in methe chloride (0.26 M), and
treated with BOC anhydride (1.24 equivalent), triethylamine (1.53 equivalent) and DMAP (0.21 equivalent) at 25 ° C for 3 days. The work and the chromatological purification provided the pure product (99%). Step 4 The N-BOC silyl ether from step 3 was treated with acetic acid / water / THF (3: 1: 1) (0.04 M) at 25 ° C for 1 day. The work and the chromatographic purification provided the pure product
(100%).
Step 5 The alcohol from step 4 was dissolved in methe chloride (0.2 M), and under nitrogen at -40 ° C treated with triethylamine (1.33 equivalents) and mesyl chloride (1.23 equivalents) for 1 hour. In a separate dry flask, naphthalene-2-thiol (1.31 equivalent) was weighed, and THF (1 M) was added, followed by hexamet ildisi lithium zido (IN in THF, 1 equivalent) and this mixture was stirred at 25 ° C. ° C for 30 minutes. The resulting solution was then added dropwise, during 30 minutes, to the previous mesylate solution, at -40 ° C. The reaction mixture was allowed to warm to 25 ° C, and was thus stirred for 4.5 hours. Work and purification provided the BOC thioether.
Step 6 Purification of the BOC thioether from step 5 was heated under nitrogen at 160-170 ° C for 1.25 hours, and recrystallized from ethyl acetate and hexanes to provide the free indole thioether in a 64% yield.
Step 7 The product of the step (1 equivalent) in CH2C12 (0.125 M) was cooled in
. . . _, «. ... t fe ... ti í e s **? * - r ice. A solution of MeMBr (1.2 equivalent) in butyl ether (1M) was added and the resulting mixture was stirred for 30 minutes. After warming up to 25 ° C, benzoyl chloride was added dropwise. The reaction was heated to reflux temperature for 3 hours, and then stirred at 25 ° C overnight. After quenching with NH4C1, the mixture was extracted with CH2C12. the organic extracts were washed with brine, dried and concentrated. The desired ketone was obtained in 55% yield after chromatographic purification.
Step 8: A solution of the product from step 1 (1 equivalent) in dry DMF (0.1 M) was treated with NaH (60% in mineral oil, 1.05 equivalent). 4-Bromometylbenzoate or methyl (1.2 equivalent) was added after 1 hour at 25 ° C and the resulting mixture was stirred overnight. Work with EtOAc / water produced the desired crude material which was purified by chromatography (56% yield).
Step 9: The step material (1 equivalent) was hydrolyzed by the action of LÍOH.H20 (1.2 equivalent) in THF / MeOH / water (3/1/1, 0.07 M). After stirring at 25 ° C overnight, the reaction mixture was quenched with AcOH and the solvent was evaporated. Working with EtOAc / water and chromatofogic purification gave the title compound in a 78% yield.
EXAMPLE 63 4- (. {5- (Benzyloxy) -3-isobutyryl-2- [(2-naphsulfanyl) methyl] -lH-indol-1-yl) methyl) benzoic acid.
Step 1 Following step 7 of Example 62 using isopropyl chloride yielded the desired ketone after chromatography.
Step 2 A procedure analogous to the step of Example 62 yielded 50% of the N-alkylated material after chromatofogic purification.
Step 3: Following step 9 of Example 62, the methyl ester was hydrolyzed to the title compound in 67% yield after chromatography.
Example 64 Acid 2-. { 3-Acetyl-5- (benzyloxy) -2- [(2-naphthylsulfanyl) methyl] -lH-indol-1-yl} acetic
Step 2 The product from step 1 of Example 80 was alkyl with methyl bromoacetate following a procedure analogous to step 8 of Example 62 to yield 65% of the desired compound after recrystallization from EtOAc.
Step 3 Following step 9 of Example 62 above, the methyl ester was hydrolyzed to the title compound in 84% yield after chromatography.
Example 65 Acid 2-. { 5- (benzyloxy) -3-isobutyryl-2- [(2-naphthylsulfanyl) methyl] -lH-indol-1-yl} acetic
Step 2 Initiate a procedure analogous to step 2 of Example 63 from the bromo methyl acetate and the isopropyl ketone described in step 1 of Example 63 (step 1, see above). This reaction yielded 66% of the N-material
. . ** - * **. t. «.- .. '. * > . ».. *. »,. * -.? t < j ^ .:.-a. - * r *. . i rented after chromatographic purification.
Step 3: Following step 3 of Example 63 of the methyl ester was hydrolyzed to the title compound in 50% yield after chromatography.
Example 66 10 Acid 4-. { 3-benzoyl -5- (benzyloxy) -2- [(2-naphthyloxy) me il] -lH-indol-1-yl} acetic
Step 1 A solution of EtMgBr in ether (3N,
2. 17 equivalents) was cooled to -70 ° C. He
.15 product from step 2 in Example 62 (1 equivalent) in ether (0.55 M) was added, and the reaction mixture was stirred to -70 ° C for 2 hours. After the addition of benzoyl chloride (3 equivalents) in ether (1.5 M), the
The reaction was stirred at -40 ° C for 2 hours, quenched with saturated NaHCO 3 at -40 ° C and allowed to warm to 25 ° C. Work-up with EtOAc / water and recrystallization from hexane / EtOAc yielded the desired ketone by 89%. 25
¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡Step 2: The material from step 1 (1 equivalent) in CH2C12 (0.25 M) was discussed with Net3 ( 2 equivalents), followed by BOC anhydride (1.24 equivalent) and DMAP (0.21 equivalent). After stirring for 20 minutes at 25 ° C, the reaction mixture was worked with CH2C12 and water. The desired pure material was obtained in a 97% yield by trituration with hexane.
Step 3: The above material (1 equivalent) in THF (0.3 M) was combined with pyridine (excess) and pyridine HF (excess) at 0 ° C. The reaction was stirred at 25 ° C for 1.5 hours. Worked with EtOAc / water followed by chromatographic purification to give the desired alcohol in 86% yield.
Step: Alcohol from step 3 (1 equivalent) in CH2C12 (0.4 M) was treated with 2,6-lutidine (2.5 equivalents) followed by SOC12 (1.2 equivalent). After 30 minutes at 25 ° C the reaction was worked with EtOAc and water. The crude product was purified by chromatography and trituration with hexane provided the corresponding chloride in a 75% yield.
Step 5: A mixture of the above material (1 equivalent), K2C03 325 mesh (2.4 equivalents), b-naphthol (1.2 equivalents) and Kl. (1.2 equivalents) in CH3CN (0.3 M) was heated to reflux temperature for 2 hours. Work-up with EtOAc / water, followed by trituration in hexane / EtOAc and chromatography of the mother liquor yielded 70% of the expected ester.
Step 6: A solution of NaOMe in MeOH was prepared by dissolving Na (3 equivalents) in MeOH (0.2 M). The product from step 5 (1 equivalent) in THF (0.04 M) was added and the reaction mixture was stirred at 25 ° C for 3 hours. Work-up with EtOAc / water followed by trituration with hexane / EtOAc afforded the indole compound by 93%.
Step 7: A solution of the product from step 6 (1 equivalent) in dry DMF (0.1 M) was treated with NaH (60% in mineral oil, 1.1 equivalent). Methyl 4-bromobutyl (1.2 equivalent) and Kl (1.2 equivalent) were added after 1 hour and the reaction mixture was stirred at 75 ° C for 3 hours. He
* ".. < - .-. go to--.. - ..*-.*, - -. , ..... - ".... *, ...,., _!.» ... »..,.,». «- Ai .--, .....,. ., ...-. . . . .- > , _ »,. .. «^., .. ^", .. ^ ...
Work with EtOAc / water followed by chromatographic purification yielded 96% of the required ester.
Step 8: The material from step 7 (1 equivalent) was hydrolyzed by the action of
LH0H.H20 (1.2 equivalent) in THF / MeOH / water
(3/1/1, 0.2 M). After stirring at 25 ° C for 2 hours, the reaction mixture was quenched with IN HCl and extracted with EtOAc and CH2C12. the organic extracts were combined, washed, dried and concentrated. The crude material was purified by trituration in hexane / EtOAc to provide the title compound in 86% yield.
Example 67 3- [(4. {3-Benzoyl-5- (benzyloxy) -2- [(2-naphthyloxy) methyl] -lH-indol-1-yl} butanoyl) amino] benzoic acid.
Step 1: The product of Example 66 (1 equivalent) was reacted with EDCI (1.37 equivalent) and 3-amino methyl benzoate (1.05 equivalent) in DMF (0.09 M) in the presence of DMAP (0.2 equivalent). The reaction was stirred at 25 ° C for 1.5 hours. Work with EtOAc / water, followed by flash chromatography afforded the desired amide in 81% yield.
Step 2: A procedure analogous to step 2 of Example 66 yielded 98% of the title compound after purification by trituration in hexane / EtOAc.
Example 68 4-. { 3-benzoyl-5- (benzyloxy) -2 -naphthyloxy) methyl] -1H-indol-1-yl} -N- [3- ( { [(Trifluoromethyl) sulfonyl] amino} carbonyl) phenyl] butanamide.
Step 1: Following step 1 of Example 67 and using the acid of Example 67 and the appropriate sulfonamide provided after the reaction overnight and working analogously to the desired product. Trituration with hexane / EtOAc yielded 100% of the title compound.
Example 69: 4- [(4- {3-Benzoyl-5- (benzyloxy) -2- [2-naphyloxy) methyl] -lH-indol-1-yl) butanoyl) amino] benzoic acid.
-m, s! A »* í * g2 ^^ Step 1 Following step 1 of Example 67 above using the acid of Example 66 and the appropriate aniline yielded 76% of the expected amide.
Step 2 A procedure analogous to step 2 of Example 67 yielded 78% of the title compound after purification by trituration in hexane / EtOAc.
EXAMPLE 70 2- (4- ({3-Benzoyl-5- (benzyloxy) -2- [2-naphidoyloxy] methyl] -lH-indol-1-yl acid} butanoyl) amino] benzoic acid.
Step 1: Following step 1 of Example 67 above using the acid of Example 66 and the appropriate aniline yielded 36% of the expected amide after chromatography.
Step 2 A procedure analogous to step 2 of Example 67 yielded 67% of the title compound after purification by trituration in hexane / EtOAc.
EXAMPLE 71 3- [(4- {3-Benzoyl-5- (benzyloxy) -2- [2-naphthyloxy) methyl] -lH-indol-1-yl} acid} butanoyl) amino] propanoic.
Step 1: Following step 1 of Example 67 above using the acid of Example 66 and the appropriate aniline yielded 96% of the expected amide 10 after chromatography.
Step 2: A procedure analogous to step 2 of Example 67 yielded 67% of the title compound after purification by trituration in hexane / EtOAc.
Example 72 3- [(4. {3-Benzoyl-5- (benzyloxy) -2- [(2-naphthyloxy) methyl] -lH-indol-1-yl} butanoi) amino] propane acid.
Following step 1 of Example 67 using the acid of Example 66 and the appropriate sulfonamine yielding 100% of the title compound. 25
^^^ g ^ - - - ^ ^ * - > ...-
Example 73 N- (4-. {3-benzoyl-5- (benzyloxy) -2- [(2-naphthyloxy) methyl] -lH-indol-1-yl}. Butannoyl) -2-methylbenzenesulfonamide.
Following step 1 of Example 67 using the acid of Example 66 and the appropriate sulfonamide yielded 80% of the title compound after chromatography.
Example 74 Acid 5-. { 3-benzoyl-5- (benzyloxy) -2- [2-naphthyloxy) methyl] -lH-indol-1-yl} pentanoic
Step 1: A solution of the product from step 6 of Example 66 (1 equivalent) in dry DMF (0.1 M) was treated with NaH (60% in mineral oil, 1.1 equivalent). 4-bromopent anoat or ethyl (1.2 equivalent) and Kl (1.2 equivalent) were added after 1 hour and the reaction mixture was stirred at 75 ° C for 2 hours. Work with EtOAc / water followed by chroma tigraphic purification yielded 92% of the required ester.
• - * '- • - ~ • > • Step 2: Step material (1 equivalent) was hydrolyzed by the action of LÍOH.H20 (1.3 equivalent) in THF / MeOH / water (3/1/1, 0.2 M). After stirring at 25 ° C for 3.5 hours, the reaction mixture was quenched with IN HCl and extracted with EtOAc and CH2C12. the organic extracts were combined, washed, dried and concentrated. The crude material was purified by trituration in hexane / EtOAc to provide
the title compound in a 95% yield.
Example 75: 3- [(5-. {3-Benzoyl-5- (benzyloxy) -2- [(2-naphthyloxy) methyl] -lH-indol-1-yl}. Pentanoyl) amino] benzoic acid
Step 1: The acid of Example 74 (1 equivalent) was reacted with EDCI (1.37 equivalent) and 3-amino methyl benzoate (1.05)
equivalent) in DMF (0.09 M) in the presence of DMAP (0.2 equivalent). The reaction was stirred at 25 ° C for 2.5 hours. Work with EtOAc / water followed by flash chromatography gave the desired amide in 78% yield. 25
, Α-l-tf-t-Ífc- * t? - M-¿-H > Step 2: A procedure analogous to step 2 of Example 74 yielded 83% of the title compound after purification by trituration in hexane / EtOAc.
Example 76 5-. { 3-benzoyl -5- (benzyloxy) -2- [(2-naphthyloxy) methyl] -lH-indol-1-yl} -N- [3- ( { [(Trifluoromethyl) sulfonyl] amino} carbonyl) enyl] pentanamide.
Step 1: Following step 1 of Example 68 using the acid of Example 75 and the appropriate sulfoamide, yielded 83% of the title compound after overnight reaction and analogous work.
Example 77 Acid 2-. { 3-Benzoyl-5- (benzyloxy) -2- [2-naphthyloxy) methyl] -1H-indol-1-yl} acetic
Step 1: Following step 1 of Example 74 using the appropriate bromide yielding 80% of the expected amide after chromatography.
A - * "• -" "* •" - ^ Step 2: A procedure analogous to step 2 of Example 74 yielding 90% of the title compound after trituration in hexane / EtOAc.
Example 78 Acid (E) -4-. { 3-benzoyl-5- (benzyloxy) -2- [(2-naphthyloxy) ethyl] -lH-indol-1-yl} -2-butenóico.
Step 1: Following step 1 of Example 74 using the appropriate bromide, it yielded 33% of the expected amide after chromatography.
Step 2: A procedure analogous to step 2 of Example 74 yielded 70% of the title compound after trituration in hexane / EtOAc.
EXAMPLE 79 3- (. {3-Benzoyl-5- (benzyloxy) -2- [(2-naphthyloxy) methyl] -lH-indol-1-yl} methyl) benzoic acid.
Step 1 Following step 1 of Example 74 using the appropriate bromide, yielded 75% of the expected amide after chromatography.
Step 2 A procedure analogous to step 2 of Example 74 yielded 92% of the title compound after trituration in hexane / EtOAc.
Example 80 l-. { l- [4- (1, 3-Benzo-iazol-2-ylcarbonyl) -benzyl] -5- (benzylsulfanyl) -2- [(2-naphthylsulfanyl) methyl] -1H-indol-3-yl} -1-ethanone.
Step 1: The thioether from step 6, Example 62 was dissolved in methylene chloride (0.12 M), and under nitrogen at 0 ° C treated with methylmagnesium bromide (1.1 equivalent), and stirred at 0 to 25 ° C. 1 hour. The mixture was re-cooled to 0 ° C and acetyl chloride was added
(1.17 equivalent). After 1 hour at 0 ° C, the reaction mixture was quenched by the addition of a saturated ammonium chloride solution in half, and working with methylene chloride. Chromatographic purification afforded the pure product (37%).
Step 2 Following the procedure for the
Example 81 step 1 and using p-Toluoyl chloride yielded the corresponding for amide.
i .. . . .. ... .j »-. . . ..,. -. -. ».» -,.,. - .. »- ,;» ».
Step 3: Following the procedure for Example 81 step 2 and using the product from step 1 above, the desired product was obtained.
Step 4 Following the procedure for step 3, Example 81 and using the material from step 3, yielded the desired benzyl bromide.
Step 5 Following the procedure for Example 81 step 4, the material from step 4 was coupled to the material from step 1 to yield the title compound.
Example 81 1-. { 1- [3- (1, 3-benzothiazol-2-ylcarbonyl) benzyl] -5- (benzylsulfanyl) -2- [(2-naphthylsulfanyl) methyl] -1H-indol-3-yl} -1-ethanone.
Step 1 M-toluoyl chloride (0 M) was added to triethylamine (2.44 equivalents) and HC k of methoxymethyl amine (1.1 equivalent) dissolved in methylene chloride at 0 ° C for 20 minutes. The reaction was allowed to warm to 25 ° C. 25 After stirring at 25 ° C for 1 day, work with
- * M - «-.-- fa --- JM-? Ai» - «» _. . . . . . - ^ ..-.-., 1? . ., "",. . *,., .. * -, ~ -. ....- . . -. "T, - .. i *" M-- < t ---- < t- "Methylene chloride and water gave the crude product in ca. 100% performance
Step 2 Under nested conditions, benzothiazole was dissolved in THF (0.35 M). BuLi (1.1 equivalent) was added at -78 ° C. After 1 hour at -78 ° C, the amide from step 1 in THF was added, for 15 minutes. The reaction was allowed to warm to 25 ° C. After stirring at 25 ° C for 1 day. Work with ethyl acetate and water and chromatography gave pure tolyl ketone product (52%).
Step 3 The tolyl ketone from step 2 was dissolved in carbon tetrachloride (0.19 M), and NBS (1.2 equivalent) and AIBN (0.11 equivalent) were added. After 1 day at 60 ° C, about 1: 1 of the starting material and product was presented. It was again exposed under the same conditions, followed by filtration and recrystallization from ethyl acetate to yield the pure bromobenzyl ketone product (28%).
-dfa --- j - »-» - «- j -« i.-...-. - .., .-. . ^ A ^ ,. i .. ..- ........ ...,., ........ ^ ..- t.-... > .-..-. * .J. . . ? l * JIMfa - ^ - ü ..
Step 4 The indole from step 1 of Example 80 was dissolved in dry DMF (0.04 M), followed by NaH (1.25 equivalent). After 45 minutes at 25 ° C, bromobenzyl ketone from step 3 (1.25 equivalent) was added and stirred for 1 hour at 25 ° C. Work, chromatography, and recrystallization from ethyl acetate / hexanes afforded the pure title compound (45%).
EXAMPLE 82 2- [3- (. {3-Acetyl-5- (benzyloxy) -2 - [(2-naphthylsulfanyl) methyl] -lH-indol-1-yl.} Methyl) benzoyl] -1 acid, 3-benzothiazole-6-carboxylic acid
Step 1: Ethyl 4-aminobenzoate was dissolved in 95% v / v HOAc / water (0.4 M) and at 25 ° C treated with sodium thiocyanate (4.1 equivalents), and stirred at 25 ° C for 20 minutes. The mixture was cooled to 5 ° C and bromide (1.17 equivalent) was added in 95% v / v of HOAa / water. After 1 hour at 0 ° C, the reaction mixture was quenched by the addition of water, and filtered, the work (ethyl acetate and sodium bicarbonate solution) gave 81% of the pure thiocyanate product.
Step 2 The aryl thiocyanate from step 1 was treated with sodium sulfide nonahydrate in water (1.2 equivalent, 1.3 M), and heated to reflux temperature for 45 minutes. The cold mixture was filtered, acidified to pH = 6 with HOAc, extracted with ethyl acetate, and concentrated to give the thiophenol product (91%):
Step 3 The thiophenol from step 2 was dissolved in
90% v / v HCOOH / water (3.3 M), and zinc powder (catalyst) was added. After 3 hours at reflux temperature, work with ethyl acetate and alkali provided the benzothiazole ester (60%). Step 4: The benzothiazole ester was dissolved (step 3) in THF / methanol / water (8: 3: 3), (0.34 M), lithium hydroxide (2 equivalents) was added, and the mixture was stirred for 2 hours. hours at 25 ° C. The job
(ethyl acetate / aqueous acid) provided the pure benzothiazole acid (100%).
Step 5: Under anhydrous conditions, the benzothiazole acid (step 4) was dissolved in THF (0.052 M).
BuLi was added at -78 ° C (2.2 equivalents). After
After 1 hour at -78 ° C to 0 ° C, the amide (1.28 equivalents) from step 1 of Example 81 was added in THF at -78 ° C for 5 minutes. After 0.5 hours at -78 ° C, the reaction was allowed to warm to 25 ° C. After stirring at 25 ° C for 2 hours, work with ethyl acetate and water and chromatography gave the pure tolyl ketone acid product (64%).
Step 6 The tolyl ketone acid from step 5 was suspended in (1: 1) THF / ethanol, (0.075 M), and concentrated sulfuric acid (excess) was added. After being at reflux temperature for 1 day, the work (ethyl acetate and
Sodium bicarbonate) and purification by chromatography gave the pure tolyl ketone ester product (69%).
Step 7 The tolyl ketone ester from step 6
was dissolved in carbon tetrachloride (0.05 M), and NBS (1.2 equivalent) and AIBN (0.15 equivalent) were added. After 1.25 hours at reflux temperature, another portion of NBS (0.3 equivalent) and AIBN (0.07 equivalent) was added. The
filtration and recrystallization from acetate
of ethyl provided the product of pure bromobenzyl ketone (22%).
Step 8: The indole from step 1 of Example 80 was dissolved in dry DMF (0.06 M), followed by NaH (1.11 equivalent). After 45 minutes at 25 ° C, the bromobenzyl ketone from step 7 anteiror (1.25 equivalent) was added and stirred for 1 hour at 25 ° C. The work provided the crude ester, 10 used in the next step.
Step 9: The crude ester from step 8 was dissolved in THF / methanol / water (8: 2: 2), (0.013 M), lithium hydroxide (4.3 equivalents) was added in 15 portions, stirring the mixture for a total of 3-4 days at 25 ° C. Work (ethyl acetate / aqueous HCl) and purification by chromatography gave pure benzothiazole acid (31%).
Example 83 Acid 5-. { 3-benzoyl -5- (benzyloxy) -2- [(2-naphthyloxy) methyl] -lH-indol-1-yl} -2-oxopentanoic.
Step 1: The indole from step 6 of Example 66 was dissolved in dry DMF (0.17 M), followed by NaH
- * M. - * --- * »» - «-.... * .-. v. - »? - .. Irtn», *. , • «-, t • • t-fr» I.IW * - (1.2 equivalent). After 1.5 hours at 25 ° C, 3-iodo-1-chloropropane was added, and it was stirred for 4 hours at 25 ° C. Work (ethyl acetate / bicarbonate solution) and trituration (ethyl acetate / hexanes) gave the product in 89% yield.
Step 2 The alkyl chloride from step 1 was dissolved in methyl ethyl ketone (0.036 M) followed by Nal (1.6 equivalent). After stirring for 1 day at reflux temperature in the dark, the work (ethyl acetate / water) provided the iodide product in 97% yield.
Step 3: NaH (1.0 equivalent) was weighed into a dry flask under nitrogen, and dry benzene (0.14 M) was added. At 0 ° C, dry DMF (0.4 M), ethyl 2-carboxyl-1,3-di-ethyl (1.0 equivalent), and iodide from step 2 (1.0 equivalent) in a separate dry flask were added. This DMF solution was then added at 0 ° C to a suspension of benzene, and the mixture was allowed to warm to 25 ° C and was stirred for 3 hours at 25 ° C. Work (ethyl acetate / water) and chromatography
? iT-M-li? i-MÉ-Mi-É-l - «- álÍ-ÍÉ-i ?? * "- '- * - > .---- * ... ^ * -... * ...., ..» ...... > .. ..., .. , ... ..... ........ -. - ....- «, -. - ...., ....... ...,. * ..., ,, .....- > "
provided the diati- noanyl ester in 54% yield.
Step 4: Silver nitrate _ (4.5 equivalents) and NCS (4.0 equivalents) were dissolved in 4: 1 v / v acet oni tri lo / water (ca 0.04 M), and a solution of the dithianyl ester was added. Step 3 (1 equivalent) in acetonitrile (0.03 M) at 25 ° C. After stirring for 5 minutes at 25 ° C, it was added
a solution of sodium sulphide, followed in one minute by a solution of sodium carbonate. Work (ethyl acetate / water) and chromatography gave the ketoester product in 17% yield. Step 5: The ketoester from step 4 was dissolved in THF / water (8: 1), (0.03 M), lithium hydroxide (1.5 equivalents) was added, and the mixture was stirred for 2 hours at 25 ° C. The work (acetate
Ethyl acetate / aqueous HCl) and purification by chromatography gave pure ketoacid (64%).
Example 84
3- [(5- { 3-Benzoyl-5- (benzyloxy) -2- [(2-naphthyloxy) methyl] -lH-indol-1-yl.} -2-oxopentanoyl) amino] benzoic acid.
Step 1: The dithianyl ester from step 3, Example 83, was dissolved in THF / ethanol / water (5: 2: 2) (0.008 M), and lithium hydroxide (11 equivalents) was added, and the mixture was stirred for 1 hour at 50 ° C. Work (ethyl acetate / aqueous HCl) and chromatography afforded pure dithianyl acid (90%).
Step 2: The dithianyl acid from step 1 was dissolved in dry methylene chloride (0.08 M), and DMF (catalyst). Oxalyl chloride was added
(1.2 equivalents), and the reaction was stirred at 25 ° C for 0.5 hours. The concentration was continued by dissolving again in dry methylene chloride, and the addition, at 0 ° C, of methyl 3-aminobenzoate (1.05 equivalents) and triethylamine (1.0 equivalents). The reaction was warmed to 25 ° C, and stirred here for 3 hours. Work (ethyl acetate / aqueous acid) and purification by chromatography gave the dithianyl ester product in 89% yield.
Step 3 The dithianyl ester from step 2 was dissolved in THF / methanol / water (6: 4: 3) (0.02 M), and lithium hydroxide (4.3 equivalents) was added, and the mixture was stirred for 3 hours at 25 minutes. ° C. Work (ethyl acetate / aqueous HCl) provided the dithianyl acid (R = 3-C00H) (91%).
Step 4 Silver nitrate (4.0 equivalents) and NCS (4.0 equivalents) were dissolved in 4: 1 v / v acetonitrile / water (ca. 0.03 M), and a solution of dithianyl acid from step 3 (1 equivalent) was added. ) in acetonitrile (0.009 M) at 25 ° C. After stirring for 10 minutes at 25 ° C, this was added to a solution of sodium sulphide, followed in one minute by a sodium carbonate solution. Work (ethyl acetate / aqueous acid) and chromatography afforded the title compound in 82% yield.
Example 85: 4- [(5-. {3-Benzoyl-5- (benzyloxy) -2- [(2-naphthyloxy) methyl] -lH-indol-1-yl.} -2-oxopentanoyl) amino] benzoic acid .
^^^^^^^^^^^^ Step 1: Step dithinyl acid
Example 84 was treated as described above by step 2, Example 84, except that ethyl 4-aminobenzoate is substituted. Purification by chromatography gave the dithianyl ester product (R = 4-COOC2H5) in 30% yield.
Step 2 The dithianyl ester from step 1 was treated as described by step 3 of Example 84. Purification by chromatography gave the dithianyl acid product (R = 4-COOH) in 89% yield.
Step 3 The dithianil from step 6 was treated as described by step 4 of Example 84. Repeating purification by chromatography followed by trituration in pentane provided the title compound in 30% yield.
Example 86
Table I reports the data for the compounds described in the above examples in cPLA2 inhibition assays (as described below). In the columns of the data in the tables, the test results are reported as an "IC50" value, which is the concentration of a compound that inhibits 50% of the activity of the phospholipase enzyme in such an assay. Where the numerical value IC50 does not appear, "NA" denotes that the inhibition activity was not detected from such compound in the corresponding assay and a blank box denotes that the compound was not tested in such assay as at the time of submitting the present application .
Activity Essays
(a) Vesicle Test
The 1-palmi t oi 1 -2 - [14C] arachidonyl phos phiol isocol (58mCi / mmol) (final concentration 6M) and 1,2-dioleiolgl icerol (final concentration 3M) were mixed and dried under a stream of water. nitrogen. 50mM of Hepes pH 7.5 (final 2x concentration of lipids) were added to the lipids and the suspension was sonicated for 3 minutes at 4 ° C. Hepes was added to the suspension 50mM pH 7.5,300mM NaCl, 2mM DTT, 2mM CaCl2 and 2mg / ml bovine serum albumin (BSA) (Sigma A7511) (final concentration 1.2x lipids). A typical assay consisted of the mixture of lipids (851) to which the inhibitor was added consecutively (51 in DMSO) and cPLA2, 10 ng for an automated system or Ing for a manual assay, in 101 of the buffer solution of BSA . This test was carried out either by manual testing or by the automated assay protocol described below.
b) Soluble Substrate Test (LysoPC)
The 1 - [14 C] -palmi t oi 1-2 -hydroxy fos fot idyl-choline was dried (57mCi / mmol)
(final concentration 4.4M) under a stream of nitrogen. The lipid was suspended again when stirring 80mM Hepes pH 7.5.1 mM EDTA (final concentration 1.2x). A typical assay consisted of a suspension (85 1) to which the inhibitor was added consecutively (51 in DMSO) and cPLA2, 200ng in 80mM Hepes pH 7.5,2mM DTT and 1M
EDTA This test was carried out in manual assay or by the automated assay protocol described below.
c) Automated Test
The lipid suspension and the inhibitor were pre-incubated for 7 minutes at 37 ° C. The enzyme was added and the incubation was continuous for an additional 30 minutes. The reaction was then quenched by the addition of decane: isopropanol: trifluoroacetic acid (192: 8: 1 w / v, 1501). A portion of the quench layer (501) was passed through a column of Silica Rainin Spherica-5 (5, 30x2. Mm) eluting with ethane: methanol: TFA (97: 3: 0.1 v / v). The level of arachidonic acid [1 C] was analyzed by an online Radiomatic Flo-One / Beta (packard) counter.
d) Manual Test
The mixture of lipid, inhibitor and enzyme was incubated at 37 ° C for 30 minutes. The reaction was quenched by the addition of heptane: isopropanol: 0.5M sulfuric acid (105: 20: 1 v / v, 200 1). Half of the quench layer was applied to a column of disposable silica gel (Whatman SIL, lml) in a vacuum manifold positioned on a scintillation vial. The arachidonic acid with [1 C] free was eluted by the addition of ethyl ether (1 ml). The level of radioactivity was measured by the liquid scintillation counter.
(e) PMN test
The PMNs were isolated using a Ficoll-Hypaque according to the manufacturers' instructions the red blood cell cells that contaminated the PMNs, were separated by hypotonic lysis, and the PMN pellet was washed once, and was suspended again in a Hanks' buffer solution at a concentration of 2xl06 cells per milliliter. The cells were pre-incubated with inhibitors for 15 minutes at 37 ° C and then stimulated with 2uM A23187. When the production of LTB4 was impaired as a measure of the inhibition of cPLA2, the reaction was quenched with an equal volume of ice cold phosphate buffered saline. The cells were separated by centrifugation, t the LTB4 present in the supernatant of the cells was measured using the LTB4 proximity probe assay provided by Amersham according to the indications of the
* ¿. *: -... • .. * - i?, Ii, íí¿ * .- ¿M, *. *. -fcfa - - - p ..- S manufacturers. In the trials reported in the previous tables, LTB4 was measured. Upon observing the production of arachidonic acid, the reaction was quenched with methanol containing arachidonic acid D8 as an internal reference. Lipids were extracted by the method of Bligh et al. ((1959) Can.J. Biochem. Physiol., 37, 911-917), and the fatty acid was converted to the pentafluorobenzyl ester and analyzed by GC-MS in a manner similar to
reported by Ramesha and Taylor ((1991) Anal Biochem. 192, 173-180).
(f) RBL test
RBL-2H3 cells were routinely cultured in an atmosphere of 5% C02 at 37 ° C, a minimum essential medium containing non-essential amino acids and 12% fetal lamb serum. The day before the experiment,
cells were plated in spinner flasks at 3xl05 cells / ml and 100 ng / ml DNI-specific IgE was added. After 20 hours the cells were harvested by centrifugation and washed once in minimal essential medium free of serum, and
resuspended up to 2xl05 cells / ml in a
serum free medium. The cells were then preincubated with the inhibitor in DMSO (1% v / v) or DMSO (1% v / v) for 15 minutes at 37 ° C followed by stimulation with DNP-BSA (300ng / ml). After 6 minutes, the cells were separated by centrifugation, and the supernatant was assayed for its PGD2 content according to known methods.
(g) Coumarin Test 10 The 7-hydroxyoumarinyl 6-heptanoate used as a monomeric substrate for cPLA2 was used as reported previously (Huang, Z. et al., 1994, Nalytical Biochemistry 222, 110-115). 15 The inhibitors were mixed with a 200μL assay buffer (80 mM Heped, pH 7.5, 1 mM EDTA) containing 7-hydroxyurea in i-1-heptanoate 60μM. The reaction was started by adding a buffer solution of 4 μg cPLA2 assay in 20 50μL. The hydrolysis of the 7- hydroxycorter imi 1 6-heptanoate ester was observed in a fluorometer upon excitation at 360 nm and monitoring the emission at 460 nm. The activity of the enzyme is proportional to the increase in emission at 460 nm
. *. * * - *** ^ ~ j é¡ / &3i & *. - & sn ***. í * * ** - - *. * ¿*,. »• *, ... * * ***. .. * *. ** l ** * *. , * * * * £ í-.z .... i. ^ ... ^. *. ",. . ^ * ^ ^. . j s ^ ¿s-táj- a * -per minute. In the presence of a cPLA2 inhibitor, the rate of increase is lower.
Example 87
The compounds of the present invention were also tested for in vivo activity in a rat leg edema test according to the procedure described below. The results are reported in table II.
Test for Rat Paw Edema Induced by Carrageenan
Each compound was suspended in absolute ethanol 0.3ml, O.lml of Tween-80 and 2. Oml PBS of Dulbecco (with calcium or magnesium). O.lml IN NaOH was added to this mixture. After the solution was complete, additional amounts of PBS were added to adjust the concentration to lmg / ml. All the compounds remained in solution. Compounds were administered intravenously in a volume of 5ml / kg to male Sprague Dawley rats at the same time that the edema was induced by the injection of 0.05ml of
••• "" '' "* '-' carrageenan of type IV at 1% within the hind paw The volume of the paw was measured before dosing with the compound and 3 hours after dosing with carrageenan.
All references to the literature and patents cited here are incorporated as if they were fully established here.
It is noted that in relation to this date, the best method known by the applicant to carry out the aforementioned invention, is that which is clear from the present description of the invention. Having described the invention as above, the content of the following is claimed as property.
Claims (109)
1. A component of the formulas: characterized in that Ri and Ri are independently selected from H, halogen, CF3, -OH, alkyl-Ci-Cio-, alkyl -S-Ci-Cio, alkoxy Ci-Cio, -CN, -N02, -NH2, -HN (C? -C6), -N (C? -C6) 2, phenyl -O-, phenyl -S-, benzyl, benzyl -O-, benzyl -S-, or a 10 portion of the formulas: R6 is selected from H, C? -C6 alkyl, C? -C6 alkoxy, phenyl, phenyl -0-, benzyl, benzyl-0-, phenyl and benzyl rings, of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, CX-C6 alkyl, alkoxy, C? -C6, -N02, NH2, -CN, -CF3, or -OH; R7 is selected from -OH, -CF3, C? -C6 alkyl, C? -C6 alkoxy, -NH- (C? -C6 alkyl), -N- (C? -C6 alkyl) 2, pyridinyl, tiethyl, furyl , pyrrolyl, phenyl, phenyl-0-, benzyl, benzyl-0-, the rings of these groups being optionally substituted by from 1 to 3 substituents - * - * * a í n ^ Á ^ et # ». *. selected from halogen, -CN, C? -C6 alkyl, C? -C6 alkoxy, -N02, -NH2, -CF3, or OH; R 2 is selected from H, halogen, -CF 3, -OH, C 1 -C 10 alkyl, C 1 -C 10 alkoxy, -CHO, -CN, -N02, -NH 2, -NH- C 1 -C 6 alkyl, N (alkyl) ? C? -C6) 2, -NS02- C? -C6 alkyl, or -S02- C? -C6 alkyl; R3 is selected from H, -CF3, lower alkyl Ci-Ce, lower alkoxy C? -C6, cycloalkyl C3-C? 0, -CHO, halogen, or a portion of the formula -L2-M2: L2 indicates a linking or linking group of the formulas - (CH2) n-, -S-, - 0-, -C (O) -, - (CH2) nC (O) -, - (CH2) nC (0 ) - (CH2) n-, - (CH2) n-0- (CH2) n-, or - (CH2) nS- (CH2) "-, -C (O) C (0) X; where X = O, M is selected from the group of lower alkyl C? -C6, lower alkoxy d-C6, cycloalkyl C3-C? Or, phenyl or benzyl, the cycloalkyl, phenyl or benzyl rings being optionally substituted by from 1 to 3 substituents selected from halogen, Ci-Cio alkyl, Ci-Cio alkoxy, -N02, -NH2, -CN, or -CF3; or a) a five-membered heterocyclic ring containing one or two rings of heteroatoms selected from N, S or O including, but not limited to, furan, pyrrolo, thiophene, imidazole, pyrazole, pyrrolidine, or tetrazole, the five-membered heterocyclic ring members being optionally substituted by from 1 to 3 substituents selected from halogen, Ci-Cio alkyl, Ci-Cio alkoxy, -N02, -NH2, -CN, or -CF3; or b) a six-membered heterocyclic ring containing one, two or three rings of heteroatoms selected from N, S or O including, but not limited to, pyridine, pyrimidine, piperidine, piperazine, or morpholine, the six-membered heterocyclic rings it being optionally substituted by from 1 to 3 substituents selected from halogen, Ci-Cio alkyl, Ci-Cio alkoxy, -CHO, N02, -NH2, -CN, -CF3 or OH; or c) a bicyclic ring portion containing from 8 to 10 atoms in the ring and optionally containing from 1 to 3 ring heteroatoms selected from N, S or 0 including, but not limited to, benzofuran, indole, indoline, naphthalene, purine, or quinoline, the bicyclic ring portion being optionally substituted by from 1 to 3 substituents selected from halogen, Ci-Cio alkyl, Ci-Cio alkoxy, -CHO, NO 2, -NH 2, -CN, -CF 3 or OH; n is an integer from 0 to 3; R4 is selected from the group of lower alkyl C6-C6, lower alkoxy C6-C6, cycloalkyl- (CH2) n-C3-C6, cycloalkyl- (CH2) n- S- (CH2) n-C3-C5, cycloalkyl - (CH2) n-0- (CH2) n-C3-C5, or of the groups of: a) - (CH2) n-phenyl-0-phenyl, - (CH2) n-phenyl-1-CH2-phenyl, - (CH2) n-0-phenyl-CH2-phenyl, - (CH2) n-phenyl- ( 0-CH2-phenyl) 2, - (CH2) n-phenyl- (0-CH2-phenyl-1) -2, -CH2-phenyl-C (O) -benzot-ia-zol or a portion of the formulas: wherein n is an integer from 0 to 3, Y is C3-C5 cycloalkyl, phenyl, benzyl, naphthyl, pyridinyl, quinolyl, furyl, thianyl or pyrrolyl; the rings of these groups being optionally substituted by from 1 to 3 substituents selected from H, halogen, -CF3, -OH, C? -C6 alkyl, C? -C6 alkoxy, -NH2, -N02, or a five-membered heterocyclic ring members containing a heteroatom selected from N, S, or O, b) a portion of the formulas - (CH2) n-A, (CH2) n-S-A, or - (CH2) n-0-A, where A is the portion: * • - » wherein D is H, C?-C6 lower alkyl, C?-C6 lower alkoxy, or -CF3; B and C are independently selected from phenyl, pyrinyl, furyl, thienyl or pyrrolyl groups, each optionally substituted by from 1 to 3, substituents selected from 10 H, halogen -CF3, -OH, alkyl -Ci-Ce, Cx-C6 alkoxy, or -N0; or c) a portion of the formulas: - * A ***** - * JiA « wherein Z is 0 or S and the phenyl and pyrimidyl rings of each portion are optionally and independently from 1 to 3 substituents selected from halogen, -CF 3, -OH, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, -NH 2 , or -N02; R5 is selected from -COOH, -C (0) -COOH, (CH2) nC (0) -COOH, - (CH2) n-C00H, -CH = CH-C00H, (CH2) n-tetrazole, alloalkyl lower Cj-Cg) or a selected portion of the formulas -L -M; wherein L1 is a binding or binding portion selected from a chemical bond, - (CH2) n-, -S-, - 0-, -C (0) -, - (CH2) nC (0), - (CH2 ) nC (0) - (CH2) n, - (CH2) n- 0- (CH2) n, - (CH2) "- S-- (CH2) n, -C (Z) -N (R6) -, -C (0) -C (Z) -N (R6) - (CH2) n, -C (Z) -NH-SO2-, or -C (Z) -NH-S02- (CH2) n, M1 is selected from the group of -COOH, - (CH2) n -COOH, - (CH2) n-C (0) -COOH, tetrazole, fifteen OÜ ^ J W? Hit i &í S & í ?. where R8, R9 or Rio can be linked anywhere in the cyclic or bicyclic system, Rs, in each presentation, is independently selected from H, -COOH, - (CH2) n -COOH, - (CH2) n-C (O) -COOH, tetrazole, 10 ® £ t ^ iíi & amp; amp; & l; s ^^^^^^^^^ l ^^ i ... > Rg is selected from H, halogen, -CF3, -OH, COOH, - (CH2) n -COOH, - (CH2) nC (0) -COOH, C6-alkyl, -OC-C6 alkyl, - NH (C? -C6 alkyl), or N (to C? -C6) 2; Rio is selected from the group of H, halogen, CF3, -OH, - (CH2) n -COOH, - (CH2) nC (O) -COOH, alkyl -C? -C6, alkyl -0-C? -C6, -NH (C? -C6 alkyl), N (C? -C6 alkyl) 2, ^^^^^^^^^ * ~. ? *. ^ * Ab. « (lower alkyl C-C) lower haloalkyl C -C] (lower alkyl C-C " Rn is selected from H, lower alkyl Ci-Ce, cycloalkyl C? -C6, -CF3, -COOH, - (CH2) n -COOH, - (CH2) n-C (0) -COOH, with the proviso that the complete portion in position 1 of indole or indoline created by any combination of R5, R8, Rg, Rio and / or R \ \ may contain at least one acid portion selected from or containing a carboxylic acid, a tetrazol, or a portion of the formulas: n is an integer from 0 to 3; or a pharmaceutically acceptable salt thereof.
2. The compound according to claim 1, characterized in that it has the formula: wherein R3 is hydrogen and Ri, R2, R4, and R5 are as described in claim 1, or a pharmaceutically acceptable salt thereof.
3. The compound according to claim 2, characterized in that it has the formula: wherein Ri, R2, R3, R, and R5 are as described in claim 2, or a pharmaceutically acceptable salt thereof.
4. The compound according to claim 2, characterized in that it has the formula: wherein Ri, R2, R3, R4, and R5 are as described in claim 2, or a pharmaceutically acceptable salt thereof.
The compound of the formulas characterized in that Ri is selected from H. halogen, -CF3, -OH, C? -C6 alkyl, C? -C6 alkoxy, -N02, -HN2, -HN (C? -C6), -N (C? -C6 ), phenyl, phenyl-O-, benzyl, benzyl-O-, or a portion of the formulas: Re is selected from H, Ci-Cd alkyl, Ci-Cd alkoxy, phenyl, -O-phenyl, benzyl, -O-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen , C? -C6 alkyl, C? -C6 alkoxy, -NH2, -N02, -CF3, or -OH; R7 is selected from - (CH2) n -COOH, - (CH2) nN- (C6-C6 alkyl) 2, - (CH2) n-NH- (C6-C6 alkyl), -CF3, C-alkyl? -C6, C3-C5 cycloalkyl, C6-C6 alkoxy, NH- (C 1 -C 6 alkyl), -N- (C 1 -C 6 alkyl) 2, pyridyl, thienyl, furyl pyrrolyl, phenyl, phenyl-O-, benzyl, benzyl-O-, adamantyl or morpholinyl, the these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C? -C6 alkyl, Ci-C6 alkoxy, -NH2, -N02, -CF3, or -OH; R2 is selected from H, halogen, -CF3, -OH, C? -C? 0 alkyl, Ci-Cio alkoxy, -CHO, -CN, N02, -NH2, -NH-C? -C6 alkyl, N ( CX-C6 alkyl) 2, N-S02-alkyl- (CH2) n-0-phenyl-CH2-phenyl, or -S02-Ci-C6 alkyl; R3 is selected from the group of lower alkyl C? -C6, lower alkoxy Ci-C?, - (CH2) n-C3-C6 cycloalkyl, - (CH2) n-S- (CH2) n-C3-C6 cycloalkyl, or the groups of: a) - (CH2) n-phenyl-O-phenyl, - (CH2) n-pheny1-CH2-phenyl, - (CH2) n-phenyl- (0-CH2-phenyl) 2, -CH2-phenyl-C (O) -benzothiazole or a portion of the formulas: (CH2), "\ ^ (CH2 c ^ Y wherein n is an integer from 0 to 3, Y is C3-Cd cycloalkyl, phenyl benzyl, naphthyl, pyridinyl, quinolyl, furyl, thienyl, or pyrrolyl; the rings of these groups are optionally substituted by from 1 to 3 substituents selected from H, halogen, -CF3, -OH, C? -C6 alkyl, C? -C6 alkoxy, -NH2, -N02, or a heterocyclic ring of 5 members, which contains 10 a heteroatom selected from N, S ,; or b) a portion of the formulas - (CH2) n_A, (CH2) n-S-A, or - (CH2) n-0-A, where A is the portion. fifteen wherein D is H, C?-C6 lower alkyl, d-C6 lower alkoxy, or -CF3; B and C are independently selected from the phenyl, pyridinyl, furyl, thienyl or pyrrolyl groups, each optionally substituted by from 1 to 3, substituents selected from H, halogen -CF 3, -OH, C 1 -C 6 alkyl, C alkoxy ? ~ C6, or -N02; or c) a portion of the formulas: wherein the phenyl and benzyl rings of each portion are optionally and independently from 1 to 3 substituents selected from halogen, -CF3, -OH, C? -C6 alkyl, C? -C6 alkoxy, or -N02; R 4 is selected from H, halogen, -CF 3, -OH, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, benzyl, benzyloxy, phenyl, phenyloxy, -C (O) -phenyl, -C (O) -benzyl , CH2- (C3-C6 cycloalkyl), -C (0) -OH, -CH = 0, -C (O) -alkyl C? ~ C6, -C (O) -O-C? -C6 alkyl, -C (O) -CF3, - (CH2) n-S-CH2- (C3-C6 cycloalkyl), the phenyl and benzyl rings of the relevant groups R3 being optionally substituted by from 1 to 3 groups selected from halogen, C? -C6 alkyl, Ci-C? alkoxy, -N02, -CF3, -C (0) -OH, or - OH; n is an integer from 0 to 3; R5 is selected from -COOH, -C (0) -C00H, (CH2) n-C (O) -COOH, - (CH2) n -COOH, -CH = CH-COOH, __ÍÍ__? *? ^ ¡^ ^ B ^ is®j i erior C -C) R8 is selected from H, -COOH, - (CH2) n -COOH, (CH2) n-C (O) -COOH, tetrazole, Rg is selected from H, halogen, -CF3, -OH, (CH2) n -COOH, - (CH2) nC (O) -COOH, -C? -C6 alkyl, -0-C? -C6 alkyl, -NH (C? -C6 alkyl), or -N (C-alkyl) ? -C6) 2; Rio is selected from the group of H, halogen, CF3, -OH, - (CH2) n -COOH, - (CH2) nC (O) -COOH, alkyl -C? -C6, alkyl -0-C? -C6, -NH (alkyl C? -C ( N (C? -C6 alkyl) 2, lower alkyl C | -Cg), Rn is selected from H, lower alkyl Ci-Ce, -CF3, -COOH, - (CH2) n -COOH, - (CH2) n-C (0) -COOH, or with the proviso that the complete portion in position 1 of indole or indoline created by any combination of R5, Rs, R9, ic and / or Rn may contain at least one acid portion selected from or containing a carboxylic acid, a tetrazole, or a portion of the formulas: or a pharmaceutically acceptable salt thereof 10 The compound of the formulas Jt &aHk * i¡Íti & ¡.? . ,, - & *. * sie¿ ^ ..-,: characterized because Ri is selected from H, halogen, -CF3, -OH, C? -C6 alkyl, C? -C6 alkoxy, -N02, -HN2, phenyl, phenyl-O-, benzyl, benzyl-O-, benzyl-S- or a portion of the formulas: Re is selected from H, C? -C6 alkyl, Ci-Ce alkoxy, phenyl, phenyl-O-, benzyl, benzyl-O-, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, Ci-C6 alkyl, C6-C6 alkoxy, -N02, -CF3, or -OH; •? fa ~ • * - '- ^ • ".«. »«.
R7 is selected from - (CH2) n -COOH, - (CH2) nN- (C6-C6 alkyl) 2, - (CH2) n-NH- (C6-C6 alkyl), -CF3, C-alkyl C6, C3-C5 cycloalkyl, Ci-Cß alkoxy, NH- (C?-C6 alkyl), -N- (C?-C6 alkyl) 2, pyridyl, thienyl, furyl pyrrolyl, phenyl, phenyl-O-, benzyl, benzyl-O-, adamantyl or morpholinyl, the pyridinyl, phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C? -C6 alkyl, C? -C6 alkoxy, -N02, -CF3, or -OH; R2 is selected from H, halogen, -CF3, -OH, Ci-Cio alkyl, Ci-Cio alkoxy, -CHO, -CN, N02, -NH2, -NH-C-C6-alkyl, N (C-alkyl? -C6) 2, -N-S02-alkyl -S02-C6-C6 alkyl; R3 is selected from H, halogen, -CF3, -OH, Ci-Cß alkyl, C?-C6 alkoxy, benzyl, benzyloxy, phenyl, phenyloxy, -C (0) -phenol, -C (O) -benzyl, CH2- (C3-C5 cycloalkyl), -C (0) -OH, -CH = 0, -C (O) -alkyl C? -C6, -C (O) -O-C? -C6 alkyl, -C (0) -CF3, - (CH2) nS-CH2- (C3-C5 cycloalkyl), the phenyl and benzyl rings of the relevant groups R3 being optionally substituted by from 1 to 3 groups selected from halogen, C? -C6 alkoxy C? -C6 alkyl, -N02, -CF3, -CO (0) -OH, or - OH; n is an integer from 0 to 3; R 4 is selected from the groups of C 1 -C 6 lower alkyl, C 1 -C 6 lower alkoxy, C 3 -C 5 - (CH 2) n -cycloalkyl, - (CH 2) n ~ S- (CH 2) n-cycloalkyl C 3 -C 5 , - (CH2) n-0- (CH2) n-cycloalkyl C? ~ C6, or the groups of: a) - (CH2) n-phenyl-O-phenyl, - (CH2) n-phenyl-1-CH2-phenyl, - (CH2) n-0-phenyl-CH2-f-enyl, - (CH2) n-phenyl- (0-CH2-phenyl) 2, - (CH2) n-phenyl- (0-CH2-pheni1) 2, -CH2-phenyl-C (O) -benzothiazole or a portion of the formulas: wherein n is an integer from 0 to 3, Y is C3-C6 alkyl, phenyl, benzyl, naphthyl, pyridinyl, quinolyl, furyl, thienyl, or pyrrolyl; the rings of these groups being optionally substituted by from 1 to 3 substituents selected from H, halogen, -CF3, -OH, Ci-Cß alkyl, Ci-Ce alkoxy, -N02, or a 5 membered heterocyclic ring, containing a heteroatom selected from N, S ,; or b) a portion of the formulas - (CH2) n-A, (CH2) n-S-A, or - (CH2) n-0-A, where A is the portion: fifteen ? ^ M * ^? & ^ ¿¡£ g £ -% *. í * < m- ^ ¿i * ^^: where D is H, lower alkyl C? ~ C6, lower alkoxy Ci-Ce, or -CF3, B and C are independently selected from the phenyl, pyridinyl, furyl, thienyl or pyrrolyl groups, each optionally substituted by from 1 to 3, preferably 1 to 2, substituent is selected from H, halogen -CF3, -OH, alkyl -C? ~ C6, alkoxy C? -C6, or -N02; or c) a portion of the formulas S, wherein Z is O or S and the phenyl and pyrimidyl rings of each portion are optionally and independently from 1 to 3 substituents selected from halogen, -CF 3, -OH, C 1 -C 6 alkyl, Ci-C 6 alkoxy, or NO2; R5 is selected from -COOH, -C (0) -COOH, (CH2) n-C (O) -COOH, - (CH2) n -COOH, -CH = CH-COOH, tojj, - ¿g &é £ m sS ^, * Rs is independently selected from H, COOH, - (CH2) n -COOH, - (CH2) n-C (O) -COOH, tetrazole, Rg is selected from H, halogen, -CF3, -OH, - (CH2) n -COOH, - (CH2) nC (O) -COOH, alkyl -C? -C6, alkyl -0-C? -C6, - NH (C? -C6 alkyl), or -N (Ci-C6 alkyl) 2; Rio is selected from the group of H, halogen, CF3, -OH, - (CH2) n -COOH, - (CH2) nC (O) -COOH, alkyl -C? -C6, alkyl -0-C? -C6, alkyl -NH (C? -C6 alkyl), N (C? -C6 alkyl) z, .. I. i l i a jfcat-Aéto. or N '? lower alkyl C -C) ° V ° "lower haloalkyl C ^ -C) o), Rn is selected from H, lower alkyl Ci-Cß, • CF3, -COOH, - (CH2) n -COOH, - (CH2) n-C (O) -COOH, or with the proviso that the complete portion in position 1 of indole or indoline created by any combination of R5, R8, Rg, R? or > and / or Ri may contain at least one acid portion selected from or containing a carboxylic acid, a tetrazole, or a portion of the formulas: * -% - < £ ¿ i - m & M ** or a pharmaceutically acceptable salt thereof A compound of the formulas characterized because Ri is selected from H. halogen, -CF3, -OH, C? -C6 alkyl, C? -C6 alkoxy, -N02, -HN2, phenyl, phenyl-O-, benzyl, benzyl-O-, or a portion of The formulas: 10 6 -O- -N- R7- R6 is selected from H, C? -Calkyl, C? -C6 alkoxy, phenyl, phenyl-O-, benzyl, benzyl-O-, the phenyl and benzyl rings of these groups by being optionally substituted by from 1 to 3 selected substituents of halogen, C? -C6 alkyl, C? -C6 alkoxy, -N02, -CF3, or -OH; R 7 is selected from - (CH 2) n -COOH, - (CH 2) nN- (C 1 -C 6 alkyl) 2, - (CH 2) "-NH- (C 1 -C 6 alkyl), -CF 3, C 1 alkyl C, C3-C5 cycloalkyl, C? -C6 alkoxy, NH- (C? -C6 alkyl), -N- (C? -C6 alkyl) 2, pyridyl, thienyl, furyl pyrrolyl, phenyl, phenyl-O-, benzyl, benzyl-O-, adamantyl or morpholinyl, the pyridinyl, phenyl and benzyl rings of these groups being optionally substituted by ^^^ táfewSjj fe ^ 1 to 3 substituents selected from halogen, C? -C6 alkyl, C? -C6 alkoxy, -N02, -CF3, or -OH; R2 is selected from H, halogen, -CF3, -OH, C? -C? 0 alkyl, Ci-Cio alkoxy, -CHO, -CN, N02, -NH2, -NH-C? -C6 alkyl, N ( C? -C6 alkyl) 2, N-S02-alkyl or -S02-C? -C6 alkyl; R3 is selected from the group of lower alkyl Ci-Cd, lower alkoxy C? -C6, - (CH2) n- C3-C6 cycloalkyl, - (CH2) nS- (CH2) n- C3-C6 cycloalkyl, or the groups of : a) - (CH2) n-phenyl-O-phenyl, - (CH2) n-pheni 1 -CH2-phenyl, - (CH2) nO-phenyl, - (CH2) n- (0-CH2-pheny1) 2 , CH2-pheni 1-C (O) -ben zot-iazole or a portion of the formulas: ^ (CH2) ^ ^, (CH;,) ^ wherein n is an integer from 0 to 3, Y is C3-C6 alkyl, phenyl, benzyl, naphthyl, pyridinyl, quinolyl, furyl, thienyl, or pyrrolyl; the rings of these groups are optionally substituted by from 1 to 3 substituents selected from H, halogen, -CF3, -OH, C? -Cd alkyl, Ci-Ce alkoxy, -N02, or a 5 membered heterocyclic ring. , which contains a heteroatom selected from N, S; or b) a portion of the formulas - (CH2) n-A, (CH2) n-S-A, or - (CH2) n-0-A, where A is the portion: i i affei4fcfcJ -J where D is H, lower alkyl C? -C6 / lower alkoxy C? -C6, or -CF3; B and C are independently selected from the phenyl, pyridinyl, furyl, thienyl or pyrrolyl groups, each optionally substituted by from 1 to 3, substituents selected from H, halogen -CF 3, -OH, C 1 -C 6 alkyl, C 1 alkoxy -C6, -NH2 or -N02; or c) a portion of the formulas wherein Z is 0 or S and the phenyl and pyrimidyl rings of each moiety are optionally and independently from 1 to 3 sub t ti tyent is selected from halogen, -CF3, OH, C? -C6 alkyl, C? -C6 alkoxy , or -N02, -NH2; R 4 is selected from H, halogen, -CF 3, -OH, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, benzyl, benzyloxy, phenyl, phenyloxy, -C (0) -phenyl, -C (0) -benzyl, CH2- (C3-C6 cycloalkyl), -C (0) -0H, -CH = 0, -C (0) -alkyl C? -C6, -C (0) -O-C? -C6 alkyl, -C (0) -CF3, - (CH2) n-S-CH2- (C3-C6 cycloalkyl), the phenyl and benzyl rings of the relevant groups R3 being optionally substituted by from 1 to 3 groups selected from halogen, C? -C6 alkyl, C? -C6 alkoxy, -N02, -CF3, -C0 (0) -0H, or -OH; n is an integer from 0 to 3; R5 is selected from -COOH, -C (0) -COOH, (CH2) n-C (O) -COOH, - (CH2) n -COOH, -CH = CH-COOH, "V OH R8 is selected from H, -COOH, - (CH2) n -COOH,; CH2) n-C (O) -COOH, tetrazole, Rg is selected from H, halogen, -CF3, -OH, (CH2) n -COOH, - (CH2) nC (O) -COOH, alkyl -C? -C6, alkyl -0-C? -C6, -NH (C 1 -C 6 alkyl), or -N (ci-c 6 alkyl) 2; Rio is selected from the group of H, halogen, CF3, -OH, - (CH2) n -COOH, - (CH2) nC (O) -COOH, alkyl -C? -C6, alkyl -0-C? -C6, -NH (C? -C6 alkyl), N (C? -C6 alkyl) 2, lower C -Cg); Rxx is selected from H, lower alkyl C? -C6, -CF3, -COOH, - (CH2) n -COOH, - (CH2) n-C (O) -COOH, or with the proviso that the complete portion in position 1 of indole or indoline created by any combination of R5, R8, R9 > RIO and / or Rn may contain at least one acid portion selected from or containing a carboxylic acid, a tetrazole, or a portion of the formulas: or a pharmaceutically acceptable salt thereof A component of the formulas characterized in that Ri is selected from -HN2, phenyl, phenyl-O-, benzyl, benzyl-O-, -N-benzyl, -N-benzyl-O-phenyl, -S-benzyl or a portion of the formulas: -afc * »R6 is selected from H, alkyl C? ~ C, C6-C6 alkoxy, phenyl, phenyl-O-, benzyl, benzyl-O-, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C? -C6 alkyl , C6-C6 alkoxy, -N02, -CF3, or -OH; R7 is selected from - (CH2) n -COOH, - (CH2) nN- (C6-C6 alkyl) 2, - (CH2) n -NH- (C6-C6 alkyl), -CF3, Ci-alkyl -Ce, C-C5 cycloalkyl, C? -C6 alkoxy, -NH- (C? -C6 alkyl), -N- (C? -C6 alkyl) 2, pyridyl, thienyl, furyl pyrrolyl, phenyl, phenyl-O- , benzyl, benzyl-O-, adamantyl or morpholinyl, the rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, Ci-Cd alkyl, C? -C6 alkoxy, -N02, -CF3, or - OH; n is an integer from 0 to 3; R3 is selected from halogen, C? -C6 alkyl, C? -C6 alkoxy, -CF3, -CH = 0, -C (O) -C? -C6 alkyl, -C (0) -0- C- alkyl C6, -C (0) -OH, -C (0) -CF3, -C (O) -phenyl, -C (O) -benzyl, -C (O) -pyrrolyl, -C (O) -25 thienyl, -C (O) -furanyl, or -C (O) -moefol ini lo; J6 ¥ * iiSt¡¡ & , M > . . . .-. "I" .. »... * n.- < > .. «-» ». a t. - - »« .- ** .. - > • . ** * «> t i at? ni? xe *.
R4 is selected from the group of, - (CH2) n- (C3-C6 cycloalkyl), - (CH2) nS- (CH2) n- (C3-C5 cycloalkyl), - (CH.) NO- (CH2) n- (C3-C6 cycloalkyl), (CH2) nS- C6-C6 alkyl, the groups of: a) -C (0) -0- (CH2) n-cycloalkyl, ~ (CH2) n-phenyl, - (CH2) n-0-phenyl, - (CH2) nS-phenyl, - (CH2) nS- ( CH2) n-phenyl, - (CH2) n-phenyl-0-phenyl, - (CH2) n-phenyl-CH2-phenyl, - (CH2) n-0-phene lo-CH2- phenyle, (CH2) n phenyl- (0-CH2-phenyl) 2, -C (0) -0-phenyl, C (0) -O-benzyl, -C (0) -0-pyridinyl, -C (0) -0-naphthyl, - (CH2) nS-naphthyl, - (CH2) nS-pi r idini lo, ( CH2) n-pyridinyl, or - (CH2) n-na ft i lo, - (CH2) n-0-naphthyl, the phenyl, pyridinyl, and naphthyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from H, halogen, -CF3, -OH, C? -C6 alkyl, C? -C6 alkoxy, -N02, or a ring containing five heterocyclic heteroatom members, selected from N, S, or 0; or b) a portion of the formulas - (CH2) n-A, (CH2) n-S-A, or - (CH2) n-0-A, where A is the portion wherein D is H, C 1 -C 6 lower alkyl, C 6 -C 6 alkoxy, • CF, R5 is selected from -COOH, -C (0) -COOH, (CH2) n-C (0) -COOH, - (CH2) n -COOH, -CH = CH-COOH, R8 is selected from H, -COOH, - (CH2) n -COOH, CH2) n-C (0) -COOH, tetrazole, - Rg is selected from H, halogen, -CF3, -OH, (CH2) n -COOH, - (CH2) nC (O) -COOH, alkyl -C? -C6, alkyl -0-C? -C6, -NH (C 1 -C 6 alkyl), or -N (C 1 -C 6 alkyl) 2, Rio is selected from the group of H, halogen, CF3, -OH, - (CH2) n -COOH, - (CH2) nC (0) -COOH, alkyl -Ci-Ce, alkyl -0-C? -C6, - NH (C? -C6 alkyl), N (C? -C6 alkyl) 2, Rn is selected from H, lower alkyl C? -C6,? CF3, -COOH, - (CH2) n -COOH, - (CH2) n-C (O) -COOH, or with the proviso that the entire portion in position 1 of indole or indolma created by any combination of R5, R
8, Rg, Rxc and / or R? may contain at least one acid portion selected from or containing an acid Carboxylic acid, a tetrazole, or a portion of the formulas: • ^ aa- «a ^ a ^. * - * * or a pharmaceutically acceptable salt thereof
9. The pharmaceutical composition characterized in that it comprises a pharmaceutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
10. The pharmaceutical composition characterized in that it comprises a pharmaceutically effective amount of a compound according to claim 5, or a salt Pharmaceutically acceptable thereof, and a pharmaceutically acceptable carrier or excipient. - g ^^ gMjjtgi?
11. The pharmaceutical composition characterized in that it comprises a pharmaceutically effective amount of a compound according to claim 6, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
12. The pharmaceutical composition characterized in that it comprises a pharmaceutically effective amount of a compound according to claim 7, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
13. The pharmaceutical composition characterized in that it comprises a pharmaceutically effective amount of a compound according to claim 8, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
14. The compound according to claim 1 characterized in that it comprises 4- (. {3-chloro-5- [(cyclopentylcarbonyl) amino] -2 - [(phenethylsulfanyl) methyl] -lH-indol-1- ylmethyl) benzoic acid c a pharmaceutically acceptable salt thereof.
15. The compound according to claim 1 characterized in that it comprises 4- [(3-chloro-5- [(cyclopentylcarbonyl) amino] -2- {[[2-furylmethyl) sulphyl] met i 1. lH-indol-1-yl) met il] benzoic acid or a pharmaceutically acceptable salt thereof.
16. The compound according to claim 1, characterized in that it comprises 4- [(3-chloro-5- [(cyclopentylcarbonyl) amino] -2- {[[4-hydroxy-6-phenyl-2-pyrimidini]] 1) Sulfanyl] -15-methyl-lH-indol-1-yl) methyl] benzoic acid or a pharmaceutically acceptable salt thereof.
17. The compound according to claim 1, characterized in that it comprises 4 - acid. { [3-chloro-5- [(cyclopentylcarbonyl) amino] -2- ( { [4- (2-thienyl) -2-pyrimidyl] sulfanyl Jmethyl) -1H-indol-1-yl] met il} benzoic acid or a pharmaceutically acceptable salt thereof. __a ^? - - £ - ^ - ^ z __! ^! ^ - + -. S? Xt > - ^ ¡¡ > - »? > a * - ^ #sJk ^? ._ - *. » . JA-, ¿-, < * -. A > *, -% j, * A ¡* .¿¡¡ & > (you *
18. The compound according to claim 1 characterized in that it comprises 4 -. { [3-chloro-5- [(cyclopentylcarbonyl) amino] -2- [(2,4-dibromo phenoxy) methyl] -lH-indol-1-ylmethyl) benzoic acid or a pharmaceutically acceptable salt thereof.
19. The compound according to claim 1 characterized in that it comprises 4 - (. {3-chloro-5- [(cyclopentylcarbonyl) amino] -2- [(cyclopentylsulfanyl) methyl] -lH-indol-1-yl}. met il) benzoic acid or a pharmaceutically acceptable salt thereof.
20. The compound according to claim 1 characterized in that it comprises 4- (. {3-chloro-5- [(cyclopentylcarbonyl) amino] -2- [(propylsulfanyl) methyl] -lH-indol-1-ylmethyl) benzoic acid or a pharmaceutically acceptable salt thereof.
21. The compound according to claim 1, characterized in that it comprises 4- ( { 2- { [4 - (tert-Butyl) phenoxy] met il.}. -3-chloro acid - '*. - ««. * t '^ iM' -5- [(cyclopentylcarbonyl) amino] -lH-indol-1-ylmethyl) benzoic acid or a pharmaceutically acceptable salt thereof.
22. The compound according to claim 1 characterized in that it comprises 4- (. {3-chloro-5- [(cyclopentylcarbonyl) amino] -2 - [(2-quinolinylsulfanyl) methyl] -lH-indol-1-ylmethyl} ) benzoic acid or a pharmaceutically acceptable salt.
23. The compound according to claim 1 characterized in that it comprises 4- [(3-chloro-5- [(cyclopentylcarbonyl) to ino] -2-. {[[(Cyclopropylmethyl) sulfanyl] methyl J-1H-indo 1-1] -yl) methyl] benzoic acid or a pharmaceutically acceptable salt thereof.
24. The compound according to claim 1 characterized in that it comprises 4- (. {2- [(benzyhydylsulfanyl) methyl] -3-chloro-5- [(cyclopentylcarbonyl) amino] -lH-i dol-1-ylmethyl] benzoic acid or a pharmaceutically salt thereof. , ..... , ».",. .., .- .., n ^ «. ~. -the*-.- . fnfr -
25. The compound according to claim 1, characterized in that it comprises 4- (. {5 - [(3-carboxypropanoyl) amino] -3-chloro-2- [(phenethylsulfanyl) methyl] -lH-indole- 1-i 1.} Met il) ben zói co or a pharmaceutically acceptable salt thereof.
26. The compound according to claim 1 characterized in that it comprises 4 - [(5- [(3-carboxypropanol) amino] -3-chloro-2-. {[[(3-methylbenzyl) sulfanyl] methyl] acid. lH-indol-1-yl) met yl] benzoic acid or a pharmaceutically salt thereof.
27. The compound according to claim 1 characterized in that it comprises 4- (. {2- ( { [4- (tert-Butyl) benzyl] sulfanyljmethyl) -5- [(3-carboxypropanoyl) amino-3-chloro) -lH- indol-1-i 1.} met i 1) benzoic or a pharmaceutically salt of the same.
28. The compound according to claim 1, characterized in that it comprises 4- (. {3-chloro-5- (3-furoi-lamino) -2- [(2-naphthylsulfanyl) methyl] -lH-indo-1-ylmethyl} ) benzoic acid or a pharmaceutically acceptable salt thereof.
29. The compound according to claim 1, characterized in that it comprises 4- (. {5- (acetylamino) -3-chloro-2- [(2-naphthylsulopylyl) methyl] -lH-indo-1-ylmethyl) benzoic acid or a pharmaceutically acceptable salt thereof.
30. The compound according to claim 1, characterized in that it comprises 4- (. {3-chloro-5- { [3- (diethylamino) propanoyl] amino] -2- [(2-naphthylsulfanyl) methyl] ] -lH-i do1-1-ylmethyl) benzoic acid 15 or a pharmaceutically acceptable salt thereof.
31. The compound according to claim 1 characterized in that it comprises 4- (. {3-chloro-2- [(2-naphthylsul-phenyl) methyl] -5- [20 ((3-thienylcarbonyl) amino] -lH-indo 1) -1-ylmethyl) benzoic acid or a pharmaceutically acceptable salt thereof.
32. The compound according to claim 1 characterized in that it comprises , * J ** £ ^ .. * ~ - *. ,., ..- * * ..., .. *: ,, ..., - ..,. . ...,.,- ...*"-., ..... ,,..Y ... . . ,, ^ ~, - \ *. * .- ******** * M 4- ( {5 { [[(Benzylamino) car onyl] amino} -3-chloro-2- [(2-naphthylsulphyl)] ethyl] -lH-indol-1-ylmethyl) benzoic acid or a pharmaceutically acceptable salt thereof.
33. The compound according to claim 1, characterized in that it comprises 4- ( { [5-. {[[(Butyl amino) carbonyl] amino} -3-chloro-2- [(2-naphthylsulphyl) methyl] ] - 1H-indol-1-yl) methyl) enzoic acid or a pharmaceutically acceptable salt thereof.
34. The compound according to claim 1 characterized in that it comprises 3- [(. {1- (4-carboxybenzyl) -3-chloro-2- [(2-naphthylsulfanyl) methyl] -lH-indol-5-yl] amino) carbonyl] benzoic acid or a pharmaceutically acceptable salt thereof.
35. The compound according to claim 1 characterized in that it comprises 4- acid. { [5- (benzyloxy) -2- [(E) -2-carboxyethenyl] -3- (2-naphthoyl) -lH-indol-1-yl] methylbenzoic acid or a pharmaceutically acceptable salt thereof. . ..- .,-,".-..-- -.. ..... 4 . ^ - »>
36. The compound according to claim 1, characterized in that it comprises 4- (. {3-acetyl-5- (benzyloxy) -2 - [(2-naphthylsulfanyl) ethyl] -lH-indol-1-yl} methyl) benzoic acid or a pharmaceutically acceptable salt thereof.
37. The compound according to claim 1 characterized in that it comprises 4- acid. { [5- (benzyloxy) -2- [(2-naphthylsulfanyl) methyl] -3- (2,2,2-trifluoroacetyl) -lH-indol-1-yl] met il} benzoic acid or a pharmaceutically acceptable salt thereof.
38. The compound according to claim 1, characterized in that it comprises 4 - (. {5 - [(4-aminobutanoyl) amino] -3-chloro-2- [(2-naphthylsulfanyl) ethyl] -lH-1-1-acid. -yl Jmethyl) benzoic acid or a pharmaceutically acceptable salt thereof.
39. The compound according to claim 1 characterized in that it comprises 4- (. {3-chloro-5- [(cyclopentylcarbonyl) amino] -2 - [(2-naphthylsulfanyl) methyl] -lH-indo 1-1-il Jmetil) benzoic or a pharmaceutically acceptable salt of the same.
40. The compound according to claim 1, characterized in that it comprises 4- (. {3-chloro-2- [(2-naphthylsulfanyl) methyl] -5 - [(2-quinoxalinylcarbonyl) amino] -1H-indole 1- il Jmet il) benzoic acid or a pharmaceutically acceptable salt thereof.
41. The compound according to claim 1 characterized in that it comprises' 4- (. {3. Chloro-5- [(2,2-dimethylpropanoyl) amino] -2- [(2-naphthylsulfanyl) methyl] -lH-indo acid. 1-1-ylmethyl) benzoic acid or a pharmaceutically acceptable salt thereof.
42. The compound according to claim 1 characterized in that it comprises 4 - (. {5 - { [(Benzyloxy) carbonylamino} - 3-chloro-2- [(2-naphthylsulfanyl) methyl] -lH-indo acid 1-1-ylmethyl) benzoic acid or a pharmaceutically acceptable salt thereof.
43. The compound according to claim 1 characterized in that it comprises 4- (. {3-chloro-5-. {[[(Cyclopentyloxy) carbonyl] amino] -2- [(2-naphthylsulfanyl) methyl] -lH-indole. -1-i 1.} Met i 1) benzoic acid or a pharmaceutically acceptable salt thereof.
44. The compound according to claim 1 characterized in that it comprises 4 - (. {5- (acetylamino) -3-chloro-2- [(2-naphthylsulfanyl) methyl] -lH-indol-1-ylmethyl) benzoic acid or a pharmaceutically acceptable salt thereof.
45. The compound according to claim 1 characterized in that it comprises 4- (. {5- ({[[(butylamino) carbonyl] amino} -3-chloro-2- [(2-naphthylsulfanyl) methyl] -lH acid -in 1-1-ylmethyl) benzoic acid or a pharmaceutically acceptable salt thereof.
46. The compound according to claim 1, characterized in that it comprises 4- (. {5- ({[[(butylamino) carbonyl] amino} -3-chloro-2- [(2-naphthysulfanyl) methyl]] -IH-indo 1-1-ylmethyl) benzoic acid or a pharmaceutically acceptable salt thereof.
47. The compound according to claim 1 characterized in that it comprises 4- (. {3-chloro-5- [(morpholinocarbonyl) amino] -2- [(2-naphthylsulphyl) methyl] -lH-indo 1-1- il Jmetil) benzoic acid or a pharmaceutically acceptable salt thereof.
48. The compound according to claim 1, characterized in that it comprises 4- (. {5- (benzylamino) -3-chloro-2- [(2-naphthylsulopyl) methyl] -lH-indo-1-ylmethyl) benzoic acid or a pharmaceutically acceptable salt thereof.
49. The compound according to claim 1 characterized in that it comprises 4- (. {3-chloro-2- [(2-naphthylsulopyl) methyl] -5- [(3-phenoxybenzyl) amino] -lH-indo1-1 acid -yl Jmethyl) benzoic acid or a pharmaceutically acceptable salt thereof.
50. The compound according to claim 1 characterized in that it comprises 4 - (. {3-chloro-5- [(cyclopentylcarbonyl) (methyl) amino] -2 - [(2-naphthylsulfanyl) methyl] -lH-indole- 1-ylmethyl) benzoic acid or a pharmaceutically acceptable salt thereof.
51. The compound according to claim 1 characterized in that it comprises 0 4 - (. {5- [acetyl (benzyl) amino] -3-chloro-2- [(2-naphthylsulfanyl) methyl] -lH-indole-1- il Jmetil) benzoic acid or a pharmaceutically acceptable salt thereof.
52. The compound according to claim 1 characterized in that it comprises 4- (. {3-chloro-2- [(2-naphthylsulfanyl) methyl] -5- [(tetrahydro-3-furanylcarbonyl) amino] -lH-indole -1-ylmethyl) benzoic acid or a pharmaceutically acceptable salt thereof.
53. The compound according to claim 1, characterized in that it comprises 4- (. {3-chloro-2- [(2-naphthylsulfanyl) methyl] -5- [(thienylcarbonyl) amino] -lH-indole-1 acid. -il Jmetil) r * t-a & -. .. ». . t, ",. benzoic acid or a pharmaceutically acceptable salt thereof.
54. The compound according to claim 1, characterized in that it comprises 4- (. {3-chloro-2- [(2-naphthylsulopyl) methyl] -5- [(1-adama-tylcarbonyl) amino] -lH-indo1- 1-ylmethyl) benzoic acid or a pharmaceutically acceptable salt thereof.
55. The compound according to claim 1, characterized in that it comprises 3- [(. {L- (4-carboxybenzyl) -3-chloro-2- [(2-naphthylsulphyl) methyl] -lH-indo1- acid. 5- 15 il.} Amino) carbonyl] benzoic acid or a pharmaceutically acceptable salt thereof.
56. The compound according to claim 1, characterized in that it comprises 20 4 - ( { 3. Chloro-2- [(2-naphthylsulphyl) methyl] -5- [(3-phenylpropanoyl) amino] -lH-indo 1-1-ylmethyl) benzoic acid or a pharmaceutically acceptable salt acceptable of it. ^ »« »^^^^» ^ ¡g £ ^^^^ »
57. The compound according to claim 1 characterized in that it comprises 4- (. {5-amino-3-chloro-2- [(2-naphthylsulfanyl) methyl] -lH-indol-1-ylmethyl) benzoic acid or a salt pharmaceutically acceptable thereof.
58. The compound according to claim 1 characterized in that it comprises N-. { chloro-l- (4-. {[[(methylsulfonyl) amino] carbonyl J-benzyl) -2- [(2-naphthylsulfanyl) methyl] -lH-indol-5-yl} cyclopentanecarboxamide or a pharmaceutically acceptable salt thereof.
59. The compound according to claim 1 characterized in that it comprises N-. { 3-Chloro-2- [(2-naphthylsulfanyl) methyl] -l- [4- (. {[[(4-nitrophenyl) sulfonyl] amino} carbonyl) benzyl] -1H-indol-5-yl} cyclopentanecarboxamide or a pharmaceutically acceptable salt thereof.
60. The compound according to claim 1, characterized in that it comprises N-. { 3-chloro-l- [4- (. {[[(2-methylphenyl) sulfonyl] amino} carbonyl) benzyl] -2- [(2-naphthylsulfanyl) methyl] -1H- indole-5-il} cyclopentanecarboxamide or a pharmaceutically acceptable salt thereof.
61. The compound according to claim 1 characterized in that it comprises N- [3-chloro-2 - [(2-naphthylsulfanyl) methyl] -1- (4-. {[[(Phenylsulfonyl) amino] carbonyl J-benzyl) -lH-indole -5-yl] cyclopentanecarboxamide or a pharmaceutically acceptable salt thereof.
62. The compound according to claim 1 characterized in that it comprises N-. { 3-Chloro-2- [(2-naphthylsulphyl) methyl] -1- [4- ( { [(Trifluoromethyl) sulfonyl] aminocarbonyl) benzyl] -lH-indol-5-yl} cyclopentanecarboxamide or a pharmaceutically acceptable salt thereof.
63. The compound according to claim 1 characterized in that it comprises 4- [5- [(cyclopentylcarbonyl) amino] -2- [(2-naphthyloxy) methyl] -3- (1-pyrrolidinylcarbonyl) -1H-indole-1-yl ] butanoic acid or a pharmaceutically acceptable salt thereof.
64. The compound according to claim 1 characterized in that it comprises 4- acid. { 5- [(Cyclopentylcarbonyl) amino] -3- (morpholinocarbonyl) -2- [(2-naphthyloxy) methyl] -1H-indol-1-yl] butanoic acid or a pharmaceutically acceptable salt thereof.
65. The compound according to claim 1 characterized in that it comprises N- [2- [(2-naphthyloxy) methyl-1- (4-oxo-4-. {[[(Trifluoromethyl) sulfonyl] aminojbutyl) -3- (1- pyrrolidinylcarbonyl) -lH-indol-5-yl] cyclopentanecarboxamide or a pharmaceutically acceptable salt thereof.
66. The compound according to claim 1 characterized in that it comprises N- [3- (morpholinocarbonyl) -2- [(2-naphthyloxy) methyl] -1- (4-oxo-4-. {[[(Trifluoromethyl) sulfonyl] aminojbutyl) -lH-indol-5-yl] cyclopentanecarboxamide or a pharmaceutically acceptable salt thereof.
67. The compound according to claim 1 characterized in that it comprises 5- [(cyclopentylcarbonyl) amino] -2- [(2- - "L i * -i naphthyloxy) methyl] -1- (4-oxo-4-. {[[(Trifluoromethyl) sulfonyl] amino J butyl) -lH-indole-3-carboxylic acid or a pharmaceutically acceptable salt thereof.
68. The compound according to claim 1 characterized in that it comprises 2- (4- {[[5- (benzyloxy) -3- (l-naphthoyl) -lH-indol-1-yl] methyl} phenyl) acetic acid or a pharmaceutically acceptable salt thereof.
69. The compound according to claim 1 characterized in that it comprises 2- (4- { [5- (benzyloxy) -3- (2-naphthoyl) -lH-indol-1-yl] met il.}. Feni acid. ) acetic acid or a pharmaceutically acceptable salt thereof.
70. The compound according to claim 1 characterized in that it comprises 2- [4- (. {5- (benzyloxy) -3- [3,5-bis (trifluoromethyl) benzoyl] -lH-indole-1-yl-yl-yl-yl} ) phenyl] acetic acid or a pharmaceutically acceptable salt thereof.
71. The compound according to claim 1 characterized in that it comprises 4- (. {3. Benzoyl-5- (benzyloxy) -2 - [(2-naphthylsulfanyl) methyl] -lH-indol-1-ylmethyl) benzoic acid or a pharmaceutically acceptable salt thereof.
72. The compound according to claim 1 characterized in that it comprises 4- (. {5- (benzyloxy) -3-isobutyryl-2- [(2-naphthylsulfanyl) met il] -lH-indol-1-yl}. met il) benzoic acid or a pharmaceutically acceptable salt thereof.
73. The compound according to claim 1 characterized in that it comprises 2 -. { 3-Acetyl-5- (benzyloxy) -2- [(2-naphthylsulfanyl) methyl] -lH-indol-1-yl} methyl) acetic acid or a pharmaceutically acceptable salt thereof.
74. The compound according to claim 1, characterized in that it comprises 2- acid. { 5- (benzyloxy) -3-isobutyryl-2- [(2-naphthylsulfanyl) methyl] -lH-indol-1-ylmethyl) acetic acid or a pharmaceutically acceptable salt thereof.
75. The compound according to claim 1 characterized in that it comprises 4- acid. { 3-Benzoyl-5- (benzyloxy) -2- [(2-naphthyloxy) methyl] -lH-indol-1-yl-J-tatanoic acid or a pharmaceutically acceptable salt thereof.
76. The compound according to claim 1, characterized in that it comprises 3 - [(4- {3-benzoyl-5- (benzyloxy) -2- [(2-naphthyloxy) methyl] -lH-indo-1-yl] Jbutanoil acid. amino) benzoic acid or a pharmaceutically acceptable salt thereof.
77. The compound according to claim 1, characterized in that it comprises 4-. { 3-Benzoyl-5- (benzyloxy) -2- [(2-naphthyloxy) methyl] -lH-indol-1-yl} -N- [3 ( { [(Trifluoromethyl) sulfonyl] amino} carbonyl) phenyl] butanamide or a pharmaceutically acceptable salt thereof.
78. The compound according to claim 1 characterized in that it comprises acid A-l (4-. {3-benzoyl-5- (benzyloxy) -2- [(2-naphthyloxy) methyl] -lH-indo1-1-yl Jbutanoil amino) benzoic acid or a pharmaceutically acceptable salt thereof.
79. The compound according to claim 1, characterized in that it comprises 2- [(4- {3-benzoyl-5- (benzyloxy) -2- [(2-naphthyloxy) methyl] -lH-indol-1-yl] Jbutanoil acid. amino) benzoic acid or a pharmaceutically acceptable salt thereof.
80. The compound according to claim 1 characterized in that it comprises 3 - [(4. {3-benzoyl-5- (benzyloxy) -2- [(2-naphthyloxy) methyl] -lH-indol-1-yl acid} butanoyl) amino] propanic or a pharmaceutically acceptable salt thereof.
81. The compound according to claim 1 characterized in that it comprises 3- [(4. {3-benzoyl-5- (benzyloxy) -2- [(2-naphthyloxy) methyl] -1H-indol-l-yl acid} butanoyl) amino] propanic or a pharmaceutically acceptable salt thereof.
82. The compound according to claim 1 characterized in that it comprises N- (4-. {3-benzoyl-5- (benzyloxy) -2- [(2-naphthyloxy) methyl] -lH-indol-1-yl} acid. butanoyl) -2-methybenzenesulfonamide or a pharmaceutically acceptable salt thereof.
83. The compound according to claim 1, characterized in that it comprises 5- acid. { 3-Benzoyl-5- (benzyloxy) -2- [(2-naphthyloxy) methyl] -lH-indol-1-yl} pentanoic or a pharmaceutically acceptable salt thereof.
84. The compound according to claim 1 characterized in that it comprises 3 - [(5. {3-benzoyl-5- (benzyloxy) -2 - [(2-naphthyloxy) methyl] -lH-indol-1-yl acid} pentanoyl) amino] benzoic acid or a pharmaceutically acceptable salt thereof.
85. The compound according to claim 1, characterized in that it comprises 5- acid. { 3-benzoyl-5- (benzyloxy) -2- [(2-naphthyloxy) methyl] -lH-indo 1-1-yl JN- [3- ( { [(Trifluoromethyl) sulfonyl] aminojcarbonyl] phenyl] p entanamide or a pharmaceutically acceptable salt thereof.
86. The compound according to claim 1, characterized in that it comprises 2- acid. { 3-Benzoyl-5- (benzyloxy) -2- [(2-naphthyloxy) methyl] -lH-indol-1-yl} acetic acid or a pharmaceutically acceptable salt thereof.
87. The compound according to claim 1 characterized in that it comprises (E) -4- acid. { 3-Benzoyl-5- (benzyloxy) -2- [(2-naphthyloxy) met il] -lH-indol-1-i 1} -2-butanoic acid or a pharmaceutically acceptable salt thereof.
88. The compound according to claim 1 characterized in that it comprises 3- (. {3. Benzoyl-5- (benzyloxy) -2 - [(2-naphthyloxy) met yl] -lH-indol-1-yl benzoic acid or a pharmaceutically acceptable salt thereof.
89. The compound according to claim 1, characterized in that it comprises 1-. { 1- [4- (1, 3-benzothiazol-2-ylcarbonyl) benzyl] -5- (benzylsulfanyl) -2- [(2-naphthylsulfanyl) methyl] -1H-indol-3-yl} -1-ethanone or a pharmaceutically acceptable salt thereof.
90. The compound according to claim 1, characterized in that it comprises l-. { l- [3- (1, 3-Benzothiazol-2-ylcarbonyl) benzyl] -5- (benzylsulfanyl) -2 - [(2-naphthylsulfanyl) methyl] -lH-indol-3-yl} -1-ethanone or a pharmaceutically acceptable salt thereof.
91. The compound according to claim 1, characterized in that it comprises 2- [3- (. {3-acetyl-5- (benzyloxy) -2 - [(2-naphthylsulphyl) methyl] -lH-indo-1-yl acid Jmethyl) benzoyl] -1,3-benzothiazole-6-carboxylic acid or a pharmaceutically acceptable salt thereof.
92. The compound according to claim 1, characterized in that it comprises 5- acid. { 3-benzoyl-5- (benzyloxy) -2- [(2-naphthyloxy) methyl] -lH-indol-1-yl} -2-oxopentanoic or a pharmaceutically acceptable salt thereof.
93. The compound according to claim 1, characterized in that it comprises "Ugly To l-aa-átefeaí tt &.. Ia-a 3 - [(5- {3-benzoyl-5- (benzyloxy) -2- [(2- naphthyloxy) methyl] -1H-indol- 1 -i 1.} -2-oxopentanoyl) amino] benzoic acid or a pharmaceutically acceptable salt thereof. 5
94. The compound according to claim 1, characterized in that it comprises 4- [(5- {3-benzoyl-5- (benzyloxy) -2- [(2-naphthyloxy) methyl] -lH-indole-1 acid. -yl.} -2- 10-oxopentanoyl) amino] benzoic acid or a pharmaceutically acceptable salt thereof.
95. The compound according to claim 1, characterized in that it comprises 15 3- (. {4- [5- [(Cyclopentylcarbonyl) amino] -2- [(2-naphthyloxy) methyl] -3- (1-pyrrolidinylcarbonyl) -1H-indol-1-yl} amino} ) benzoic acid or a pharmaceutically acceptable salt thereof.
96. The compound according to claim 1, characterized in that it comprises 3- [(4- {5- [(cyclopentylcarbonyl) amino] -3- (morpholinocarbonyl) -2- [(2-naphthyloxy) meyyl] - 1H- indol-1-yl Jbutanoyl) amino] benzoic acid or a salt Pharmaceutically acceptable thereof. . .A > a. ^ J-t-a - ¿, «- J --- ^
97. The compound according to claim 1 characterized in that it comprises N- [2 - [(2-naphthyloxy) methyl] -l-. { 4-oxo-4- [3- ( { [(Trifluoromethyl) sulfonyl] amino.}. Carbonyl) anilino] butyl J -3- (1-pyrrolidinylcarbonyl) -lh-indol-5-yl] cyclopentanecarboxamide or a salt pharmaceutically acceptable thereof.
98. The compound according to claim 1, characterized in that it comprises N- (3- (morpholinocarbonyl) -2- [(2-naphthyloxy) 1-1- got { 4-Oxo-4- [3- ( { [(Trifluoromethyl) sulfonyl] amino] carbonyl Jcarboni 1) anilino] butyl J-lH-indol-5-yl) cyclopentanecarboxamide or a pharmaceutically acceptable salt thereof.
99. The compound according to claim 1 characterized in that it comprises 2- (4-. {[[5- (benzyloxy) -3- (1-naphthoyl) -lH-indol-1-yl] phenyl) acetic acid or a salt pharmaceutically acceptable thereof.
100. A method for inhibiting phospholipase activity in a mammalian subject in need thereof characterized in that and administers to the subject an effective therapeutic amount of a pharmaceutical composition according to claim 9.
101. A method for inhibiting phospholipase activity in a mammalian subject in need thereof characterized in that and administers to the subject an effective therapeutic amount of a pharmaceutical composition according to claim 10.
102. A method for inhibiting phospholipase activity in a mammalian subject in need thereof characterized in that and administers to the subject an effective therapeutic amount of a pharmaceutical composition according to claim 11.
103. A method for inhibiting phospholipase activity in a mammalian subject in need thereof characterized in that and administers to the subject an effective therapeutic amount of a pharmaceutical composition according to claim 12.
104. A method for inhibiting phospholipase activity in a mammalian subject in need thereof characterized in that it delivers to the subject an effective therapeutic amount of a The pharmaceutical composition according to claim 13.
105. A method for the treatment of an anti-inflammatory response in a mammalian subject 10 need thereof, characterized in that it comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition according to claim 9. 15
106. A method for the treatment of an anti-inflammatory response in a mammalian subject in need thereof, characterized in that it comprises administering to the subject a The therapeutically effective amount of a pharmaceutical composition according to claim 10.
107. A method for the treatment of 25 an anti-inflammatory response in a subject ^ ¿& 3¡ | ^ ^^^^^^^^^^ mammal that needs it, characterized in that it comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition according to claim 11.
108. A method for the treatment of an anti-inflammatory response in a mammalian subject in need thereof, characterized in that it comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition according to claim 12.
109. A method for the treatment of an anti-inflammatory response in a mammalian subject in need thereof, characterized in that it comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition according to claim 13. ....
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/030,062 | 1998-02-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA00008295A true MXPA00008295A (en) | 2002-07-25 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999043651A2 (en) | Inhibitors of phospholipase enzymes | |
AU765427B2 (en) | Inhibitors of phospholipase enzymes | |
US6828344B1 (en) | Inhibitors of phospholipase enzymes | |
CA2322163A1 (en) | Inhibitors of phospholipase a2 | |
US5684034A (en) | 1H-indole-3-acetamide sPLA2 inhibitors | |
US5095031A (en) | Indole derivatives which inhibit leukotriene biosynthesis | |
US6916841B2 (en) | Inhibitors of phospholipase enzymes | |
NZ567162A (en) | 1, 3-disubstituted indole derivatives for use as PPAR modulators | |
KR20080102181A (en) | Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (s1p) receptor antagonist biological activity | |
Ziakas et al. | New analogues of butylated hydroxytoluene as anti-inflammatory and antioxidant agents | |
CZ126096A3 (en) | Peptide derivative and pharmaceutical composition containing thereof | |
AU646251B2 (en) | 3-indolyl thioacetate derivatives | |
JPH01110682A (en) | Antiallergic novel benzothiophene | |
US6025390A (en) | Heteroaromatic pentadienoic acid derivatives useful as inhibitors of bone resorption | |
MXPA00008295A (en) | Inhibitors of phospholipase enzymes | |
EP2001846A1 (en) | Indole derivatives as inhibitors of the soluble adenylate cyclase | |
CZ20003113A3 (en) | Phospholipase inhibitors | |
WO2007107385A2 (en) | Soluble adenylate cyclase inhibitors | |
EP2001843A2 (en) | Soluble adenylate cyclase inhibitors | |
MXPA00008292A (en) | Inhibitors of phospholipase enzymes | |
MXPA00008294A (en) | Inhibitors of phospholipase a2 | |
CZ20003117A3 (en) | Phospholipase inhibitors | |
MXPA99001864A (en) | Inhibitors of phospholipase enzymes |